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Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a 
necrotizing small vessel vasculitis with few or no immune deposits. Vasculitis means 
inflammation of the blood vessel wall. Small vessel vasculitis predominantly affects 
small vessels; these are defined as small intraparenchymal arteries, arterioles, 
capillaries, and venules. However, in AAV medium-sized arteries and veins, i.e. the main 
visceral arteries and their branches, may also be affected.1 AAV comprises a group 
of diseases consisting of granulomatosis with polyangiitis (GPA, formerly Wegener’s 
granulomatosis), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with 
polyangiitis (EGPA, formerly Churg-Strauss syndrome). Some consider renal limited 
vasculitis (RLV) to be a separate subtype of AAV. GPA, MPA and EGPA are associated 
with circulating ANCA specific for antigens located within neutrophil granules and 
monocyte lysosomes. The classical antigens in AAV are proteinase 3 (PR3)2-5 and 
myeloperoxidase (MPO).6 Up to approximately 10% of patients diagnosed with AAV 
are ANCA-negative using currently available indirect immunofluorescence (IIF) and 
Enzyme-Linked Immuno Sorbent Assays (ELISA).7-12
AAV is a rare disease. The overall incidence of AAV in Europe, Northern America and 
Japan is approximately 20 per million/year. The incidence of GPA is higher in Northern 
Europe, whereas that of MPA is higher in Southern Europe and Japan.13-15 AAV has a 
peak incidence of 65 per million/year between the ages of 65 and 74 years, although 
it can occur at any age.16,17 Data from the United Kingdom (UK) show prevalences of 
148 per million for GPA and 65 per million for MPA.13,15-17 The prevalence is generally 
higher in men; women more often develop the disease at a younger age.17,18 The overall 
prevalence of AAV is highest in Caucasians.18,19 A study in France showed that the 
prevalence of AAV was twice as high in Europeans (105 per million) compared to 
non-Europeans (53 per million, mainly African and Asian descent).20 PR3-ANCA is 
more common than MPO-ANCA in the UK and Northern Europe, while MPO-ANCA is 
more prevalent than PR3-ANCA in Southern Europe and Asia.13,16,21 These data show 
that AAV is quite diverse regarding the incidence and prevalence in different regions, 
different races and over age.
Patients typically present with prodromal “flu-like” symptoms, such as fever, 
polymyalgia, polyarthralgia, headache, malaise, anorexia, and unintended weight loss 
during several weeks or months.22,23 These symptoms are non-specific and overlap 
with symptoms of many other non-vasculitic diseases. Some patients may initially 
present with focal vasculitic disease such as cutaneous vasculitis, bloody-purulent 
rhinitis, scleritis, or arthritis. During the disease course more disease manifestations 
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may occur and various organs may become involved. Virtually every organ can be 
affected by the disease,24-27 but organs commonly involved are: ear, nose and throat 
(ENT), kidneys, lungs, skin, eyes and the nervous system.22,23,28,29 The organs involved in 
the various ANCA-associated vasculitides overlap, but some organs are involved more 
commonly in specific disease entities. For example, ENT involvement occurs in about 
90% of patients with GPA and in 35% of patients with MPA.22,23 ANCA-associated 
glomerulonephritis (AAGN) is commonly seen in GPA and MPA and is characterized 
by a pauci-immune necrotizing crescentic glomerulonephritis.23,30,31
It is challenging for physicians to recognize AAV at an early stage. In a large survey 
study of 701 GPA patients, time between disease onset and diagnosis was 3-12 months 
for most patients. Of these patients, 44% visited one to three physicians, 45% visited 
four to eight physicians, and 11% visited nine or more physicians before the final 
diagnosis was made. Only 7% of the patients received a diagnosis of GPA upon their 
first visit to a physician.18 The diagnosis of AAV is based on the clinicopathologic 
disease manifestations and ANCA-serology. The gold standard for diagnosing AAV is 
histology of a lesion from an affected organ.
Without treatment, average patient survival is approximately five months: 82% of 
patients die within the first year after diagnosis and more than 90% die within two years. 
The most common causes of death are rapidly progressive renal failure and respiratory 
failure.32 Modern immunosuppressive treatment has changed the fulminant disease 
course of AAV into a more chronic course, characterized by remission and relapses. 
Standard treatment consists of remission induction with high dose glucocorticoids 
and high dose oral or intravenous pulse cyclophosphamide or rituximab for three 
to six months, followed by remission maintenance treatment with azathioprine or 
methotrexate while glucocorticoids are slowly reduced and withdrawn.10,33 Rituximab 
– a monoclonal anti-B cell agent – has been thoroughly investigated in recent years and 
is used more and more to substitute cyclophosphamide as induction treatment.12,34 
Intravenous methylprednisolone or plasma exchange can be added as induction 
therapy in case of severe or life-threatening vasculitic disease at presentation, such 
as pulmonary hemorrhage.11,35
This introduction provides a general overview of the two major ANCA-associated 
vasculitides, namely GPA and MPA, with a special focus on renal involvement. EGPA 
is beyond the scope of this thesis. Below, an overview of three perspectives is given: 
the patient’s perspective, the physician’s perspective and the researcher’s perspective. 
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The last part of the general introduction lists the incentives for and aims of the studies 
described in this thesis, and provides a thesis outline.
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Assessment tools in vasculitis have always been based on consensus of expert 
physicians and what they consider relevant in terms of disease activity, disease extent 
and tissue damage. Examples are the Birmingham Vasculitis Activity Score (BVAS),36-38 
the Disease Extent Index39 and the Vasculitis Damage Index.40 The patient’s perspective 
is missing. Studies showed that patients and physicians rate disease manifestations 
and impact differently in AAV with no or very low correlation between both.41-47
In recent years, attention for the patient’s perspective has increased in the research 
field of AAV, following a trend in medicine in general. Patient care should not only be 
focused on curing the patient, but also on maintaining or improving quality of life (QoL). 
Patient-reported outcome (PRO) is a way to measure the QoL.
Qualitiy of Life in AAV
Studies in AAV have reported reduced QoL compared to the general population.41,43,46-50 
Most of these studies used the Short Form 36 (SF-36), which is a generic measure 
combining a physical component summary (PCS) score and a mental component 
summary (MCS) score.51 A higher score indicates a better QoL. In two studies, both 
including approximately 400 patients, the PCS and MCS were lower compared to the 
general UK population. Physical components scored worse than mental components 
(figure 1).48,50 Treatments aimed at the physical consequences of AAV will probably 
give most improvement in QoL.
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Figure 1 | Median SF-36 scores of the study by Basu et al. (410 AAV patients, 318 chronic disease 
controls, 470 general population controls). 
This fi gure shows that QoL is scored lower by AAV patients compared to the general population 
controls. QoL is scored similar between AAV patients and chronic disease controls, i.e. 
infl ammatory arthritis or chronic kidney disease. Physical components scored worse than mental 
components in the AAV group. PF, Physical Function; RP, Role Physical; BP, Bodily Pain; GH, 
General Health; VT, Vitality; SF, Social Functioning; RE, Role Emotional; MH, Mental Health; AAV, 
ANCA-associated vasculitis; QoL, Quality of Life. Reproduced from Basu et al. (Ann Rheum Dis 
2014;73:207-211) with permission.
One major limitation of the SF-36 is that the scoring system is not disease-specifi c. 
Therefore, a vasculitis-specifi c PRO tool is being developed. This tool is based on 
ranked vasculitis-related burdens.52 Patients (n=264) from 3 countries (Germany, 
United States, United Kingdom) ranked 40 vasculitis-related items and listed the fi ve 
most important aspects of the disease in their daily live. Eighty-one percent of these 
patients had AAV, the remaining 19% had other vasculitides. On a scale of 0-10 (0 = no 
impact on QoL, 10 = extremely negative impact on QoL), the impact of vasculitis on 
QoL was scored as 4.6 ± SD 2.4. Symptoms with the highest burden were fatigue, 
loss of energy, weight gain, joint pain, and sinusitis. Most commonly mentioned in the 
free text section were fatigue and energy loss, pain and musculoskeletal symptoms.42
Due to the differences in perception of “illness” by patients and physicians it is 
important to incorporate disease-specifi c PRO instruments in the clinical management 
of the disease in order to tailor clinical management. Treatment goals should be 
extended beyond induction of remission and its maintenance, which, in itself, also 
can partly recover QoL.
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This part focuses on important aspects of the pathogenesis of AAV in fundamental 
research. Research on clinical management will be discussed in the next part: 
Physician’s perspective.
Pathogenesis
The exact pathogenesis of AAV is unknown, but neutrophils are considered to play 
a key role. Due to currently unknown triggers, cytokines are released that stimulate 
priming and accumulation of circulating neutrophils. Potential triggers are infections 
(particularly infections with Staphylococcus aureus)53-55 and silica exposure,56 combined 
with a genetic predisposition.57-59 After neutrophil priming, PR3 and MPO are exposed 
on the neutrophil cell membrane, where they become accessible to ANCA produced by 
B-cells. When ANCA bind to their specific antigens, the neutrophil becomes activated 
and degranulates leading to the production of reactive oxygen species and release of 
proteolytic enzymes. Neutrophils that are activated by ANCA can also directly interact 
with endothelial cells through β2-integrin and other adhesion molecules expressed by 
activated endothelial cells. Both mechanisms are cytotoxic for the endothelial cells.60 
In addition, neutrophils release factors that activate the alternative pathway of the 
complement system. This pathway generates C5a, which recruits and primes more 
neutrophils.61-66 The role of the complement system was long underestimated, probably 
because of the characteristic pauci-immune immunofluorescence pattern seen in renal 
biopsies of AAGN. The importance of the complement system is supported by the 
presence of activation components of the alternative pathway in plasma and tissue of 
AAV patients.61,62,65,66
These different processes, which occur simultaneously, amplify the inflammatory 
process resulting in acute necrotic injury to blood vessel walls. There is evidence that 
during this inflammatory process neutrophil extracellular traps (NETs) are formed 
through NETosis. NETosis is a specific form of cell death, which is characterized 
by the release of decondensed chromatin threads containing cytoplasmic proteins 
including PR3 and MPO. NETs have been demonstrated to have a beneficial role in the 
defense against infections, but have also been implicated in autoimmune diseases, in 
which they trigger and promote a vasculitic response by presenting PR3 and MPO in 
their decondensed chromatin threads (figure 2 and 3).67,68 In addition, abnormalities 
in cellular immunity seem to play an important role in the pathogenesis of AAV 
demonstrated by evidence of altered T cell characteristics with an increase in activated 
and memory T cells. The homeostasis of CD4+ T cells seems disturbed in AAV patients 
with an amplification of the auto-immune response due to activated CD4+ cells.69-72
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Figure 2 | Current hypothesized pathogenesis of ANCA-associated vasculitis. 
A trigger activates the release of cytokines, which stimulate priming and accumulation of 
circulating neutrophils. PR3 and MPO are exposed on the neutrophil, making them accessible 
to ANCA produced by B-cells. ANCA binding to the exposed antigens activate the neutrophil: 
release of proteolytic enzymes, interaction with endothelial cells, activate alternative pathway of 
the complement system. The processes amplify the infl ammatory process resulting in vasculitis. 
In addition, NETs are formed by neutrophil cell death (NETosis), which promote the vasculitic 
infl ammation process. ANCA, Antineutrophil cytoplasmic autoantibody; PR3, proteinase 3; MPO, 
myeloperoxidase; NET, neutrophil extracellular traps. Reproduced from Jennette et al. (Nat Rev 
Rheumatol 2014;10:463-473) with permission.
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Figure 3 | Current hypothesized pathogenesis of ANCA-associated vasculitis focusing more on 
complement system acitvation. 
Activated neutrophils stimulate the complement system, i.e. alternative pathway. C5a is produced 
which recruits and primes more neutrophils. NETs are formed by NETosis of neutrophils. This is 
an amplifying process resulting in vasculitis. ANCA, Antineutrophil cytoplasmic autoantibody; 
PR3, proteinase 3; MPO, myeloperoxidase; NET, neutrophil extracellular traps; TF, Tissue Factor. 
Reproduced from Chen et al. (Nat Rev Nephrol 2017;13:359-367) with permission.
ANCA and other autoantibodies
MPO-ANCA and PR3-ANCA are defi ning features of AAV. Their presence is used 
to establish the diagnosis of AAV and there is increasing evidence that they play an 
important role in its pathogenesis.73 Low levels of circulating MPO-ANCA and PR3-
ANCA have been detected in healthy individuals and it has been demonstrated 
that epitope specifi city of MPO-ANCA differs between AAV patients and healthy 
individuals.74,75 Varying epitope-specifi city of ANCA will infl uence their effects and 
their potential for pathogenicity.
ANCA can be detected in patient sera by IIF and ELISA. The cytoplasmic ANCA (cANCA) 
pattern seen on IIF is associated with the presence of PR3-ANCA, while the perinuclear 
ANCA (pANCA) pattern is associated with MPO-ANCA.2-6,76 Up to approximately 10% 
of patients with AAV are currently ANCA-negative using these techniques.7-12 Roth et 
al., however, detected MPO-ANCA in 14/21 patients that were tested ANCA-negative 
with standard detection techniques, using purifi ed IgG in a highly sensitive epitope 
excision/mass spectrometry approach. They demonstrated that serum ceruloplasmin 
masked the detection of the ANCA-epitope in these patients, resulting in negative 
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results on routine assays. Through purification of IgG, ceruloplasmin was eliminated 
from the assay allowing detection of MPO-ANCA. MPO-ANCAs against this specific, 
covered epitope were shown to have pathogenic properties: they were capable to 
activate neutrophils in vitro and to induce nephritis in mice.75
Although ANCA seem to play a role in the pathogenesis of AAV, a correlation between 
the titer of these antibodies and the level of disease activity or the prediction of a 
relapse by a rise of the titer, is not yet shown convincingly. A meta-analysis described 
that a rise in—or persistence of—ANCA has modest predictive value for future disease 
relapse in AAV patients. Therefore, the isolated use of serial ANCA measurements is 
insufficient for therapeutic decision-making.77
Currently described factors that influence the detection of ANCA and the assessment of 
their pathogenicity are epitope specificity, masking of (pathogenic) epitopes, modified 
antigens and technical limitations of current assays. The International Consensus 
Statement on Testing and Reporting ANCA advocated to screen for the presence of 
ANCA with IIF and confirm positive results on IIF with PR3-ANCA and MPO-ANCA 
specific ELISA.78,79 Current clinical practice often consists of making a presumptive 
diagnosis of AAV based on the clinical presentation, ANCA positivity with ELISA and 
a low suspicion for another disease, with obtaining a biopsy as soon as possible to 
confirm the diagnosis. A recent study showed a large variability between different 
IIF methods and a high diagnostic performance of PR3-ANCA and MPO-ANCA by 
ELISA. Therefore, the use of both IIF and ELISA testing of each sample is not deemed 
necessary anymore for maximal diagnostic accuracy.80 Different immunoassays have 
been developed for the detection of ANCA to improve their performance. Although 
these assays at the moment do not replace current methodologies, future research 
may change this.81
In addition to classical ANCA, the presence of other autoantibodies has also been 
reported in AAV. Recently, studies described the presence of anti-plasminogen 
autoantibodies (α-PLG) in 22%-43% of PR3-AAV and 6%-27% of MPO-AAV patients 
in different cohorts.82-84 The presence of these antibodies disturbs the conversion of 
plasminogen into plasmin, thereby inhibiting fibrinolysis.82,83 These antibodies were 
associated with a susceptibility for thrombosis in PR3-ANCA patients with 56% (5/9) 
of the PR3-AAV patients with a thrombotic event being α-PLG positive compared to 
9% (5/57) of randomly selected disease controls with idiopathic thrombosis.82 Their 
presence was also associated with significantly more (cellular) crescents and fibrinoid 
necrosis in renal biopsies accompanied by a worse renal function at diagnosis and 
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during follow-up.83 The assays used in the different studies to detect α-PLG were, 
however, not clearly defined and showed some differences between each other. 
Therefore, we investigated different ELISA set-ups for detecting α-PLG in order to 
optimize the assay and present an assay to promote uniform reporting. Chapter 2 
presents an optimized ELISA and validates the presence of α-PLG in AAV using this 
new assay.
A few years ago, an unexpected finding introduced a new theory: in patients with 
AAV harboring PR3-ANCA, the presence of antibodies against complementary PR3 
(cPR3, the peptide translated from the antisense DNA strand) was detected. These 
antibodies had an idiotypic relationship with antibodies against PR3. Immunizing 
mice with cPR3 resulted not only in the production of antibodies against cPR3, but 
also against PR3. In several microorganisms, such as Staphylococcus aureus, genetic 
sequences were identified with similarities to the antisense DNA of PR3. These 
genetic sequences encode proteins of Staphylococcus aureus that resemble human 
cPR3. When antibodies are made against the amino acid sequence of the epitope of 
Staphylococcus aureus, these antibodies will also bind to cPR3. This phenomenon is 
referred to as molecular mimicry. The concept of molecular mimicry is a theoretically 
important concept in thinking on the etiology of autoimmune diseases. Above findings 
led to the hypothesis that a foreign protein homologous to cPR3 could elicit an immune 
response by inducing the formation of antibodies. These antibodies would then cross-
react with cPR3 and elicit an anti-antibody response causing the formation of anti-
idiotypic antibodies. Following this hypothesis, the anti-idiotypic antibodies are the 
actual ANCA and are reactive against the PR3-antigen and in this way could cause 
AAV.85,86 Interestingly, dual reactivity to cPR3 and plasminogen due to a homologue 
amino acid sequence has been described in PR3-AAV.82
Kain et al. described the presence of another type of autoantibodies, namely against 
human lysosomal-associated membrane protein-2 (hLAMP-2) in approximately 
80-95% of European patients presenting with AAGN with or without other systemic 
manifestations of AAV.87-89 hLAMP-2 is a protein integrated in the membranes of 
intracellular vesicles of neutrophils that also contain MPO and PR3. In contrast to 
MPO and PR3, this protein shuttles between lysosomes, endosomes and the cell 
membrane.90 The availability of hLAMP-2 on the surface of neutrophils or endothelial 
cells is abundant and hLAMP-2 is therefore directly accessible to circulating antibodies. 
Antibodies directed against hLAMP-2 have been detected in PR3-ANCA, MPO-ANCA 
and ANCA-negative patients. In vitro, anti-hLAMP-2 antibodies activate neutrophils 
and directly kill microvascular endothelial cells. When 15 Wistar Kyoto (WKY) rats 
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were intravenously injected with hLAMP-2 specific rabbit immunoglobulin G (IgG), 
which cross-reacts with rat LAMP-2, these rats developed hematuria, proteinuria, 
renal leukocyte infiltration, focal capillary necrosis and glomerular crescents. These 
anti-hLAMP-2 antibodies seem to be directed against 2 major epitopes, of which one 
shows homology with an amino acid sequence of mature FimH. FimH is a bacterial 
adhesin located at the tip of type 1 fimbriae that is crucial for attachment of Gram-
negative pathogens, like Escherichia coli, to host epithelia. Due to this molecular 
mimicry - resembling amino acid sequence - between the epitopes of hLAMP-2 and 
FimH, an infection with Escherichia coli could theoretically cause the production of 
antibodies that also react with hLAMP-2. Injection of 10 WKY rats with recombinant 
FimH fusion protein resulted in antibodies to rat LAMP-2 and pauci-immune necrotizing 
glomerulonephritis similar to human disease in nine of them. Of the patients who 
tested positive for anti-hLAMP-2 autoantibodies, circa 70% turned out to have had an 
infection with FimH-expressing bacteria during the 12 weeks before presenting with 
AAGN.87 After initializing immunosuppressive therapy, hLAMP-2 autoantibody titers 
became undetectable. During clinical relapse the autoantibodies became detectable 
again.89 These findings suggest a pathogenicity of this novel ANCA. However, to date, 
the presence of anti-hLAMP-2 autoantibodies in patients with AAGN has not been 
confirmed by other research groups.91
Animal models
The first animal model in AAV was described in 2002 and was a MPO-AAV mouse 
model. They developed hematuria and proteinuria, and the kidneys showed 
comparable histopathologic lesions as seen in human AAGN.92 Hereafter, a rat model 
was developed for MPO-AAV in which rats were immunized with human MPO and 
developed anti-human MPO-ANCA. These rats develop a disease similar to AAV.93
A PR3-AAV animal model is still lacking. The antibody transfer techniques used in the 
MPO-ANCA models were unsuccessful for PR3-ANCA.94 In 2012, Little et al. published 
on a mouse model with a human immune system. This model has great potential, but 
also some limitations such as the chimeric nature of the immune response (human 
immune system in a mouse), and the model is technically challenging and expensive.95
Genetics
Evidence for an important role of genetics in the pathogenesis of AAV is growing.96-98 
A genome-wide association study in 2012 demonstrated several important genes that 
also made a distinction between ANCA serotypes.58 A meta-analysis identified 33 
genetic variants associated with AAV and confirmed the stronger genetic basis of 
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subdivisions based on ANCA-specificity compared to clinical diagnosis. Identified 
genes encode alpha-1-antitrypsin, are part of the major histocompatibility complex 
system or are involved in different distinct inflammatory processes.59
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The last perspective that will be introduced here is the physician’s perspective. In 
this section, the focus is on the treatment options for AAV and disease relapse. The 
treatment of AAV is challenging and much research is performed to optimize treatment. 
One of the challenges in particular is disease relapse. Chapter 6 of this thesis is a 
clinical review giving an overview of the diagnosis and management of AAV for general 
practitioners.
Diagnosis of AAV and renal histopathology
Current practice is to make a presumptive diagnosis of AAV based on the clinical 
presentation, ANCA positivity with ELISA and a low suspicion for another disease, with 
obtaining a biopsy as soon as possible to confirm the diagnosis. The gold standard for 
establishing a diagnosis of renal involvement in AAV is a renal biopsy. Light microscopy 
shows necrotizing and crescentic glomerulonephritis. Immunofluorescence microscopy 
shows a pauci-immune pattern, which means a negative or subdued granular pattern 
for immunoglobulins and complement.23,30,31,99 Renal histology of patients from 
the CYCAZAREM, MEPEX and RITUXVAS trials was evaluated with regard to renal 
outcome. These studies showed that, in addition to baseline renal function, also the 
amount of active (cellular crescents, fibrinoid necrosis and tubulitis) and chronic renal 
lesions (glomerulosclerosis, tubular atrophy and interstitial fibrosis) were associated 
with renal outcome. Chronic lesions and tubulitis were associated with adverse renal 
outcome, while cellular crescents and fibrinoid necrosis were associated with recovery 
of renal function. In addition, the percentage of normal glomeruli is strongly associated 
with renal outcome; a higher percentage of normal glomeruli at diagnosis is associated 
with a better renal function and dialysis-independency at one-year follow-up.100-102 
Based on these findings, Berden et al. proposed a histopathological classification of 
AAGN based on glomerular pathology as assessed by light microscopy (figure 4). This 
classification is based on four categories: focal, crescentic, sclerotic, and mixed class. 
Depending on the predominant glomerular phenotype, each renal biopsy with AAGN 
can be classified into one of these four classes. If the biopsy contains ≥50% normal 
glomeruli (not affected by the disease process), it will be classified as focal class; with 
≥50% cellular crescentic glomeruli as crescentic class; and with ≥50% globally sclerotic 
glomeruli as sclerotic class. The mixed class includes biopsies wherein no glomerular 
feature predominates and all aforementioned glomerular phenotypes are present in 
varying degrees. Tubulointerstitial lesions are not included in the classification. This 
classification was shown to be associated with one- and five-year renal function and 
development of ESRF.103 Validation studies and a meta-analysis confirmed the good 
prognosis for focal class and a bad prognosis for sclerotic class. In addition, these 
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studies showed a contradiction regarding the prognosis of crescentic and mixed 
class.104 Due to this contradiction and the national characters of these validation 
studies, a large international validation study consisting of a worldwide cohort was 
called for. In addition to this, not much is known about the interobserver variability 
regarding this classifi cation. Chapter 4 describes a large international validation 
study with a worldwide cohort which also analyzed the interobserver variability of the 
histopathological classifi cation of AAGN.
Figure 4 | Histopathologic classifi cation of ANCA-associated glomerulonephritis. 
This classifi cation classifi es each renal biopsy with AAGN into a class based on the predominant 
glomerular phenotype. AAGN, ANCA-associated glomerulonephritis. Reproduced from Berden et 
al. (J Am Soc Nephrol 2010;21:1628-1636) with permission.
Renal involvement in AAV (ANCA-associated glomerulonephritis)
Some patients present with ESRF due to AAGN and others develop it during follow-up 
despite treatment. Approximately 80% of patients with GPA and 90% of patients with 
MPA develop kidney involvement during the disease course.23 AAGN progresses to 
ESRF requiring renal replacement therapy in approximately 20-40% of patients.105-108 
Data on outcome after renal transplantation in AAGN are based on relatively small 
cohorts. Reported one year graft survival rates are 86-100% and fi ve year graft survival 
rates are 69-100%. Relapse rates ranged from 1.0-2.0% per patient year of follow-
up.109-113 Due to the small cohort studies a large cohort study was needed. In addition, 
data focusing on the impact of renal disease recurrence in the graft was lacking. 
Therefore, we performed a national study on the outcome of renal transplantation in 
a Dutch cohort of AAGN patients with special focus on the impact of renal disease 
recurrence on graft survival. This study is described in chapter 5 of this thesis.




Currently, standard treatment consists of inducing remission with high dose 
glucocorticoids and high dose oral or intravenous pulse cyclophosphamide or 
rituximab for three to six months, followed by maintenance therapy with azathioprine 
or methotrexate while glucocorticoids are slowly reduced and withdrawn.10,33 In case 
of severe or life-threatening vasculitic disease, intravenous methylprednisolone or 
plasma exchange can be added to induction therapy.11,35 Initially, patients were treated 
with cyclophosphamide for a longer period.22,53,114,115 In mild AAV (serum creatinine 
<150 µmol/L and no critical organ manifestations) methotrexate can substitute 
cyclophosphamide in the induction regimen, but immunosuppressive therapy should 
not be stopped at 12 months, because of the higher chance for a relapse.8 Azathioprine 
can be substituted by methotrexate as maintenance therapy in AAV patients with a 
creatinine <150 µmol/L.33,116
In patients with generalized AAV, cyclophosphamide can be substituted with 
azathioprine as remission maintenance therapy. This has no negative effect on 
disease relapse or severe adverse events.10 This could decrease the toxic effect of 
cyclophosphamide. However, a long-term follow-up study (median follow-up of 
8.5 years) showed that it remains uncertain whether it is beneficial to convert to 
azathioprine after three to six months of induction cyclophosphamide therapy instead 
of converting after 12 months, because on the long term there was no difference 
in the risk of relapse, end-stage renal failure (ESRF), developing malignancies and 
death.117 In addition, intravenous pulse cyclophosphamide showed to cause lower 
cumulative cyclophosphamide dose compared to daily oral cyclophosphamide. This 
did not affect the remission rate at 18 months or adverse events with less leucopenia 
or mortality in case of pulse cyclophosphamide.7,118 However, on the long term, 
pulse cyclophosphamide showed to have a higher relapse rate compared to the daily 
cyclophosphamide with no difference in mortality, morbidity or adverse events.119
In case of severe renal involvement (serum creatinine >500 µmol/L or dialysis 
dependency at diagnosis), plasma exchange is superior to intravenous 
methylprednisolone as adjunctive therapy regarding dialysis-independency at three 
months and progression to ESRF at one year. There was no difference in patient survival 
and adverse events at one year.11 The long-term follow-up study (four years median 
follow-up) showed no difference between both groups regarding developing ESRF or 
death.120 The benefit of routine use of plasma exchange or use in case of specific organ 
manifestations (e.g. severe renal dysfunction, lung hemorrhage) remains unclear.121
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Mycophenolate mofetil (MMF) showed to have comparable remission induction (at six 
months) and infection rates as cyclophosphamide, but with a higher relapse rate.122 
MMF is a less potent drug than azathioprine for maintenance therapy in AAV patients 
with renal involvement.9
Refractory disease and relapse
Refractory disease with current therapy modalities and disease relapse are challenges 
in the treatment of AAV. It would be helpful if we can identify patients on forehand who 
have a higher risk for a (renal) relapse so that the clinical management can be adapted 
to it. Therefore, studies on risk factors and predictors of (renal) relapse are needed for 
optimizing clinical management. Chapter 3 of this thesis investigates risk factors and 
predictors for renal relapse. It is important to balance the risk of disease relapse and 
the risk of treatment related adverse effects, and identifying risk factors helps with 
balancing between these two.123,124
Due to the high relapse rates, despite treatment with immunosuppressive drugs, 
new treatment modalities are continuously being developed. One of the drugs under 
investigation is rituximab, a monoclonal antibody directed against CD20. Rituximab 
induces B cell depletion in peripheral blood, that is sustained for approximately 6-18 
months, without affecting the plasma cell population.125 In 2010, the RITUXVAS 
(newly diagnosed AAV with renal involvement; median glomerular filtration rate: 
12-20 ml/min/1.73 m2; interquartile range 5-44 ml/min/1.73 m2) and RAVE trials 
(newly or relapsing severe AAV) compared rituximab with cyclophosphamide for 
remission induction. Noteworthy, patients in the RITUXVAS trial receiving rituximab 
also received two intravenous cyclophosphamide pulses. The rituximab group in the 
RAVE trial received placebo instead of azathioprine as maintenance therapy. There was 
no difference in remission induction and adverse events in patients with severe AAV. 
Rituximab showed superiority in treating patients with relapsing disease,12,34 and is 
also the preferred agent for refractory disease.126 At two year follow-up of RITUXVAS 
patients there was no difference regarding death, ESRF and relapse.127 In another 
cohort the risk for malignancy was lower in patients treated with rituximab compared 
to cyclophosphamide.128
Rituximab was also compared with azathioprine as maintenance therapy in the 
MAINRITSAN trial in newly diagnosed and relapsing AAV. Patients receiving rituximab 
as maintenance therapy had more sustained disease remission (BVAS of zero) at 28 
months compared to patients receiving azathioprine, especially in the case of PR3-
ANCA specificity. There was no difference in severe adverse events.129 Currently a new 
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trial (RITAZAREM, ClinicalTrials.gov Identifier: NCT01697267) compares rituximab 
with azathioprine as maintenance therapy after induction therapy in patients with 
disease relapse.
There is ongoing debate on the optimal duration of maintenance treatment. Current 
guidelines suggest at least 24 months to prevent disease relapse. Therefore, the 
REMAIN study compared relapse rates following 24 or 48 months of conventional 
remission maintenance therapy. This study showed that 48 months of maintenance 
therapy (azathioprine and prednisolone) had less relapses and an improved renal 
survival at 48 months compared to 24 months maintenance therapy. There was no 
difference in the incidence or severity of adverse events or patient survival between 
both groups.130 Currently, there is still controversy about the duration of glucocorticoids 
use. It differs among trials and also among local practices at what rate corticosteroids 
are tapered and when they are completely stopped. A meta-analysis showed that longer 
courses of glucocorticoids are associated with fewer relapses.124 On the contrary, this 
is also associated with many side-effects.131-133 A randomized trial on a C5a receptor 
inhibitor (avacopan) showed that it was an effective treatment in replacing high-dose 
glucocorticoids in treating AAV patients with newly diagnosed or relapsing disease.134
Ongoing trials worth mentioning are PEXIVAS and CLASSIC. PEXIVAS (ClinicalTrials.
gov Identifier: NCT00987389) is a double trial in which the role for adjuvant plasma 
exchange is investigated further and, in addition, low dose glucocorticoids are 
compared with standard dose glucocorticoids.135 The CLASSIC (ClinicalTrials.gov 
identifier: NCT02222155) trials investigate the use of an oral C5a inhibitor (CCX168) 
as a novel induction approach.




Chapter 2 presents an optimized ELISA for the detection of α-PLG. With this new 
assay, we validated the presence of α-PLG in AAV.
Chapter 3 is a clinicopathologic study using biopsies from the CYCAZAREM and 
MEPEX trial. It investigates risk factors and predictors for renal relapse using two 
different statistical methods. This study has a special focus on the histopathologic 
classification of AAGN.
Chapter 4 is a worldwide validation study of the histopathologic classification of AAGN 
which also investigated the interobserver variability of the classification.
Chapter 5 describes the outcome of renal transplantation in a Dutch cohort of AAGN 
patients, focusing on renal disease recurrence and graft survival rates within five years 
of transplantation. The focus of the study was the impact of disease recurrence in the 
allograft on graft survival.
Chapter 6 of this thesis gives an overview of the clinical presentation, diagnosis and 
management of AAV.
Chapter 7 gives a summary of the results in this thesis and discusses them.
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Introduction: Anti-plasminogen antibodies (α-PLG) were previously detected in a 
subpopulation of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) patients, showing a relation to renal lesions and outcome. Several studies showed 
different proportions of α-PLG positive AAV patients, possibly due to differences in 
the assays used. We here present a new, optimized α-PLG Enzyme-Linked Immuno 
Sorbent Assay (ELISA) and validate the presence of α-PLG in AAV.
Methods: Different ELISA set-ups were tested regarding plasminogen (PLG) antigen, 
concentrations, coating buffers, blocking agents, and environmental conditions.
Results: Purified lysine-PLG (lys-PLG) showed better differentiation between positive 
samples and negative samples than glutamic acid-PLG (glu-PLG). Therefore, lys-PLG 
was used as coating antigen. With the optimized α-PLG ELISA we found α-PLG in 
14.3% of the myeloperoxidase (MPO)-ANCA patients, whereas all our proteinase-3 
(PR3)-ANCA patients tested in our new assay were negative.
Conclusions: Concluding, in this study we have combined important technical findings 
and methods from previous studies to optimize the α-PLG assay, which can be used for 
future research purposes and will aid in uniform reporting of α-PLG status of patients.
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INTRODUCTION
Recently, the presence of anti-plasminogen antibodies (α-PLG) in patients with anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) received much 
attention, especially in relation to the nature and severity of renal lesions.1–3 These 
antibodies inhibit fi brinolysis by disturbing the conversion of plasminogen (PLG) 
to plasmin.1,2 A study on patients with AAV showed that patients with α-PLG had 
signifi cantly more glomerular fi brinoid necrosis accompanied by worse renal function.2 
Evidently, the presence of α-PLG in AAV may be an important hallmark for a specifi c 
phenotype of the disease.2,3 Three important studies on α-PLG in AAV reported 
differences in the proportion of α-PLG positive AAV patients ranging between 22%-
43% for proteinase-3 (PR3)-AAV and 6%-27% for myeloperoxidase (MPO)-AAV.1–3 
It is possible that differences in α-PLG assays were to some extent responsible for 
these discrepant results. We therefore optimized the method for α-PLG Enzyme-Linked 
Immuno Sorbent Assay (ELISA) and with this new assay, we validated the presence 
of α-PLG in AAV.
METHODS
Positive controls
Eleven positive controls were derived from the studies of Bautz et al. and Berden 
et al.1,2 These positive samples consisted of serum or plasma exchange (PEX) fl uid. 
These patients had the following ANCA-specifi cities: 5 MPO-ANCA, 5 PR3-ANCA 
and 1 ANCA negative. These were detected with WIESLAB® MPO-ANCA / MPO IU, 
WIESLAB® Capture MPO-ANCA / CAP MPO IU, WIESLAB® PR3-ANCA / PR3 IU and 
WIESLAB® Capture PR3-ANCA / CAP PR3 IU (Euro Diagnostica, Malmö, Sweden). 
Patients had been diagnosed with AAV according to the 2012 revised International 
Chapel Hill Consensus Conference Nomenclature of Vasculitides.4
Healthy and disease controls
Samples from 220 healthy controls were used during the different steps for optimizing 
the assay. Samples of 157 disease controls were used. Of these samples 77 were anti-
beta-2 glycoprotein 1 (β2GP1) positive, which is an autoantibody found in systemic 
lupus erythematosus and anti-phospholipid syndrome.5 The remaining 80 samples 
were positive for anti-cyclic citrullinated peptides (CCP), which is an autoantibody 
found in rheumatoid arthritis.6 Samples from healthy and disease controls were 
collected at Euro Diagnostica, Malmö, Sweden.




For setting-up and optimizing the α-PLG assay 104 randomly selected samples of 
patients with ANCA positivity were used. Samples were not selected with respect to 
disease state. Of these samples 55 were PR3-ANCA positive and 49 were MPO-ANCA 
positive. These samples were collected at Euro Diagnostica, Malmö, Sweden. ANCA 
specificity of each patient was determined using WIESLAB® MPO-ANCA / MPO IU, 
WIESLAB® Capture MPO-ANCA / CAP MPO IU, WIESLAB® PR3-ANCA / PR3 IU and 
WIESLAB® Capture PR3-ANCA / CAP PR3 IU (Euro Diagnostica, Malmö, Sweden). 
The use of the samples in this study was approved by the Lund University ethics 
committee. All patients gave written informed consent to store samples for future 
development of analytical methods for the purpose of hospital care and treatment or 
similar activity. This study was conducted in accordance with the 1964 Declaration of 
Helsinki and subsequent amendments. This study was also performed according to the 
‘Netherlands Code of Conduct for Scientific Practice’, an ethical code for performing 
observational studies with patient material approved by the Federatie van Medisch 
Wetenschappelijke Verenigingen (Federation of Medical Scientific Organisations) 
together with the legal and ethical committee of the Koninklijke Nederlandse Akademie 
van Wetenschappen (Royal Dutch Academy of Science) and the Nederlandse 
Organisatie voor Wetenschappelijk Onderzoek (Dutch Organisation for Scientific 
Research). The data of the patients were analyzed anonymously.
Anti-plasminogen antibody assay
For developing an α-PLG assay we optimized each step in the assay by testing different 
alternatives for each step. These steps and their alternatives were:
· Coating material: glutamic acid plasminogen (glu-PLG), purified glu-PLG,  
 lysine-plasminogen (lys-PLG) or purified lys-PLG obtained from Calbiochem 
 and from Haematologic Technologies. Contaminating Immunoglobulin G (IgG) 
 was removed from commercially obtained PLG by affinity chromatography on 
 a Protein G HP SpinTrap column from GE Technologies using as binding buffer 
 0.01 phosphate, 0.15 M NaCl, 0.01 M EDTA pH 7.0.
· Coating buffer: 0,05 M Sodium Carbonate pH 9.5 or PBS.
· Blocking buffer: PBS with BSA 1%, gelatin 1% or Stabilcoat (Surmodics).
· Diluent: PBS with 0,05% Tween 20 and 2g/l BSA. Different serum dilutions 
 (1:50, 1:100, 1:200, 1:400) and purified IgG from the serum samples were 
 tested as primary antibodies.
· Wash: 0,15M NaCl with 0,05% Tween 20.
Box 1 | Anti-plasminogen antibody ELISA assay
High binding microtiter plates were coated overnight with 3 µg/ml protein G 
purifi ed lysine-plasminogen at room temperature. Carbonate buffer pH 9,6 was 
used as coating buffer. Plates were blocked for 60 minutes with 1% BSA in PBS at 
room temperature. After washing with PBS-Tween, serum and PEX fl uid at 1/100 
dilution were added in duplicates into appropriate microtiter wells and incubated 
at 37°C for 60 minutes. Wells were washed and incubated (30 minutes at 37°C) 
with a 1:5000 dilution of Sigma goat anti-human IgG-alkaline phosphatase. After 
washing, 4-nitrophenyl phosphate was used as the substrate at room temperature, 
and the 96-well microtiter plate was analyzed spectrophotometrically at 405 nm 
after 30 minutes.
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· Conjugated secondary antibodies: Sigma goat anti-human IgG HRP, Sigma 
 goat anti-human IgG AP or Dako rabbit anti-human IgG HRP.
· Conjugate buffer: PBS with 0,05% Tween 20, 2g/l BSA and 1g/l bovine IgG.
· Substrate: para-Nitrophenylphosphate.
We tested different suppliers of antigen, different temperatures (room temperature 
and 37°C) and different time frames (30, 60 and 120 minutes) for each step. Box 1 
describes the optimized assay.
IgG purifi cation from serum or PEX fl uid
IgG was purifi ed from the sera or PEX fl uid using the Melon Gel IgG Purifi cation Kit 
(Pierce Protein Research Products; Thermo Scientifi c). SDS-PAGE was used to confi rm 
the integrity of isolated IgG and Coomassie blue staining was used to visualize isolated 
IgG.
Testing different anti-human IgG conjugates
We tested different conjugates in varying concentrations to obtain the best signal of 
bound α-PLG on the plate coated with PLG. The conjugates tested were: Sigma goat 
anti-human IgG HRP 1/10000 and 1/20000, Sigma goat anti-human IgG AP 1/5000 
and 1/10000, Dako rabbit anti-human IgG HRP 1/30000 and 1/50000.
Glu-plasminogen inhibition assays
Two inhibition assays were performed:
1. Glu-PLG 2 µg/ml was coated and incubated with strong positive control serum 
 1/200, healthy control serum 1/200 or Sigma goat anti-human IgG AP 
 1/10000. The sera were mixed with an increasing amount of soluble PLG (0-
 10µg/ml) and the conjugate was mixed with an increasing amount of human 
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 IgG (0-10 µg/ml) for inhibition.
2. Soluble glu-PLG for inhibition (0-10 µg/ml) was pre-incubated overnight with 
 polyclonal rabbit antibodies (α-PLG and anti-Chromogranin-A (CgA)), human 
 sera (strong positive control and healthy control) or diluent. This was then 
 added to a plate coated with glu-PLG 1 µg/ml. Swein anti-rabbit AP and goat 
 anti-human AP were used for signal detection.
SDS-PAGE and Western blot
SDS-PAGE was performed with four proteins: unreduced glu-PLG, unreduced lys-PLG, 
reduced glu-PLG, reduced lys-PLG. Western blot was performed using rabbit α-PLG 
as specific antibody.
Titration curves plasminogen coating
Plates were coated with glu-PLG, purified glu-PLG, lys-PLG and purified lys-PLG in 
concentrations varying from 0 to 5 µg/ml. Samples from four positive controls and 
four negative controls in dilutions of 1/100 and 1/200 were tested. In addition, rabbit 
α-PLG, rabbit anti-CgA and diluent were tested. We performed the titrations with and 
without BSA block.
Statistical analysis
χ2-test was performed to compare the spectrophotometrical results of purfied 
glu-PLG and purified lys-PLG as coating antigens. A P-value <0.05 was considered 
statistically significant. Based on this, the cut-off value for α-PLG positivity was at the 
97.5th percentile (mean + 2 standard deviation) of the healthy controls. All statistical 
calculations were performed using SPSS (v25.0; IBM Corp, Armonk, NY).
RESULTS
Setting up the anti-plasminogen assay
We started with glu-PLG as antigen, and set up an ELISA using different serum dilutions 
(1:50, 1:100, 1:200, 1:400) and purified IgG from the samples. Results showed 
unspecific binding and therefore IgG was removed from the antigen samples by running 
the PLG antigens through a Protein G affinity column. Most of the background binding 
disappeared and protein G purified PLG was used in all experiments after this.
Unspecific background binding was still present after purification of the antigen and, 
therefore, different set-ups were tested to obtain differentiation between a strong 
positive control and negative controls (i.e. one healthy control and a sample with 
only a saline buffer). Different combinations of coating buffers, blocking agents and 
2
A. Goceroglu - Binnenwerk.indd   49 22-6-2020   13:01:54
49
α-plasminogen antibodies in ANCA-associated vasculitis
diluents were tested. Optimal results distinguishing positive from negative controls 
were obtained with the combination carbonate buffer for coating and blocking with 1% 
BSA. Taking this set-up as baseline, we took further steps to optimize the assay. For the 
anti-human IgG conjugate we compared Sigma goat anti-human IgG HRP, Sigma goat 
anti-human IgG AP, and Dako rabbit anti-human IgG HRP. The Sigma goat anti-human 
IgG AP differentiated best between the positive and negative controls.
Specifi city for glu-plasminogen
Minimal inhibition was obtained in a set-up where human PLG was added as an inhibitor 
to an ELISA with glu-PLG as the epitope, in contrast to a control condition in which 
rabbit α-PLG IgG was inhibited by soluble human PLG. Therefore, SDS-PAGE and 
Western blot were performed to test to which protein structure the α-PLG bind best. 
SDS-PAGE showed the presence of four proteins: unreduced glu-PLG, unreduced 
lys-PLG, reduced glu-PLG, reduced lys-PLG. No other protein was detected. When 
Western blot was performed with rabbit α-PLG, it showed strong binding for the 
unreduced PLG variants and weak binding for the reduced PLG variants (Figure 1). 
This indicates the importance of epitope conformation and this probably is true also 
for humans in vivo, explaining why different forms of the proteins react with different 
patient sera.
                                                                
Figure 1 | SDS-PAGE and Western blot with rabbit anti-plasminogen antibodies.
(A) SDS-PAGE showed the presence of four 4 proteins. (B) Western blot with rabbit anti-
plasminogen antibodies showing strong binding for the unreduced plasminogen variants and weak 
binding for the reduced plasminogen variants.
1, reduced glutamic acid plasminogen; 2, reduced lysine-plasminogen; 3, unreduced glutamic acid 
plasminogen (88 kDa); 4, unreduced lysine-plasminogen (83 kDa). The arrows show the direction 
of movement of the proteins.
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Lys-plasminogen as antigen coating
Lys-PLG had a more saturated titration curve than glu-PLG with maximal saturation 
at lys-PLG 3 µg/ml. An assay with purified glu-PLG coating 2,5 µg/ml, 1/100 diluted 
samples, was performed on 8 positive controls, 22 ANCA samples and 13 healthy 
controls. Of the 8 positive controls, in this assay only two were positive. When 
performing the same assay with purified lys-PLG coating 2,5 µg/ml, the same two 
positive controls were positive, but in addition, there were three positive controls 
which were weakly positive. In both assays, none of the ANCA samples showed α-PLG 
positivity.
Using purified lys-PLG showed more spectrophotometrical differentiation between 
positive samples and negative samples compared to purified glu-PLG. In the case 
of using glu-PLG as coating antigen, the difference was not statistically significant 
(P=0.058). When using lys-PLG, the difference was statistically significant (P=0.001). 
Therefore, the assay was further optimized using lys-PLG as the coating antigen (Figure 
2). We performed several assays with PLG antigens from different suppliers, different 
coating concentrations, serum dilutions and time periods at room temperature and 
at 37°C. All this was done in order to reduce unspecific binding and increase specific 
binding.
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Figure 2 | Spectrophotometrical results.
(A) Spectrophotometrical results using purifi ed glutamic acid plasminogen as an antigen in the 
assay. Optical density was measured with spectrometry using light of 405 nanometer for the 
detection of anti-plasminogen antibodies in the serum samples. (B) Spectrophotometrical results 
using purifi ed lysine-plasminogen as an antigen in the assay. Optical density was measured with 
spectrometry using light of 405 nanometer for the detection of anti-plasminogen antibodies in the 
serum samples. Purifi ed lysine-plasminogen showed more spectrophotometrical differentiation 
between positive samples and negative samples compared to purifi ed glutamic acid plasminogen 
(Figure 2).
Abbreviations: gluPLGp, purifi ed glutamic acid plasminogen; OD, optical density; nm, nanometer; 
lysPLGp, purifi ed lysine-plasminogen.
Testing the current assay
With the current assay (Box 1), we tested a new cohort of samples. This cohort 
consisted of 75 ANCA positive patients (35 MPO-ANCA, 40 PR3-ANCA), 135 disease 
controls (anti- β2GP1 positive [n=55], anti-CCP positive [n=80]), 175 healthy controls, 
11 positive controls (5 MPO-ANCA, 5 PR3-ANCA and 1 ANCA negative) and 1 negative 
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control (healthy control who was negative in all previous tests). The cut-off value for 
α-PLG positivity was 31 U/ml and higher based on the 97.5th percentile of 175 healthy 
controls (Figure 3). Table 1 shows the results.
Figure 3 | Anti-plasminogen antibody concentrations in serum samples from 175 healthy con-
trols.
The cut-off value for anti-plasminogen antibodies positivity was set to 31 U/ml and higher based on 
the 97.5th percentile of the healthy controls.








% α-PLG positive 
patients
MPO-ANCA 5 30 35 14.3
PR3-ANCA 0 40 40 0.0
Anti-β2GP1 11 44 55 20.0
Anti-CCP 10 70 80 12.5
Positive controls 7 4 11 63.6
Negative control 0 1 1 0.0
Abbreviations: α-PLG, anti-plasminogen antibodies; ANCA, anti-neutrophil cytoplasmic antibody; 
MPO, myeloperoxidase; PR3, proteinase-3; anti-β2GP1, anti-beta-2 glycoprotein 1; anti-CCP, anti-
cyclic citrullinated peptides.
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DISCUSSION
We developed an optimized assay for the detection of α-PLG, focusing on its usefulness 
in studies on AAV. We tested different assay set-ups with for example different types of 
PLG antigens and coating buffers. Importantly, we found that purifi ed lys-PLG showed 
better spectrophotometrical differentiation between positive and negative samples 
than glu-PLG when used as a coating antigen (Figure 2).
Using our assay, we found that 14.3% of MPO-ANCA patients tested had α-PLG, 
whereas all our PR3-ANCA patients tested negative. However, α-PLG were detected 
in PR3-ANCA samples from our positive controls. Our results show discrepancies 
with previous studies. Bautz et al. described the presence of α-PLG in 22% (16/72) 
of patients with PR3-AAV and in 6% (2/34) of patients with MPO-AAV. In the PR3-
AAV group, this proportion was signifi cantly higher compared to healthy and disease 
controls. There was no difference between MPO-AAV and the controls.1 Berden et 
al. found α-PLG in approximately 25% of patients with PR3-AAV and with MPO-AAV. 
Both were signifi cantly higher than in healthy and disease controls.2 Hao et al. detected 
α-PLG in 42.8% (3/7) of PR3-AAV patients and in 16.4% (16/97) of MPO-AAV patients. 
The proportion of AAV-patients with α-PLG was signifi cantly higher than in healthy 
controls.3 Although our positive control samples came from the studies of Bautz et al. 
and Berden et al.,1,2 the discrepancy can be explained by the following: in the present 
study we have combined important technical fi ndings/methods from the previous 
studies, which have led to the optimized α-PLG assay here presented. A known 
challenge in the α-PLG assay is the chance for false positive results. We optimized each 
step in the assay by testing different alternatives taking into account the assays used 
in the previous studies on α-PLG in AAV. Therefore, our assay is slightly different from 
the assays used previously, which could partly explain the discrepancy. The ultimate 
experimental set-up investigating what could have caused the discrepancies of the 
studies thus far conducted would entail that the optimized assay developed by us 
would be used on selected patients from the previous studies and in parallel with the 
assays used for these studies. Unfortunately, this set-up lay beyond the scope of the 
current experimental design.
In our assay we used purifi ed PLG proteins as coating antigens. The PLG delivered by 
vendors is purifi ed from blood, which means it can contain trace amounts of IgG. This 
will cause unspecifi c binding in the assay giving high background signals and therefore 
we decided to purify the PLG delivered by the vendor. This could also be a possible 
explanation for the discrepancies of our study with previous studies. Only Hao et al. 
described the purifi cation of the PLG coating protein in their assay, but they did not 
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mention whether they purified it themselves or whether it was assumed to be purified.3 
This could be the most critical confounder that other studies encountered, if a protein 
was purchased and assumed to be purified, but in reality contained considerable 
amounts of contaminating IgG.
Originally, α-PLG were described in view of anti-complementary PR3 antibodies which 
were suggested to develop within an idiotypic antibody response.1,7 This scenario 
assumed a typical combination of PR3-ANCA and α-PLG. With the repetitive finding 
of MPO-AAV patients having α-PLG in the absence of PR3-ANCA antibodies, this 
hypothesis became less likely than previously thought.
In previous studies, Bautz et al. and Hao et al. included diagnostic sera from patients 
with active disease at baseline, which is equal to the time of diagnosis.1,3 In the study by 
Berden et al., a few patients were included who were in clinical remission at baseline.2 
These studies showed data suggesting a transient nature of α-PLG. Be it in only a few 
cases (n=3), Berden et al. did show disappearance of the α-PLG in two patients after 
treatment; however, there was also one patient in remission who remained positive for 
α-PLG.2 In the study by Bautz et al., nine PR3-ANCA positive patients with thrombotic 
events during follow-up were reported, and five of them were positive for α-PLG in 
the presence of active disease, while the others were in remission and were negative 
for α-PLG at the time of the thrombotic event.1 Hao et al. described 48 patients with 
sequential samples of whom 7 were positive for α-PLG during active disease; at 
remission during follow-up only one of the patients remained positive. In fact, Hao et 
al. noted that there was a better association between the levels of α-PLG and disease 
activity compared to ANCA levels and disease activity.3 Therefore, these results 
suggest that α-PLG may be transient in nature. However, no firm conclusions can be 
drawn because of limited available data. The exact biology behind the occurrence and 
disappearance of these antibodies is not known and needs further study. In our study, 
samples were not selected with respect to disease state, since this was beyond the 
scope of our study.
The various studies on α-PLG in AAV had differences in their assays, which could have 
been responsible for the discrepancies in the results.1–3 Different concentrations of 
coating antigen and different conjugated secondary antibodies were used to detect 
antibody-antigen complexes. In order to prevent false positive results, we optimized 
each step in the assay and used purified PLG as coating antigen to prevent background 
and unspecific binding. One assay used sera as samples while others used purified 
IgG with different definitions for positivity. In the previous studies a 97.5th percentile 
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(mean + 2 standard deviation) threshold of healthy controls was used as a cut-off point 
for α-PLG positivity. Hao et al. tested the samples one time.3 Bautz et al. analyzed the 
highest value measured, not mentioning how often a sample was tested.1 Berden et al. 
tested all samples 6 times and considered a patient α-PLG positive when in >50% of 
the occasions the assay was positive.2 In our study samples were tested one time for 
α-PLG positivity. In addition, there was little information in these studies regarding the 
PLG antigen used for coating. Only Hao et al. specifi ed their antigen further describing 
that it was human PLG supplied by Abcam (Cambridge, UK). The product information 
describes that this is a full length natural human PLG protein, so we assume that this 
probably is glu-PLG.3 We demonstrated that using lys-PLG as a coating antigen showed 
better differentiation between negative and positive controls.
An important discussion point regarding α-PLG remains its epitope-specifi city. Also 
in the fi eld of ANCA-specifi city this still is an ongoing discussion. It is thought that 
varying epitope-specifi city of ANCA will infl uence their physiological effects and their 
potential for pathogenicity. Currently described factors that infl uence the detection of 
ANCA and the assessment of their pathogenicity are epitope specifi city, masking of 
(pathogenic) epitopes, modifi ed antigens and technical limitations of current assays.8–10 
Several epitopes relevant for PR3-ANCA AAV and MPO-ANCA AAV are described in the 
literature. These are linear and conformational epitopes. Especially, the conformational 
epitopes form a major problem for diagnostic purposes and pathogenic studies.8–10 
Similar issues will form a challenge in future research for α-PLG. Of the previous studies 
on α-PLG in AAV, only Bautz et al. described the target epitope of the detected α-PLG, 
which was also found on complementary PR3 as discussed previously.1 Glu-PLG and 
lys-PLG are biologically correlated; removing the PAp domain - which consists of 
several amino acids - changes glu-PLG into lys-PLG.11 In the activation process, glu-
PLG and lys-PLG are both open conformations, which are distinct from each other.12 
Open conformation glu-PLG and open conformation lys-PLG can both be converted 
to plasmin by tPA or uPA. Glu-PLG can fi rst be converted into lys-PLG and then into 
plasmin or glu-PLG can directly be converted into plasmin. Unfortunately, little is 
known about the exact mechanism of conformational changes of PLG in its different 
states.13 Reactivity to each conformational state may be important in different ways 
biologically and must be further investigated for their pathogenic characteristics and 
potential diagnostic purposes.
In the present study we have combined important technical fi ndings/methods from 
previous studies which have led to the optimized α-PLG assay here presented. Until 
now, there were many uncertainties and differences in the setup and results of hitherto 
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used assays. Our optimized assay can be used for future research purposes and will 
aid in uniform reporting on α-PLG, opening the way to further explore their relevance 
in AAV.
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Introduction: Relapse in ANCA-associated vasculitis (AAV) has been studied 
previously, but there are few studies on renal relapse in particular. Identifying patients 
at high risk of renal relapse may aid in optimizing clinical management. We investigated 
which clinical and histological parameters are risk factors for renal relapse in ANCA-
associated glomerulonephritis (AAGN).
Methods: Patients (n = 174) were newly diagnosed and had mild–moderate or severe 
renal involvement. Data were derived from two trials of the European Vasculitis Society: 
MEPEX and CYCAZAREM. The Cox regression model was used to identify parameters 
increasing the instantaneous risk (= rate) of renal relapse (useful for instant clinical 
decisions). For identifying predictors of renal relapse during follow-up, we used Fine 
& Gray’s regression model. Competing events were end-stage renal failure and death.
Results: The cumulative incidence of renal relapse at 5 years was 9.5% (95% CI: 4.8-
14.3%). In the Cox model, sclerotic class AAGN increased the instantaneous risk of 
renal relapse. In Fine & Gray’s model, the absence of interstitial infiltrates at diagnosis 
was predictive for renal relapse.
Conclusions: In this study we used two different models to identify possible 
relationships between clinical and histopathological parameters at time of diagnosis 
of AAV with the risk of experiencing renal relapse. Sclerotic class AAGN increased 
the instantaneous risk of renal relapse. This association is most likely due to the high 
proportion of sclerosed glomeruli reducing the compensatory capacity. The absence 
of interstitial infiltrates increased the risk of renal relapse which is a warning sign that 
patients with a relatively benign onset of disease may also be prone to renal relapse. 
Renal relapses occurring in patients with sclerotic class AAGN and renal relapses 
occurring in patients without interstitial infiltrates were mutually exclusive, which may 
indicate that they are essentially different.
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INTRODUCTION
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the 
major subtypes of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV). Approximately 80% of patients with GPA and 90% with MPA develop kidney 
involvement during the disease course.1 ANCA-associated glomerulonephritis (AAGN) 
progresses to end-stage renal failure (ESRF) in approximately 20–40% of patients.2–5 
The gold standard for establishing AAGN is a renal biopsy, which typically shows a 
pauci-immune necrotizing crescentic glomerulonephritis,6,7 which can be grouped into 
four classes.8 Relapse in ANCA-associated vasculitis has been studied previously, but 
there are few studies on renal relapse in particular. It is important to fi nd a balance 
between the risk of relapse and the risk of treatment-related adverse effects.
Identifying patients at high risk of renal relapse may aid in optimizing clinical 
management. Previous relevant studies mainly focused on relapse in general with 
clinical data,2,5,9–19 identifying proteinase 3 (PR3)-ANCA, GPA, lung or cardiovascular 
involvement, and better renal function at presentation as associated with relapse 
in general.2,10–14,16,17,19 Note that different statistical analyses were used in these 
reports to determine the infl uence of various parameters on relapse; some published 
studies employed Fine & Gray’s regression model while others used the standard Cox 
regression model. Both models are correct but address different research questions.
If more than one endpoint can occur, a competing risk analysis must be performed. In the 
case of renal relapse, ESRF and death are competing events, because the occurrence 
of one of them precludes the occurrence of renal relapse. Fine & Gray’s regression 
model is used to estimate the effect of a risk factor on the cumulative incidence of renal 
relapse (CIR), which denotes the probability of experiencing renal relapse before time 
t. The classical Cox regression model is used to investigate the effect of risk factors 
on the rate of renal relapse. The parameters in the Cox regression model are hazard 
ratios and the interpretation is the traditional one. Note that relationships between risk 
factors (or explanatory parameters) and cause-specifi c hazards do not lead to simple 
relationships between explanatory variables and cumulative incidence. It is important 
to emphasize that both approaches are valid but that they answer different research 
questions and may render different results. Thus, the effect of a parameter on the CIR 
might be different from its effect on the rate of renal relapse. Estimation based on Fine 
& Gray’s model is useful for making predictions from the start of the disease, whereas 
the rate looks at parameters that increase the instantaneous risk of renal relapse and 
is useful for instant clinical decisions. In the present study, we apply both methods 
and discuss implications from their results.
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We investigated whether diagnostic clinical and histological parameters are associated 
with renal relapse in patients with AAV with primary renal involvement. The study 
aim was to identify diagnostic tools that may be helpful in monitoring and managing 
patients with AAV, in particular in relation to renal relapse.
METHODS
Patients
Patients included in this study were newly diagnosed with AAV with either mild to 
moderate or severe renal involvement (serum creatinine ≤ or > 500 µmol/L (≤ or > 5.8 
mg/dl)). Patients were derived from two international multicenter randomized clinical 
European Vasculitis Society (EUVAS) trials: MEPEX and CYCAZAREM.11,20 Inclusion 
criteria for both trials are described elsewhere.11,20 The diagnosis was based on a 
clinical presentation compatible with ANCA-associated vasculitis and substantiated 
by a positive ANCA serology and/or histology.
The MEPEX and CYCAZAREM trial follow-up continued until 12 and 18 months after 
diagnosis, respectively. During the trials, patients received protocolized treatment 
regimens.11,20 After these follow-up periods, patients were treated according to their 
local physician’s standards. Patients were included and followed-up in the period June 
1, 1995, through 30 November, 2006. Patients were included in this study only if 
histological data obtained from renal biopsy at the time of study entry, clinical data, 
and long-term follow-up data were available.
Disease definitions were adapted from the Chapel Hill Consensus Conference on the 
Nomenclature of Systemic Vasculitis and a previous European Union Study.21,22 Both 
trials were conducted according to the 1964 Declaration of Helsinki and subsequent 
amendments. The trials were approved by the local ethics committees of the 
participating centers throughout Europe. All patients gave written informed consent. 
The ethics for the use of the data and material for subsequent studies, including this 
study, was approved by the West Midlands Multi-centre Research Ethics Committee, 
date 22/09/2004 (reference number: MREC/98/7/37). In addition, this study was 
performed according to the ‘Netherlands Code of Conduct for Scientific Practice’, an 
ethical code for performing observational studies with patient material approved by 
the Federatie van Medisch Wetenschappelijke Verenigingen (translated: Federation 
of Medical Scientific Organisations) together with the legal and ethical committee 
of the Koninklijke Nederlandse Akademie van Wetenschappen (translated: Royal 
Dutch Academy of Science) and the Nederlandse Organisatie voor Wetenschappelijk 
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Onderzoek (translated: Dutch Organisation for Scientifi c Research). The data of the 
patients were analyzed anonymously.
Clinical and histological parameters
Candidate parameters for clinical predictors of renal relapse in this study were serum 
creatinine levels, age, sex, diagnosis (GPA or MPA), ANCA-antigen specifi city (PR3-
ANCA or myeloperoxidase (MPO)-ANCA), and receiving plasma exchange during 
induction therapy. Patients were subdivided into two groups of GPA and MPA based 
on the clinical criteria. Renal-limited vasculitis was regarded as a form of MPA.
Candidate parameters for histological predictors were determined from paraffi n 
sections of renal biopsies. Stains used for evaluation were silver, periodic acid–Schiff, 
hematoxylin and eosin, and trichrome. Sections were reviewed by two of a panel of 
fi ve participating pathologists (IMB, FF, LHN, RW, and/or JAB). Both pathologists, 
blinded to patient data and the other observer’s results, scored the biopsies 
separately and according to a previously standardized protocol, which was proven to 
be comprehensive and reproducible when used for histologic analysis.23 One of the 
histological parameters included in this previously standardized protocol is interstitial 
infi ltrates. Interstitial infi ltrates were scored according to the following categories:
- None: <10% of the unscarred parenchyma infi ltrated.
- Mild: 10 to 25% of the unscarred parenchyma infi ltrated.
- Quite dense: 26 to 50% of the unscarred parenchyma infi ltrated.
- Very dense: >50% of the unscarred parenchyma infi ltrated.
In this study, only biopsies with a minimum of seven whole glomeruli were analyzed for 
glomerular lesions and the histopathological classifi cation system of AAGN.8 During 
plenary meetings, the panel of fi ve pathologists decided upon the fi nal scores to 
achieve consensus for each biopsy.
Clinical outcomes
The clinical outcome parameter was fi rst renal relapse. A renal relapse was defi ned as 
a rise in serum creatinine of >30% or a fall in estimated glomerular fi ltration rate >25% 
and/or new hematuria or proteinuria (all attributable to active vasculitis), as indicated 
by the Birmingham Vasculitis Activity Score.24–26 Patients were followed up until the 
last visit or death.




In this study, more than one endpoint could occur, namely renal relapse, ESRF, or 
death. The event of interest was renal relapse, while ESRF and death were competing 
events. Two regression models used in the competing risks framework were estimated 
here: Fine & Gray’s model and Cox model. To study the effect of risk factors on the CIR 
the former model is employed while the latter is used to study the effects of risk factors 
on the rate of renal relapse, i.e. the cause-specific hazard. For more details concerning 
the difference between the two models, see Andersen et al. and Koller et al.27,28 The 
technical aspects of competing risks were described previously by Putter et al. 29
Univariate analyses with both methods were performed on every clinical and 
histological parameter. These analyses were performed on all patients without ESRF 
at baseline (n = 149), except for glomerular lesions and the histopathological class of 
AAGN. In addition, we performed a χ2-test to see whether the percent of renal relapse 
differed significantly between the histopathological classes. Also, a Pearson correlation 
test was performed to investigate whether the presence of interstitial infiltrate was 
correlated with interstitial fibrosis. All baseline parameters were included as fixed 
covariates.
Because of the number of parameters (13 in this study) and the relatively low number 
of events, inclusion of too many parameters carries the risk of “overfitting”.30 Therefore, 
predefined smaller sets of entry parameters were included in the multivariate analyses, 
as follows: based on the original publication of the histopathological classification 
system of AAGN8; based on parameters described previously more than once as being 
associated with relapse; and based on only histological parameters.
We denoted hazard ratios estimated by employing Cox regression model as cause-
specific hazard ratio (csHR) and the hazard ratios estimated by using Fine & Gray’s 
regression model as Fine & Gray’s HR (F&G HR). All hazard ratios are provided with 
95% confidence intervals (CI). A P value of less than 0.05 was considered significant. 
Statistical analyses were performed in SPSS (version 20.0; SPSS Inc, Chicago, IL) 
and R 2-18 (http://cran.r-project.org). All analyses concerning competing risks were 
performed with the mstate library.31,32
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RESULTS
Patients
A total of 174 patients with newly diagnosed AAV and a renal biopsy at diagnosis were 
included in this study. Table 1 shows the baseline patient characteristics. The median 
follow-up time was 102 months (range: 38–136 months).
Table 1 | Baseline characteristics of all patients
Characteristic Value
Number of patients 174








































Data are presented as n (%) unless otherwise noted.
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; ESRF, end-stage renal failure; GPA, 
granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NR, not 
reported/not performed; PLEX, plasma exchange therapy; PR3, proteinase 3.
aMean (SD).
bOnly patients with at least 7 whole glomeruli in their renal biopsy and no ESRF at baseline.
Renal relapse
Of the 174 patients, 25 could not experience a renal relapse because they had ESRF 
at baseline. Of the remaining 149 patients, 22 were chronic kidney disease (CKD) 
stage 1-2 and 127 were CKD stage 3-5. Of these 22 CKD stage 1-2 patients, 5 (22.7%) 
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developed CKD stage 3-5 within 5 years of follow-up. None of these 5 had experienced 
a renal relapse. In total, 31 patients experienced a renal relapse during follow-up. The 
CIR at 5 years was 9.5% (95% CI: 4.8-14.3%).  A total of 19 patients developed ESRF 
during follow-up without experiencing renal relapse, and 29 died without experiencing 
renal relapse and without developing ESRF during follow-up. All patients who died 
during the follow-up period had CKD stage ≥ 3 at baseline. Seventy patients had none 
of these events during follow-up (Figures 1 and 2).
Figure 1 | Events.
Overview of different events experienced by 174 patients during follow-up. Twenty-fi ve patients 
presented with ESRF at baseline. Nineteen of them died during follow-up. Thirty-one patients 
experienced renal relapse during follow-up; six of them developed ESRF, of whom four died, and 
three died without ESRF during follow-up. Nineteen patients developed ESRF without renal relapse 
(competing event 1), of whom 10 died at a later timepoint. Twenty-nine patients died without 
experiencing renal relapse or ESRF (competing event 2). Seventy patients experienced no event 
during follow-up.
Abbreviations: DSF, disease-free survival; ESRF, end-stage renal failure; ESRF0, end-stage renal 
failure at baseline.
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Figure 2 | Cumulative incidence of renal relapse, end-stage renal failure or death.
Cumulative incidence of patients who experienced renal relapse (event of interest) and patients 
who developed ESRF or died (competing events). This fi gure illustrates the probability of 
experiencing a renal relapse and the probability of developing ESRF or dying without experiencing 
a renal relapse.
Abbreviations: CI, cumulative incidence; ESRF, end-stage renal failure.
Of the 149 patients, 113 had adequate renal tissue samples (at least seven whole 
glomeruli in the renal biopsy) for classifi cation purposes. Their diagnostic renal 
biopsies were classifi ed as follows: 23 focal class (20.4%), 58 crescentic class (51.3%), 
18 mixed class (15.9%), and 14 sclerotic class (12.4%) (Table 2). Of these 113 patients, 
24 experienced a renal relapse during follow-up. The numbers of patients having a 
renal relapse per class were 5/23 (21.7%) focal class, 9/58 (15.5%) crescentic class, 
4/18 (22.2%) mixed class, and 6/14 (42.9%) sclerotic class (χ2-test: P=0.167). The 
distribution of patient ages did not differ across classes. In particular, patients from the 
sclerotic class were not older than those in other classes. During the trials, therapies 
given to the patients did not differ among the four classes. Fourteen patients developed 
ESRF during follow-up without experiencing renal relapse (competing event 1). Twenty 
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patients died without experiencing renal relapse and without developing ESRF during 
follow-up (competing event 2) (Figure 3).
Table 2 | Baseline characteristics of patients per histopathological class
Characteristic
Value per class
Focal class Crescentic class Mixed class Sclerotic class
Number of patients 23 58 18 14
Age (years) 55.4 ± 13.8a 60.4 ± 13.6a 59.8 ± 9.2a 63.8 ± 12.3a

































































Data are presented as n (%) unless otherwise noted.
Sample size: 113 patients (patients with at least 7 whole glomeruli in their renal biopsy and no 
end-stage renal failure at baseline).
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; 
MPA, microscopic polyangiitis; MPO, myeloperoxidase; NR, not reported/not performed; PLEX, 
plasma exchange therapy; PR3, proteinase 3.
aMean (SD).
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Figure 3 | Events of the 113 patients with ≥7 glomeruli in their renal biopsy without end-stage 
renal failure at baseline.
Twenty-four patients experienced a renal relapse during follow-up. Of these 24 patients, four 
developed ESRF, of which three died, and four died without ESRF during follow-up. Fourteen 
patients developed ESRF without renal relapse (competing event 1), of whom 7 died at a later 
timepoint. Twenty patients died without renal relapse and without ESRF (competing event 2). Fifty-
fi ve patients experienced no event during follow-up.
Abbreviations: DSF, disease-free survival; ESRF, end-stage renal failure.
Competing risks analyses
To investigate which parameters are associated with the CIR, Fine & Gray’s regression 
model was used. The traditional Cox regression model was used to estimate the effect 
of the parameters on the rate of renal relapse.27
Fine & Gray’s regression model
The univariate analyses showed that age, interstitial infi ltrates, and intra-epithelial 
infi ltrates were associated with CIR (S Table 1 in the supplementary material). Older 
age was associated with a lower risk for experiencing a renal relapse. Higher scores of 
interstitial infi ltrates and intra-epithelial infi ltrates, which are both signs of acute disease 
activity, were associated with a lower risk for renal relapse. The histopathological class 
and CKD stage were not signifi cantly associated with the risk of renal relapse.
Among all histological parameters, only interstitial infi ltrates had a signifi cant 
association on the risk of renal relapse (the CIR) in the multivariate analysis (Table 3). 
Although there was a correlation between interstitial infi ltrates and interstitial fi brosis, 
this correlation was relatively weak (r=0.236, P=0.004). Therefore, interstitial fi brosis 
was not predictive for renal relapse. Patients with mild infi ltrates had a four times lower 
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risk for renal relapse than patients without interstitial infiltrates (F&G HR: 0.09; 95% 
CI: 0.02–0.39; P = 0.001). This association persisted when correcting for the patient 
cohort indicator.
Table 3 | Multivariate analysis with Fine & Gray’s model based on histological parameters
Renal relapse
















































Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; NS, not significant; F&G HR, Fine and Gray’s 
hazard ratio.
aReference group: No intra-epithelial infiltrates. 
Among all clinical parameters, only age, corrected for other parameters, was associated 
with patients experiencing a renal relapse (S Table 2 in the supplementary material).
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Cox regression model for renal relapse
Among all baseline parameters, only the histopathological class was a signifi cant risk 
factor for renal relapse in the univariate analyses (S Table 3 in the supplementary 
material). CKD stage was not associated with renal relapse. After correction for age, 
baseline serum creatinine, and plasma exchange therapy, the histopathological class 
remained the only statistical signifi cant risk factor for experiencing a renal relapse 
(Table 4). Focal and crescentic class biopsies were associated with a lower cause-
specifi c hazard ratio compared to sclerotic class biopsies. Focal class had a 10.1 times 
lower rate than the sclerotic class (csHR: 0.10; 95% CI: 0.02–0.60; P = 0.01), and 
crescentic class had a 4.7 times lower rate than the sclerotic class (csHR: 0.21; 95% 
CI: 0.07–0.62; P = 0.004). Patient cohort (MEPEX or CYCAZAREM) did not affect 
these associations.
Table 4 | Multivariate analyses with both models based on the original publication of the 




Cox regression model Fine & Gray’s model

















Age 0.3 0.98 (0.96-1.01) 0.02 0.97 (0.94-0.996)






















Sample size: 113 patients
Abbreviations: 95% CI, 95% confi dence interval; csHR, cause-specifi c hazard ratio; NS, not 
signifi cant; F&G HR, Fine and Gray’s hazard ratio.
aReference group: No plasma exchange therapy received.
With the inclusion of histopathological class, baseline serum creatinine, ANCA type, 
and diagnosis, only the histopathological class was a signifi cant risk factor for renal 
relapse (Table 5). Again, focal and crescentic classes were associated with a lower 
rate compared to sclerotic class. In this model, focal class had a 10.8 times lower rate 
than the sclerotic class (csHR: 0.09; 95% CI: 0.02–0.55; P = 0.009), and crescentic 
class had a 4.8 times lower hazard rate than the sclerotic class (csHR: 0.21; 95% CI: 
0.07–0.64; P = 0.006). There was no effect of patient cohort on these associations.
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Cox regression model Fine & Gray’s model

















Diagnosisa 0.2 0.55 (0.20-1.51) 0.9 0.96 (0.24-3.87)
PR3-ANCAb 0.6 0.61 (0.09-4.22) 0.3 0.45 (0.10-2.03)






















Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic antibody; 
csHR, cause-specific hazard ratio; MPO, myeloperoxidase; NS, not significant; PR3, proteinase 3; 
F&G HR, Fine and Gray’s hazard ratio.
aReference group: Granulomatosis with polyangiitis.
bReference group: Negative. 
DISCUSSION
This study shows that the histopathological class of AAGN in the renal biopsy at 
diagnosis is a risk factor for renal relapse. More specifically, sclerotic class was 
associated with a higher rate of renal relapse during long-term follow-up. It is important 
to emphasize that the effect of sclerotic class on the risk of renal relapse, i.e. the 
cumulative incidence, estimated by the Fine & Gray’s model is different from its effects 
on the rate, i.e. the cause-specific hazard, estimated by the Cox regression proportional 
hazard model. This is because the way in which risk factors (or explanatory variables) 
are associated with the cause-specific hazards may not coincide with the way these 
covariates are associated with the cumulative incidence. The sclerotic class in AAGN is 
defined by ≥50% globally sclerosed glomeruli, meaning that the majority of glomeruli 
are non-functioning and that the compensatory ability of the kidneys is relied on 
heavily. Therefore, in these patients, a renal relapse may become more readily apparent 
because the compensatory capacity of a sclerotic class kidney is reduced. Moreover, 
with fewer functioning glomeruli, these glomeruli may become more vulnerable to a 
second hit, i.e., a relapse. In patients with AAGN that is not in the sclerotic class, minor 
relapses may remain subclinical because of the relatively higher number of preserved 
glomeruli and their compensatory ability. Patients’ treatments were not based on the 
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histopathological classifi cation. Therefore, the sclerotic class may provide a setting 
in which renal relapse may be more likely to be detected than in the setting of another 
histopathological class.
To investigate the effect of risk factors on the risk of renal relapse, i.e. the cumulative 
incidence, we applied Fine & Gray’s regression model. Results show that absence 
of interstitial infl ammatory infi ltrates is associated with the risk of renal relapse. 
Patients with these infi ltrates had a lower risk for future renal relapse than patients 
without these infl ammatory infi ltrates. The association of interstitial infi ltrates with 
renal relapse persisted when corrected for other histological parameters. Previous 
EUVAS studies focused on predictive clinical and serological parameters for relapse 
in general. Walsh et al. investigated clinical and serological parameters predictive for 
relapse in general in a European cohort consisting of 535 patients. In that study, PR3-
ANCA, lower serum creatinine levels at presentation, cardiovascular involvement, and 
GPA were independently associated with an increased risk for relapse, whether in 
the kidney or any other organ.19 Our study is based on the histopathological data of 
those patients from the previous study by Walsh et al. who had a renal biopsy with 
suffi cient tissue for proper evaluation; thus, we could investigate which histological 
parameters are predictive for renal relapse. Our fi nding that the absence of interstitial 
infi ltrates is predictive for renal relapse is in line with the fi nding by Walsh et al. that 
better renal function increases the risk for a relapse in general because absence of 
interstitial infi ltrates also correlates with better renal function at the time of biopsy.33,34 
Experiencing a renal relapse has a negative infl uence on renal outcome.35 Therefore, 
clinicians should realize that renal relapses must be identifi ed and treated, and keep 
in mind that those patients with a relatively benign clinical course at onset in particular 
will be prone to developing a renal relapse.
This study shows a higher cumulative risk for ESRF or death compared to renal relapse 
as shown in Figure 2. These results may have been infl uenced by the inclusion of 
patients from the MEPEX trial which included patients with serum creatinine >500 
µmol/L or immediate dialysis dependency. Nineteen patients (11%) had ESRF during 
follow-up without experiencing a (clinical) renal relapse. It is possible that these 
patients had subclinical renal relapses, but they were not detected clinically. Based 
on this knowledge, we emphasize the need for chronic kidney disease management 
and renal protective strategies.
Our study has a number of limitations. Because of the sample size and relatively low 
number of events, we were limited in the size of the predefi ned multivariate analyses. 
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To avoid bias, all multivariate analyses were predefined before the start of this study. To 
use the best possible predefined analyses, we constructed them based on the literature 
regarding the histopathological classification system of AAGN. Unfortunately, repeat 
biopsies during the time of renal relapse were not performed because it is generally 
considered that the risk of taking a biopsy would not weight against the benefit of a 
histologically proven renal relapse, keeping in mind that these can be diagnosed with 
a high level of certainty on the basis of the clinical findings.
In conclusion, we used two regression models to identify possible relationships 
between clinical and histopathological parameters at time of diagnosis of AAV with 
the risk of renal relapse, i.e. the cumulative incidence, and the effect on the rate of 
renal relapse, i.e. the cause-specific hazard. The effect of sclerotic class on the risk 
of renal relapse estimated by the Fine & Gray’s regression model was different from 
its effects on the rate estimated by the Cox regression model. Most likely, the lack of 
compensatory function in the largely sclerosed kidneys gives rise to the identification 
of a relatively high number of renal relapses. A strong predictive parameter for renal 
relapse was the absence of interstitial infiltrates as determined with the Fine & Gray 
model. Combining these results with those of previous studies, it seems that the patient 
with AAV characterized by a relatively benign clinical setting at onset is prone to a renal 
relapse. In this study, renal relapses occurring in patients with sclerotic class AAGN 
and renal relapses occurring in patients without interstitial infiltrates were mutually 
exclusive, which may indicate that they are essentially other kinds of relapses. Further 
studies are called for to look further into the characteristics of renal relapses in AAV, in 
particular to find out whether the histopathological data at disease onset could serve 
as a guideline for the management of renal relapses in AAV.
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SUPPLEMENTARY MATERIAL
ANCA-associated glomerulonephritis: risk factors for renal relapse
S Table 1 | Univariate analyses with Fine & Gray’s model
Parameter
              Renal relapse
P Value F&G HR (95% CI)
Clinical parameters
Gendera 0.9 1.04 (0.47-2.30)
Serum creatinine
    ≤ 100 µmol/L
    101-200 µmol/L







Age 0.003 0.96 (0.94-0.99)
Diagnosis (GPA, MPA)b 0.4 0.73 (0.33-1.62)
PR3-ANCAc 0.4 1.43 (0.63-3.24)
MPO-ANCAc 0.4 0.73 (0.32-1.64)
Plasma exchange therapyd 0.5 0.70 (0.24-2.02)
CKD stage 0.2 0.59 (0.26-1.34)
Interstitial lesions
Interstitial infi ltrates
    None
    Mild infi ltrate
    Quite dense infi ltrate










    None
    Focal









    None
    Small foci







Intra-epithelial infi ltratese 0.04 0.43 (0.20-0.94)
Glomerular lesions
Histopathological class
    Focal
    Crescentic
    Mixed









Fibrinoid necrosis 0.5 0.99 (0.97-1.01)
Abbreviations: 95% CI, 95% confi dence interval; ANCA, anti-neutrophil cytoplasmic antibody; 
CKD, chronic kidney disease; GPA, granulomatosis with polyangiitis; MPA, microscopic 
polyangiitis; MPO, myeloperoxidase; NS, not signifi cant PR3, proteinase 3; F&G HR, Fine and 
Gray’s hazard ratio.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.
dReference group: No plasma exchange therapy received.
eReference group: No intra-epithelial infi ltrates.
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S Table 2 | Multivariate analysis with Fine & Gray’s model based on clinical parameters and 
histopathological class
Parameter
             Renal relapse
P Value F&G HR (95% CI)
Gendera 0.9 1.04 (0.40-2.68)
Serum creatinine
    ≤ 100 µmol/L
    101-200 µmol/L







Age 0.02 0.97 (0.94-0.99)
Diagnosis (GPA, MPA)b 0.8 0.88 (0.24-3.16)
PR3-ANCAc 0.2 0.38 (0.08-1.82)
MPO-ANCAc 0.3 0.54 (0.18-1.61)
Plasma exchange therapyd 0.7 0.80 (0.21-3.01)
Histopathological class
    Focal
    Crescentic
    Mixed










Sample size: 112 patients
Abbreviations: 95% CI, 95% confidence interval; ANCA, anti-neutrophil cytoplasmic antibody; 
GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; NS, 
not significant; PR3, proteinase 3; F&G HR, Fine and Gray’s hazard ratio.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.
dReference group: No plasma exchange therapy received.
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S Table 3 | Univariate analyses with Cox regression model
Parameter
                            Renal relapse




    ≤ 100 µmol/L
    101-200 µmol/L







Age 0.4 0.99 (0.97-1.02)
Diagnosis (GPA, MPA)b 0.3 0.68 (0.33-1.40)
PR3-ANCAc 0.6 1.26 (0.60-2.64)
MPO-ANCAc 0.8 0.90 (0.43-1.89)
Plasma exchange therapyd 0.6 1.28 (0.52-3.16)
CKD stage 0.5 0.77 (0.33-1.78)
Interstitial lesions
Interstitial infi ltrates
    None
    Mild infi ltrate
    Quite dense infi ltrate










    None
    Focal









    None
    Small foci







Intra-epithelial infi ltratese 0.1 0.58 (0.29-1.19)
Glomerular lesions
Histopathological class
    Focal
    Crescentic
    Mixed









Fibrinoid necrosis 0.3 0.99 (0.97-1.01)
Abbreviations: 95% CI, 95% confi dence interval; ANCA, anti-neutrophil cytoplasmic antibody; 
CKD, chronic kidney disease; csHR, cause-specifi c hazard ratio; GPA, granulomatosis with 
polyangiitis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3.
aReference group: Female.
bReference group: Granulomatosis with polyangiitis.
cReference group: Negative.
dReference group: No plasma exchange therapy received.
eReference group: No intra-epithelial infi ltrates.
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Introduction: Renal involvement is very common in antineutrophil cytoplasmic 
autoantibody (ANCA) associated vasculitis (AAV). Therefore, a histopathological 
classification of ANCA-associated glomerulonephritis was developed, which consisted 
of the classes: focal, crescentic, mixed, and sclerotic. This classification was associated 
with renal outcome. Subsequent validation studies showed contradiction regarding the 
crescentic and mixed classes and the association with renal outcome. Here, we present 
a worldwide validation study and also analysed interobserver variability.
Methods: We included 145 patients from 10 centers worldwide with at least five 
glomeruli in their diagnostic renal biopsy. Seven pathologists scored renal biopsies 
of patients to determine the histopathological classification and to evaluate 
tubulointerstitial parameters. In addition, clinical data was collected. The primary 
outcome of the study was renal function at 5 years (eGFR5). Interobserver variability 
was a secondary outcome.
Results: Renal function at baseline and during follow-up were most favorable in the 
focal class and worst in the sclerotic class, consistent with primary findings. However, 
there was no difference between crescentic and mixed class regarding renal function 
at baseline and during follow-up. A multivariate analysis showed that the best model 
for predicting eGFR5 included eGFR0, having sclerotic class, age, proteinuria0, and 
interstitial fibrosis and tubular atrophy. There was a moderate agreement between the 
pathologists in classifying the diagnostic renal biopsies; kappa (κ) 0.56.
Conclusions: Our study showed a difference between focal and sclerotic class 
regarding renal outcome, but no difference between crescentic and mixed class. These 
findings show that the histopathologic classification of AAGN is a valuable tool in 
the management of patients with AAV, but needs further improvement to distinguish 
biopsies with crescentic and mixed features better.
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INTRODUCTION
The most common primary systemic small-vessel vasculitis in adults is antineutrophil 
cytoplasmic autoantibody (ANCA) associated vasculitis (AAV).1 AAV includes 
granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), 
microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis 
(EGPA, formerly Churg-Strauss syndrome). There is also a limited disease variant 
called renal limited vasculitis (RLV), which only affects the kidneys. In GPA around 20 
percent of the patients have glomerulonephritis at presentation.2 ANCA-associated 
glomerulonephritis (AAGN) occurs in approximately 80 to 90 percent of patients with 
GPA and MPA during the disease course.1;2 Renal involvement in EGPA is less frequent 
and less severe.3 Renal involvement in AAV has an important impact on morbidity 
and mortality.4-8 AAGN can rapidly progress to renal failure, especially if treated 
inappropriately. Currently, 20 to 40% of patients with AAV develop end stage renal 
disease (ESRD).9-11
The gold standard for establishing a diagnosis of AAGN is a renal biopsy. Light 
microscopy shows necrotizing and crescentic glomerulonephritis accompanied by a 
pauci-immune pattern, i.e. a negative or subdued granular pattern for immunoglobulins 
and complement.12;13 Electron microscopy shows degranulation of neutrophils and 
subendothelial edema due to endothelial injury with few or no immune deposits.14 
The amount of acute and chronic lesions in the renal biopsy may vary considerably 
from patient to patient. Also, patients’ outcome varies considerably.15;16 Several 
clinicopathologic studies showed substantial prognostic value of specifi c pathologic 
lesions –or the absence thereof– in renal biopsies for renal outcome in AAV.
Frequently described associations in the literature are: 1) percentage of normal 
glomeruli and favorable renal outcome, 2) percentage of sclerotic glomeruli and adverse 
renal outcome.16-19 Moreover, the presence of cellular crescents, which indicates active 
disease, was associated with the probability of renal recovery with immunosuppressive 
therapy.16;18 These fi ndings led to the introduction of a histopathological classifi cation of 
AAGN in 2010.20 The classifi cation is based on four categories named focal, crescentic, 
sclerotic and mixed class. Depending on the predominant glomerular phenotype, each 
renal biopsy with AAGN can be classifi ed into one of these classes. The classifi cation 
system was shown to be associated with ESRD and renal function at 1- and 5-year 
follow-up in the original study consisting of 100 patients.20
Since 2010, several validations studies in adult and pediatric cohorts worldwide have 
been published.21-43 All these studies show that the focal class has the best renal 
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outcome, while the sclerotic class has the worst outcome.25 Contradiction exists 
regarding the crescentic and mixed classes; in some studies, renal function was better 
in the crescentic class, whereas in others renal outcome was significantly better in 
the mixed class, and in addition some did not show a difference.25 Because of this 
contradiction, a large international validation study consisting of a worldwide cohort 
was called for. We here present a worldwide validation study, driven by the original 
investigators, including a collaboration between 10 centers worldwide. In this study, 
we also analysed interobserver variability to investigate to what extent this could play 
a role in the hitherto described discrepancies.
METHODS
Study cohort
Patients from 10 centers worldwide were included. Inclusion criteria were: 
histopathologically proven AAGN, available diagnostic renal biopsy with at least 
five glomeruli and a follow-up of at least 3 years (including patients that developed 
ESRD or died within the first 3 years). Exclusion criteria were: age under 18 years, 
overlap syndrome (e.g., AAGN combined with anti-glomerular basement membrane 
disease), and participation in a previous validation study. This study was conducted 
in accordance with the 1964 Declaration of Helsinki and subsequent amendments.
Diagnostic renal biopsies
Biopsy slides were collected at Leiden University Medical Center. All biopsies with at 
least five glomeruli were considered sufficient for this study, based on recent findings 
that biopsies containing three to nine glomeruli were also valid for the prognostic 
capability of the classification.22 The biopsies were scanned with the Ultra-Fast Scanner 
(UFS) at a magnification of 40x. The scanned biopsy were uploaded on a highly secured 
website, where they were accessible only for a group of seven pathologists (FF, KJ, 
YO, SW, LHN, JAB and IMB). These pathologists, blinded to the clinical data, scored 
the biopsies independently. The scoring form (S Document 1 in the supplementary 
material) was a modified version of the original scoring form for AAGN that was 
published in 1996.44 In short, the scoring consisted of the histopathological class, 
inflammatory infiltrates, interstitial fibrosis and tubular atrophy (IFTA), and tubulitis. 
Each case was scored by two pathologists. In case of disagreement between these two 
pathologists, a third pathologist (IMB or JAB) made the final decision on the case. For 
analytic purposes, tubulointerstitial scores from two pathologists were averaged and 
categorized as: inflammatory infiltrate in <25% or ≥25% of unscarred parenchyma; 
IFTA in <25% or ≥25% of cortical area; and tubulitis foci with <5 or ≥5 cells/tubular 
cross section.
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Clinical data
For each patient we retrieved the following data from the clinical records at participating 
centers: patient demographics, diagnosis (GPA, MPA, EGPA, or RLV), serum and urine 
laboratory values, and details on induction and maintenance therapy. Renal function 
was expressed as eGFR, calculated with the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation, adjusted for race/ethnicity (Caucasian/Asian or 
other).45-47 eGFR was calculated at the time of biopsy (eGFR0) and at 1- and 5-year 
follow-up (eGFR1 and eGFR5, respectively). The eGFR calculation was omitted, when 
patients reached ESRD; in that case, eGFR was considered 0 for analytic purposes.
Outcomes
The primary outcome of the study was renal function at 5 years (eGFR5). Secondary 
outcomes were: renal function at 1 year (eGFR1), renal relapse, ESRD, death and 
interobserver variability. A renal relapse was defi ned as a rise in serum creatinine 
of >30% or a fall in estimated glomerular fi ltration rate >25% and/or new hematuria 
or proteinuria (all attributable to active vasculitis), as indicated by the Birmingham 
Vasculitis Activity Score.48-50 ESRD was defi ned as a need for renal replacement 
therapy (dialysis for at least three months or transplantation) or as an eGFR value 
below 15 mL/min that persisted for at least three months. Renal survival was expressed 
as the time between diagnosis and ESRD.
Statistical analyses
Continuous variables were expressed as mean±SD. Categorical variables were 
expressed as numbers (%). Numerical data of groups were compared with the student’s 
t-test or one-way analysis of variance. Categorical data of groups were compared 
with Fisher’s exact test or the chi-square test. Renal survival was analyzed with the 
Kaplan Meier survival analysis and log-rank test. Pearson’s correlation coeffi cients 
were calculated to identify variables correlating with eGFR5. Stepwise multiple linear 
regression analysis was performed to fi nd the best model for predicting eGFR5. 
Interobserver agreement was investigated by calculating the κ for the histopathological 
classifi cation, and the ICC for tubulointerstitial parameters. Values of κ or ICC 
were interpreted as following: >0.75, excellent agreement; 0.40-0.75, fair to good 
agreement; and <0.40, poor agreement.51;52 All analyses were performed with SPSS 
version 23 (IBM Corp., Armonk, NY, USA). P values <0.05 were considered signifi cant.





Histopathological and clinical data of 157 patients were collected. Twelve cases were 
excluded, because of missing clinical data or an insufficient number of glomeruli in the 
biopsy (i.e. less than five glomeruli). The baseline characteristics of the 145 included 
patients, all diagnosed between 1991 and 2011, are shown in Table 1.
Table 1 | Characteristics of the total cohort
Total (n=145)
Age at biopsy, year, mean±SD 61.2±12.7
Male (%) 83 (57.2)
Diagnosis (%)a
    GPA 63 (45.0)
    MPA 71 (50.7)
    EGPA 2 (1.4)
    RLV 4 (2.9)
Diagnostic delay, months, mean±SD 3.1±9.0
ANCA specificity (%)b
    PR3 50 (37.0)
    MPO 73 (54.1)
    Negative 6 (4.4)
    Double positive 6 (4.4)
Center
    Cochin Hospital, Paris 6 (4.1)
    General University Hospital in Prague 38 (26.2)
    Leiden University Medical Center, Leiden 36 (24.8)
    Medical University of Innsbruck 7 (4.8)
    Medical University of Vienna 9 (6.2)
    Necker Hospital, Paris 4 (2.8)
    Rigshospitalet Copenhagen 7 (4.8)
    Teinekeijnkai Hospital Sapporo 7 (4.8)
    JCHO Sendai Hospital, Sendai 24 (16.6)
    Weill Cornell Medical College New York 7 (4.8)
ANCA, antineutrophil cytoplasmic autoantibody; EGPA, eosinophilic granulomatosis with 
polyangiitis; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MPO, 
myeloperoxidase; PR3, proteinase-3; RLV, renal-limited vasculitis; SD, standard deviation.
a The AAGN diagnosis was not further specified in 5 patients.
b ELISA test results were available in 135 patients. 
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Histopathological classes and clinical parameters
Of the diagnostic biopsies, 52 (35.9%) were focal class, 37 (25.5%) crescentic class, 39 
(26.9%) mixed class, and 17 (11.7%) were sclerotic class (Table 2). GPA predominated 
in the focal class, while MPA predominated in the mixed class. There was no difference 
between the crescentic and sclerotic class regarding the diagnosis. Although there 
was no signifi cant difference in the prevalence of myeloperoxidase (MPO-)ANCA and 
proteinase-3 (PR3-)ANCA specifi city among the classes, the crescentic and mixed 
class showed a predominance of MPO-ANCA, while the focal class showed a slight 
predominance of PR3-ANCA. MPO- and PR3-ANCA were found in equal numbers in 
the sclerotic class.
Histopathological classes and renal function
Focal class had the highest eGFR at baseline (Table 2). After one and fi ve year follow-
up, focal class still had the highest eGFR. Sclerotic class had the lowest eGFR at 
baseline and during follow-up. Renal functions at baseline and during follow-up were 
not signifi cantly different between the crescentic and mixed classes. Proteinuria at 
the time of the biopsy was lowest in the focal class, and comparable between the 
crescentic, mixed, and sclerotic class.















Age at biopsy, year, mean±SD 59.7±12.6 61.6±11.4 60.6±14.4 65.9±11.7 0.37
Male (%) 33 (63.5) 24 (64.9) 18 (46.2) 8 (47.1) 0.22
Diagnosis (%)a 0.005
    GPA 33 (63.5) 14 (40.0) 8 (21.6) 8 (50.0)
    MPA 17 (32.7) 19 (54.3) 27 (73.0) 8 (50.0)
    EGPA 1 (1.9) 0 (0.0) 1 (2.7) 0 (0.0)
    RLV 1 (1.9) 2 (5.7) 1 (2.7) 0 (0.0)
ANCA specificity (%)b 0.13
    PR3 23 (47.9) 13 (37.1) 7 (19.4) 7 (43.8)
    MPO 19 (39.6) 21 (60.0) 25 (69.4) 8 (50.0)
    Negative 3 (6.3) 0 (0.0) 3 (8.3) 0 (0.0)
    Double positive 3 (6.3) 1 (2.9) 1 (2.8) 1 (6.3)
Diagnostic delay, months, mean±SD 4.7±12.9 1.4±2.7 2.4±3.2 3.6±11.5 0.39
eGFR0, ml/min/1.73 m
2, mean±SD 49.9±29.3 18.0±15.7 26.7±18.6 19.4±11.8 <0.001
Proteinuria class at biopsy (%)c 0.005
    Normal 4 (8.7) 1 (3.1) 2 (5.3) 0 (0.0)
    Moderately increased 18 (39.1) 4 (12.5) 3 (7.9) 3 (18.8)
    Severely increased 24 (52.2) 27 (84.4) 33 (86.8) 13 (81.3)
eGFR1, ml/min/1.73 m
2, mean±SD 61.4±23.9 37.3±20.6 37.7±21.1 20.3±16.0 <0.001
eGFR5, ml/min/1.73 m
2, mean±SD 59.7±21.1 34.9±20.4 37.3±23.7 19.3±20.0 <0.001
Renal relapse during follow-up (%) 20 (40.0) 14 (40.0) 11 (28.9) 3 (18.8) 0.33
ESRD during follow-up (%) 1 (1.9) 9 (24.3) 6 (15.4) 8 (47.1) <0.001
Death during follow-up (%) 15 (28.8) 15 (40.5) 9 (23.1) 6 (35.3) 0.40
ANCA, antineutrophil cytoplasmic autoantibody; eGFR0/1/5, estimated glomerular filtration rate at 
baseline, at 1 year and at 5 years respectively; EGPA, eosinophilic granulomatosis with polyangiitis; 
ESRD, end-stage renal disease; GPA, granulomatosis with polyangiitis; MPA, microscopic 
polyangiitis; MPO, myeloperoxidase; PR3, proteinase-3; RLV, renal-limited vasculitis; SD, standard 
deviation.
a The AAGN diagnosis was not further specified in 5 patients.
b ELISA test results were available in 135 patients.
c In accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines, 
normal level of proteinuria was defined as protein excretion of <0.15 g/day, or as a negative protein 
dipstick test; moderately increased proteinuria was defined as a protein excretion rate of 0.15–
0.50 g/day, or as trace on protein dipstick test; severely increased proteinuria was defined as total 
protein excretion >0.50 g/day, or as + or more on protein dipstick. The proteinuria class could be 
determined in 132 patients.
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Predictors of renal function in time
Va riables signifi cantly associated with eGFR5 were: age, clinical diagnosis (MPA or 
GPA), ANCA serology (MPO-ANCA or PR3-ANCA), eGFR0, the amount of proteinuria at 
time of biopsy, the histopathological classifi cation, the extent of interstitial infi ltrate, the 
amount of interstitial fi brosis and tubular atrophy (IFTA), and the amount of tubulitis. 
When performing a stepwise multivariate regression analysis, the best predicting 
model for eGFR5 included eGFR0, having sclerotic class, age, proteinuria0, and IFTA 
(Table 3).












β P-value β P-value β P-value β P-value β P-value
eGFR0 0.65 <0.001 0.61 <0.001 0.56 <0.001 0.49 <0.001 0.41 <0.001
Histopathological
classifi cationa
    Sclerotic
-0.23 0.001 -0.22 0.002 -0.22 0.002 -0.17 0.02
Age -0.15 0.04 -0.22 0.004 -0.24 0.002
Proteinuria0 -0.27 0.001 -0.27 <0.001
IFTA category -0.21 0.006
eGFR0/5, estimated glomerular fi ltration rate at baseline and at 5 years respectively; IFTA, 
interstitial fi brosis and tubular atrophy.
a Focal class as reference.
Renal relapse and end-stage renal disease
During a mean follow-up duration of 8.0±5.4 years, 48 (33.1%) patients experienced 
at least one renal relapse. There was no difference between crescentic and mixed 
class regarding the number of patients who experienced a renal relapse (P=0.34; 
S Table 1 in the supplementary material). Twenty-four (16.6%) patients developed 
ESRD. At 10 years follow-up renal survival was signifi cantly different between the 
four histopathological classes, but not between crescentic and mixed class (Figure 
1). A total of 45 (31.0%) patients died. When combining death and/or ESRD within 10 
years as one outcome, no difference was seen between crescentic and mixed class (S 
Figure 1 in the supplementary material).




Focal 52 49 43 27 17 17
Crescentic 37 29 27 14 10 7
Mixed 39 34 32 23 14 13
Sclerotic 17 11 9 7 3 2
Figure 1 | Renal survival according to histopathological class. 
At 10-year follow-up, renal survival was different between the four classes (P<0.001), but not between 
crescentic and mixed class (P=0.98).
Treatment
The majority of patients received corticosteroids and cyclophosphamide as induction 
therapy (106 [74.1%] patients; S Table 2 in the supplementary material). Patients 
receiving corticosteroids and cyclophosphamide had a similar 10-year renal survival 
rate compared to patients receiving other treatment regimens as induction therapy 
(P=0.17). Maintenance therapy consisted for most patients of corticosteroids together 
with azathioprine or mycophenolate mofetil (83 [61.5%] patients). Ten-year renal 
survival rates did not differ between patients with no or minimal maintenance therapy 
(only corticosteroids) compared to patients with maintenance therapy consisting of 
multiple immunosuppressive drugs (P=0.37). Plasma exchange was more frequently 
used in patients with crescentic class compared to the other classes (24.3% versus 
10.4%, P=0.04; S Table 2 in the supplementary material). Within the crescentic class, 
renal survival at 10 years did not differ between patients that received and patients 
that did not receive plasma exchange therapy (P=0.34).
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Interobserver agreement
Agreement on the histopathological class between the two pathologists was observed 
in 99 (68.3%) cases; kappa (κ) 0.56 (Figure 2). This agreement rate corresponds to 
moderate agreement. In seven cases there was complete disagreement between 
three pathologists. We discovered three possible reasons for disagreement when re-
evaluating the cases that lacked agreement (n=46); technical (e.g., differences between 
histological stains), interpretative (e.g., different interpretations of the defi nitions) 
and errors (e.g., miscalculations and incomplete scorings). The intraclass correlation 
coeffi cient (ICC) between two pathologists was 0.57 for interstitial infi ltrate, 0.46 for 
IFTA, and 0.36 for tubulitis.
Figure 2 | Interobserver agreement on histopathological class.
DISCUSSION
Our worldwide multicenter study on the histopathological classifi cation of AAGN 
showed a favorable outcome in the focal class and a poor outcome in the sclerotic 
class, which is in line with our original study and previous validation studies. There 
was no difference between renal outcome in the crescentic and mixed class, which is 
in contrast to fi ndings of the original study, but it is in line with results from a recent 
meta-analysis.25
Overall, our data show that the histopathological classifi cation is associated with 
renal function and the development of ESRD during follow-up. This association with 
eGFR5 persists after correcting for other baseline values. However, the crescentic 
and mixed class were indiscriminate regarding renal function and developing ESRD. 
Although these fi ndings suggest that a revision of the original classifi cation is called 
for, we are reluctant to lump the crescentic and mixed class, in particular because 
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other studies showed that cellular crescents are an important factor for predicting 
potential reversibility of renal impairment during follow-up.16;18 This kind of information 
can be used for therapeutic purposes and tailoring treatment for individual patients. 
An additional factor not yet incorporated in the current classification, but which have 
shown some predictive value for long-term renal outcome, are fibrous crescents.15 
Currently it is investigated whether these can be of additive value for predicting renal 
outcome in the current classification.
There are four possible explanations for the conflicting results regarding crescentic 
and mixed class: differences in patient populations, differences in treatment, moderate 
interobserver agreement and insufficiency of the histopathologic classification. 
Epidemiologic studies showed that there is a difference in distribution of GPA/MPA/
EGPA and ANCA-specificity around the globe.53;54 Since there is an association 
between the histopathological class and diagnosis, and both variables are associated 
with renal outcome as shown above, differences in patient population could partly 
be an explanation for the conflicting results. Unfortunately, our cohort was not 
large enough to analyze this hypothesis. Regarding treatment, our study showed 
that patients with crescentic class received plasma exchange more frequently than 
patients in the other classes. However, a subanalysis showed that the use of plasma 
exchange did not affect renal survival within the crescentic class. This is an interesting 
finding, because crescentic class is considered an active and potentially reversible 
disease state, which could be reversed with the right treatment.16;18;20 Our study is 
insufficient for firm conclusions on whether the therapy must be considered in addition 
to the histopathological classification for predicting outcome. A third explanation is 
interobserver agreement which was moderate in this study. In addition, the scoring 
was performed by seven experienced nephropathologists, and therefore we cannot 
translate this level of agreement to the clinical practice in a one-on-one fashion. This 
agreement level could influence the observed contradiction in the previous studies.
A fourth explanation is insufficiency of the histopathologic classification. The current 
histopathologic classification of AAGN is only based on glomerular lesions, not 
taking tubulointerstitial parameters into account, because these did not have an 
additional predictive value in the original study and made the classification only more 
complicated.20 The importance of tubulointerstitial parameters for renal outcome in 
AAGN, even when used in addition to the histopathologic classification of AAGN, has 
been shown in other studies.15;16;18;29;36;40;42;55-58 In our study, the extents of interstitial 
infiltrate, IFTA, and tubulitis were significantly associated with eGFR5 in the univariate 
analysis. In the multivariate analysis, only IFTA remained significantly associated 
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with eGFR5. These data suggest that including tubulointerstitial parameters in the 
classifi cation system will lead to refi nements for the prognostication of patients at 
time of diagnosis, although the poor to moderate interobserver agreement regarding 
tubulointerstitial variables must also be considered.
The international patient cohort from three different continents was a strength of 
this study. Only one previous validation study included patients from more than two 
countries.40 In addition, our study included a large group of different pathologists 
for scoring the renal biopsies, which made it possible to investigate interobserver 
agreement. Our study also has some limitations. Due to the international character 
there was a wide variety of therapeutic regimens and the study had a retrospective 
design. Therefore, there was some missing data; but less than 7% of data were missing 
on renal function, diagnosis, serology, and therapy.
In conclusion, our study showed a signifi cant difference between focal and sclerotic 
class regarding renal outcome, but no difference between crescentic and mixed 
class. This last observation was also described by a number of previous studies. 
These fi ndings show that the histopathologic classifi cation of AAGN is a valuable 
tool in the management of patients with AAV, but in the near future, adjustments are 
needed to improve its prognostic value, especially for the crescentic and mixed class. 
Currently, we are performing a study to evaluate a more detailed scoring system for 
both glomerular and interstitial variables. Results from that study will determine how to 
adjust the histopathological classifi cation for AAGN for more sophisticated prognostic 
value.
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Histopathological classification of ANCA-associated glomerulonephritis: 
interobserver variability and clinical outcome
S Table 1 | Subanalyses for outcomes in the crescentic and mixed classes
Crescentic (n=37) Mixed (n=39) P-value
Follow-up, yrs 7.3 ± 5.2 8.3 ± 5.3 0.41
Renal relapses 14 (40.0) 11 (28.9) 0.34
ESRD within 10 yrs 9 (24.3) 6 (15.4) 0.40
Time to ESRD, yrs 6.2 ± 6.7 3.5 ± 2.8 0.31
Death 15 (40.5) 9 (23.1) 0.14
Time to death, yrs 6.6 ± 5.5 4.6 ± 4.5 0.39
Death within 10 yrs 11 (29.7) 7 (17.9) 0.29
Data are presented as mean ± SD or as number (percentage).
ESRD, end-stage renal disease
S Figure 1 | Combined outcome of ESRD/death in the crescentic and mixed classes over time. 
P-value (log-rank) = 0.57
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S Table 2 | Treatment according to histopathological class









Plasma exchange 20 (14.0) 5 (9.8) 9 (24.3) 4 (10.3) 2 (12.5)
Corticosteroids only 19 (13.3) 4 (7.8) 4 (10.8) 6 (15.4) 5 (31.3)
Corticosteroids and
 cyclophosphamide
106 (74.1) 43 (84.3) 30 (81.1) 23 (59.0) 10 (62.5)
Corticosteroids and
 azathioprine or MMF
8 (5.6) 2 (3.9) 1 (2.7) 4 (10.3) 1 (6.3)
Corticosteroids and
 mizoribine
5 (3.5) 1 (2.0) 0 (0.0) 4 (10.3) 0 (0.0)
Corticosteroids and
 rituximabb
5 (3.5) 1 (2.0) 2 (5.4) 2 (5.2) 0 (0.0)









Initially none 5 (3.7) 2 (4.1) 1 (2.9) 2 (5.6) 0 (0.0)
Corticosteroids only 27 (19.9) 8 (16.3) 4 (11.4) 7 (19.4) 8 (50.0)
Corticosteroids and
 cyclophosphamide
8 (5.9) 5 (10.2) 1 (2.9) 2 (5.6) 0 (0.0)
Corticosteroids and
 azathioprine or MMF
83 (61.0) 29 (59.2) 25 (71.4) 21 (58.3) 8 (50.0)
Azathioprine or MMF 5 (3.7) 3 (6.1) 2 (5.7) 0 (0.0) 0 (0.0)
Corticosteroids and
 mizoribine
8 (5.9) 2 (4.1) 2 (5.7) 4 (11.1) 0 (0.0)
MMF, mycophenolate mofetil.
a Data on induction therapy was missing in 2 patients.
b One of these patients also received 2 doses of intravenous cyclophosphamide.
c Data on maintenance therapy was available in 142 patients. Six patients did not receive 
maintenance therapy due to death or dialysis dependency.
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S Document 1 | Scoring questionnaire
Overall






Inflammatory infiltrate present in:
3 Infiltrates
a) <10% of unscarred parenchyma
b) 10 to 25% of unscarred parenchyma
c) 26 to 50% of unscarred parenchyma
d) >50% of unscarred parenchyma




5 Interstitial fibrosis and tubular atrophy
a) No interstitial fibrosis and tubular atrophy
b) Mild interstitial fibrosis and tubular atrophy (<25% of cortical area)
c) Moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area)
d) Severe interstitial fibrosis and tubular atrophy/loss (>50% of cortical area)
6 Intra-epithelial infiltrate
a) No mononuclear cells in tubules
b) Foci with 1 to 4 cells/tubular cross section or 10 tubular cells
c) Foci with 5 to 10 cells/tubular cross section
d) Foci with >10 cells/tubular cross section
Vessels
7 Is vasculitis present in the small vessels (arterioles and/or arteries)?
a) Yes
b) No
8 Are large vessels present in the biopsy?
a) Yes (please answer question 9)
b) No (proceed to question 10)
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11 Do you have any comments?
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Introduction: Data on the outcome of renal transplantation in anti-neutrophil 
cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) patients are 
still limited. In particular, how disease recurrence in the renal allograft defines graft 
outcome is largely unknown. Therefore, we conducted a multi-center observational 
clinical and histopathological study to establish recurrence rate of AAGN in the 
allograft, and the impact of recurrence on allograft survival.
Methods: Using the nationwide Dutch Pathology Registry (PALGA), we retrospectively 
collected clinical and histopathological data of consecutive AAGN patients who had 
developed end-stage renal failure and received a kidney allograft in one of six Dutch 
university hospitals between 1984 and 2011. Transplant biopsies were scored 
using the Banff ‘09 classification. Renal disease recurrence was scored using the 
histopathological classification of AAGN.
Results: The post-transplantation recurrence rate of AAGN was 2.8% per patient year, 
accumulating to recurrence in a total of 11 out of 110 AAGN patients within the first 5 
years after transplantation. Four of these 11 patients lost their graft, with one-year and 
5-year graft survival rates of 94.5% and 82.8%, respectively. By multivariate analysis, 
AAGN recurrence was independently associated with subsequent graft loss.
Conclusions: In this study in 110 Dutch patients, the recurrence rate of AAGN within 
5 years after kidney transplantation appeared slightly higher than in previous reports. 
Moreover, recurrence of AAGN contributed independently to kidney allograft loss, 
emphasizing the importance of clinical vigilance, since early treatment might be critical 
to rescuing the allograft.
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INTRODUCTION
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the 
major subtypes of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV). Approximately 80% of patients with GPA and 90% of patients with MPA develop 
kidney involvement during the disease course.1 ANCA-associated glomerulonephritis 
(AAGN) progresses to end-stage renal failure (ESRF) in approximately 20-40% of 
patients.2-5 Data regarding the outcome of renal transplantation in AAGN patients 
are limited with only a few multi-center cohort studies. The studies vary widely with 
respect to graft survival and disease relapse rates; they reported 1-year graft survival 
rates of 86-100% and 5-year graft survival rates of 69-100%. In these studies, 
relapse rates ranged from 1.0-2.0% per patient year of follow-up.6-10 National and 
international registry studies reported 1-, 3-, 5, and 10-year graft survival rates of 
95%,11 70%,12 82-96%,11, 13 and 80%,14 respectively. These registry studies focused 
solely on graft survival and provided limited in-depth disease-specifi c data. Almost 
none of the published studies took into account histopathological fi ndings. Only Little 
et al. commented briefl y on vascular changes within the renal graft, but the complete 
renal transplant histopathology was not formally reviewed.9
In the current study, we investigated the outcome of renal transplantation in a Dutch 
cohort of AAGN patients, focusing on renal disease recurrence and graft survival rates 
within fi ve years of transplantation. We formally reviewed the complete renal transplant 
histopathology and assessed the impact of disease recurrence within the allograft on 




The study cohort included 113 patients who were retrospectively recruited from six 
academic hospitals in the Netherlands using a nationwide search for AAGN patients 
who received a renal transplant. We used the Dutch Pathology Registry (PALGA) 
(www.palga.nl), a nationwide network and registry of histo- and cytopathology in the 
Netherlands, encompassing all pathology laboratories.15 Only patients with one of 
the following diagnoses were included: GPA (formerly Wegener’s granulomatosis), 
MPA, proteinase 3 (PR3-)AAV, myeloperoxidase (MPO-)AAV, AAV not further 
specifi ed, renal limited vasculitis (RLV), systemic vasculitis, or pauci-immune rapidly 
progressive glomerulonephritis. Experienced, academically based nephrologists and 
nephropathologists verifi ed the diagnosis of each patient by reviewing the medical 
and histology reports. The diagnosis was based on a clinical presentation compatible 
A. Goceroglu - Binnenwerk.indd   108 22-6-2020   13:01:59
108
Chapter 5
with AAGN and substantiated by a positive ANCA serology and/or histology (light 
microscopy and immunofluorescence and/or electron microscopy). Because the 
PALGA search was limited to patients with a renal transplant sample, we performed an 
additional, center-specific search for transplanted AAGN patients. Nephrologists at the 
participating centers searched their hospital’s clinical database for additional patients. 
In summary, 113 patients with 34 native kidney biopsies and 136 renal transplant 
samples were included in this study. Diagnostic definitions were adapted from the 
1994 Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis.16 
All transplantations occurred between 1984 and 2011. We verified our search strategy 
using the Renine database (https://www.renine.nl/page?id=registry), which registers 
all patients in the Netherlands who receive chronic renal replacement therapy. This 
verification revealed no additional AAGN patients who were transplanted between 
1984 and 2011. All patients were Caucasian and had ESRF secondary to AAGN. Only 
the first renal transplantation of each patient was analyzed.
We also performed a search for native renal biopsies of all included patients. This 
resulted in 34 native renal biopsies from 31 patients. This number was relatively 
low, because many of the native renal biopsies were taken in regional non-academic 
hospitals, where the tissue specimens were either not accessible or not preserved. 
In case of non-accessibility or non-availability, the histology reports were additionally 
reviewed centrally by an experienced, academically based nephropathologist (I.M.B.).
Patients transplanted after September 2000 received daclizumab as induction therapy 
(100 mg/day on the day of transplantation and 10 days after transplantation). The 
general maintenance regimen of the transplanted patients in this cohort was a triple 
therapy consisting of prednisolone, mycophenolate mofetil (MMF) and a calcineurin 
inhibitor (CNI). Fifty-one patients remained on this triple therapy regimen. In 22 
patients, MMF or CNI was switched to azathioprine. Sixteen patients continued taking 
prednisolone and CNI, seven continued taking MMF and CNI, one continued taking 
prednisolone only, and four continued taking CNI only. In one patient, fingolimod was 
added to the standard regimen. In five patients, CNI was switched to a mammalian 
target of rapamycin (mTOR) inhibitor (three patients received sirolimus, and two 
received everolimus); in one patient, MMF was switched to everolimus, and a protein 
kinase C inhibitor was added. One patient continued on MMF, CNI and everolimus, 
and one patient continued on CNI and sirolimus.
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Data collection
Patient data included clinical data, histology reports and —where available— native 
renal biopsies and/or renal transplant samples. Clinical data were collected using a 
questionnaire for review of the medical reports, which was completed by experienced 
nephrologists working in the participating academic hospitals. Native renal biopsies, 
renal transplant samples and histology reports were collected by experienced 
nephropathologists working at the participating academic centers. Data until January 
2013 were collected. This study was conducted in accordance with the Declarations 
of Helsinki and Istanbul.
Clinical parameters
The following clinical data of the recipient between the time of diagnosis and the time 
of renal transplantation were collected: gender, date of birth, diagnosis (GPA/MPA), 
ANCA positivity during active disease (yes/no, PR3-ANCA/MPO-ANCA, cytoplasmic 
(c)ANCA/perinuclear (p)ANCA), time interval between diagnosis and transplantation, 
and (time on) dialysis. Clinical data at the time of transplantation included age, date 
of transplantation, donor type (deceased/living), and ANCA positivity. Clinical data 
collected after transplantation involved serum creatinine levels, date of last visit, 
disease relapse/renal disease recurrence, graft loss, death, ANCA positivity two and 
fi ve years after transplantation, and transplantation-related immunosuppressive 
therapy. In case of disease relapse, the therapy regimen used to achieve disease 
remission was noted.
Patients were subdivided into two groups of GPA and MPA in accordance with 
established diagnostic defi nitions. RLV was regarded as a form of MPA. ANCA was 
categorized as PR3-ANCA in case of a positive PR3-ANCA ELISA or a positive cANCA 
pattern by indirect immunofluorescence (IIF) microscopy, and as MPO-ANCA in case 
of a positive MPO-ANCA ELISA or a pANCA pattern on IIF microscopy.
Parameters considered for analyses were: gender, age at transplantation, GPA/MPA, 
ANCA-type, time between diagnosis and transplantation, time on dialysis, donor type, 
ANCA status at transplantation, renal disease recurrence, and an acute rejection 
episode.
Histology
Native renal biopsies and renal disease recurrence in the graft with an available 
biopsy were scored according to the histopathological classifi cation of AAGN.17 All 
renal transplant samples were scored according to the Banff ’09 classifi cation.18-20 
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The class was based on the first renal graft biopsy confirming the renal disease 
recurrence. All samples were scored centrally by an experienced, academically based 
nephropathologist (I.M.B.) who was blinded with respect to the clinical data.
Study outcomes
The primary clinical outcomes were renal disease recurrence and graft loss. The 
secondary outcome was disease relapse. Renal disease recurrence refers to the 
manifestation of the disease in the graft, independent of other organ involvement. 
Disease relapse refers to renal disease recurrence and/or extra-renal disease 
manifestations. Renal disease recurrence was defined as an increase in serum 
creatinine and new-onset hematuria or proteinuria (all attributable to active vasculitis) 
and/or histological confirmation. The appearance of cellular crescents and/or fibrinoid 
necrosis in the renal graft biopsy was considered evidence of renal disease recurrence. 
Extra-renal disease relapse was defined as new, worsened or recurred manifestations 
(all attributable to active vasculitis). Disease relapse was based on the expert opinion 
of the academically based nephrologists and nephropathologist (I.M.B.).
Statistical Analysis
Graft survival censored for death with a functioning graft was analyzed using 
the Kaplan-Meier survival method. For univariate analyses, log rank test and Cox 
regression analyses were used, with graft loss, renal disease recurrence and disease 
relapse as outcomes. In the univariate analyses, significant associations were found 
only with graft loss as outcome; therefore, multivariate Cox regression analyses were 
only performed with graft loss as dependent variable. All baseline parameters were 
considered to be fixed covariates. To assess the effect of renal disease recurrence and 
acute rejection on graft loss, both were considered to be time-dependent covariates. 
Due to the relatively low number of events, inclusion of all variables in the multivariate 
Cox regression analysis was not statistically feasible.21 Therefore, we analyzed one 
multivariate Cox regression model based on the outcomes of the univariate analyses 
(all variables with P<0.05). For Cox regression analyses, hazard ratio (HR) and 95% 
confidence interval (CI) were calculated. A P-value <0.05 was considered statistically 
significant. All statistical calculations were performed using SPSS (v20.0; IBM Corp, 
Armonk, NY) and GraphPad Prism software (v6; GraphPad Software Inc, La Jolla, CA).
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RESULTS
Patients and events
A total of 113 AAGN patients who received a renal transplant from 1984 through 2011 
were included (Table 1). In three patients (3%) the graft did not gain proper function 
after transplantation and these were excluded from analyses. Of the remaining 110 
patients, 88 (80%) retained the graft and did not die during the follow-up period. 
Fifty-seven of them (65%) completed the fi ve years of follow-up. The remaining 31 
patients (35%) had their last visit within fi ve years of transplantation (median: 27.9 
months, interquartile range (IQR): 21.0-41.8); two of them were lost to follow-up 
(reason unknown).
During follow-up, 79 patients (72%) experienced no event and six patients (5%) died 
with a functioning graft within fi ve years of transplantation without experiencing a 
disease relapse (Figure 1). These six patients died due to infection (n=3), cancer (n=2), 
or a cardiovascular event (n=1).
Thirteen patients (12%) experienced 16 disease relapses (three patients experienced 
two relapses) within fi ve years of transplantation (Figure 1). Of these 16 relapses, two 
involved extra-renal organs only, fi ve involved the renal graft only, and nine involved 
both the renal graft and extra-renal organs (Table 2). The fi rst disease relapse occurred 
within a median of 22.1 months (IQR: 10.3-46.3) following transplantation. The risk of 
experiencing a fi rst disease relapse within 5 years of renal transplantation was 3.3% 
per patient year. The fi rst renal disease recurrence occurred within a median of 18.0 
months (IQR: 10.3-45.9). The risk of experiencing a fi rst renal disease recurrence 
within fi ve years was 2.8% per patient year. The relapses were equally distributed 
between 1986 and 2012.
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Table 1 | Baseline characteristics of renal transplant recipients with end-stage renal failure due 
to ANCA-associated vasculitis
Characteristic Value
Number of patients 113
Age at transplantation (years) 52.2 (14.7)a
Male 77 (68.1)
Diagnosis
      GPA




      PR3
      MPO
      ACPAb
      Negative
      Double positive
      ANCA-positive not further specified








Time between diagnosis and transplantation (months) 50.0 (26.6 – 95.2)c
Dialysis before transplantationd
      Yes
      No (preemptive transplantation)




Time on dialysis before transplantationd (months) 24.0 (16.7 – 40.3)c
Donor type
      Deceased
      Living
67 (59.3)
46 (40.7)
ANCA status at time of transplantation
      Positive
      Negative





      Before 1990
      1990 - 2000




Data are presented as n (%) unless otherwise noted.
aMean (SD).
bFormer nomenclature for ANCA, and referred primarily to PR3-ANCA. These patients were tested 
before 1990, and no further specified test results were reported at a later time point.
cMedian (25th and 75th percentile).
dIrreversible dialysis dependency.
Abbreviations: GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; ANCA, 
anti-neutrophil cytoplasmic antibody; PR3, proteinase 3; MPO, myeloperoxidase; ACPA, anti-
cytoplasmic antibody; SD, standard deviation, NR, not reported/not performed.
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Figure 1 | Events.
Flowchart of the different events, which the 113 patients experienced within fi ve years of renal 
transplantation. 
Abbreviation: AAV, ANCA-associated vasculitis.
The occurrence of (and time to fi rst) relapse was not associated with any of the baseline 
characteristics listed in table 1, including type of immune-suppressive regimen. Four 
patients with renal disease recurrence in the graft, lost their grafts due to the disease 
recurrence within fi ve years of transplantation. One of these patients experienced the 
fi rst renal disease recurrence ten months after transplantation, which entered into 
remission following plasmapheresis, prednisolone and cyclophosphamide treatment. 
This patient’s second renal disease recurrence occurred 13 months after the fi rst event, 
and despite treatment with an increased dose of prednisolone with continuation of 
MMF and CNI, the patient lost the graft. In the other patients, the disease recurrences 
leading to graft loss were treated with prednisolone and cyclophosphamide (Table 
2). These four grafts were lost before remission was achieved. All other patients 
were treated to remission without graft loss. At the time of relapse, 13 patients were 
ANCA-positive, two patients were ANCA-negative, and in one, the ANCA titer was not 
reported.
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Twelve patients lost their grafts due to other causes than renal disease recurrence of 
AAGN: interstitial fibrosis and tubular atrophy (n=4), acute rejection (n=3), (uro)sepsis 
(n=2), post-transplant lymphoproliferative disorder (n=1), infarction (n=1) and acute 
cyclosporine toxicity (n=1). The 1-year graft survival rate was 94.5% (95% CI, 90.2%-
98.8%), and the 5-year graft survival rate was 82.8% (95% CI, 75.0%-90.6%) (Figure 
2). The era in which the transplantation was performed had no significant effect on 
graft survival (Figure 3).
Figure 2 | Death-censored renal graft survival.
Kaplan-Meier curve of renal graft survival among 110 renal transplant recipients with 
ANCA-associated vasculitis. During follow-up 16 patients lost their graft within five years of 
transplantation. The one-year graft survival rate was 94.5% (95% CI, 90.2%-98.8%), and the 
5-year graft survival rate was 82.8% (95% CI, 75.0%-90.6%). The data was censored for death 
with a functioning graft.
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Figure 3 | Death-censored renal graft survival according to transplantation era.
Kaplan-Meier curves of renal graft survival according to the era’s in which the 110 renal transplant 
recipients with ANCA-associated vasculitis were transplanted. The patients were divided into three 
era’s: before 1990, 1990-2000 and after 2000. These era’s were chosen in accordance with the 
study by Little et al.(9) There was no difference in graft survival between the groups (log-rank test: 
P=0.13).




Of the 136 renal transplant samples taken from these 110 patients within five years 
of transplantation, 108 fulfilled the criteria (≥7 glomeruli and ≥1 artery) for scoring 
using the Banff ’09 classification (Table 3).18-20 Of the 108 suitable samples, 24 were 
protocol biopsies (median: 4 months, IQR: 3 – 14), all the other biopsies were taken 
for cause. During follow-up, 23 patients experienced 28 biopsy-confirmed acute 
rejection episodes, three of which showed signs of humoral rejection. Six episodes 
were subclinical acute rejections detected by protocol biopsies.
Table 3 | Overview of the histological findings in 108 renal transplant samples of 110 patients





Normal 13 11 0.7 (0.3-3.0)
Acute rejection 28e  23 5.2 (0.5-16.8)
Borderline changes 9e  8 1.3 (0.8-5.5)
IFTA 25 21 12.0 (1.3 – 28.3)
CNI toxicity 8 8 2.1 (0.9-10.5)
ATN 4 4 0.3 (0.2-0.3)
Renal disease recurrence 10e  10 19.0 (9.7-31.8)
BK-nephropathy 1 1 22.3
TMA 1 1 0.4
Pyelonephritis 1 1 0.4
Infarction 2 2 0.1 and 1.7 
Extensive vasculopathy 1 1 0.9
Slight hyalinosis 1 1 1.1
aAdapted from the Banff ’09 classification.
bThe total number of samples/episodes differs from 108, since categories may coincide in the same 
sample and some numbers represent number of episodes rather than number of samples (see e).
cThe total number of patients in the table differs from the total number of the cohort (n=110), 
since histological lesions may coincide in the same patient and not all patients were biopsied after 
transplantation.
dTime in months: median (IQR).
e These numbers represent episodes: in some cases more than one biopsy has been performed on 
the same episode.
Abbreviations: Tx, transplantation; IFTA, interstitial fibrosis and tubular atrophy; CNI, calcineurin 
inhibitor; ATN, acute tubular necrosis; TMA, thrombotic microangiopathy; IQR, interquartile range.
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Renal biopsies were available for 10 of the 14 renal disease recurrences. All ten biopsy-
confi rmed recurrences were fi rst-time renal disease recurrences. The histopathological 
classes of these ten recurrences were focal (5), crescentic (1), and mixed class (4) 
(Table 2). The biopsies contained a median of 16 glomeruli (IQR: 12-22). In the three 
patients who had lost their graft within fi ve years of transplantation as a result of their 
fi rst renal disease recurrence, one recurrence was focal, and two were mixed class. In 
one of the patients with a mixed class recurrence, the recurrence changed to crescentic 
class before graft loss (S Table 1 in the supplementary material).
Outcome statistical analyses
Four baseline parameters were associated with graft loss in a univariate Cox regression 
analysis (S Table 2 in the supplementary material). Male gender of the recipient (HR 
0.33, 95% CI 0.12-0.88, P=0.03) and a living donor (HR 0.22, 95% CI 0.05-0.95, 
P=0.04) were associated with better graft survival. Experiencing renal disease 
recurrence (HR 12.43, 95% CI 3.61-42.89, P<0.001) and experiencing an acute 
rejection (HR 3.18, 95% CI 1.08-9.36, P=0.04) were signifi cantly associated with 
worse graft survival. No baseline parameter was associated with either renal disease 
recurrence or disease relapse (S Table 3 in the supplementary material).
In the multivariate analysis with graft loss as outcome and including all baseline 
parameters that were statistically signifi cant in the univariate analysis, only the 
associations with gender of the recipient (HR, 0.27; 95% CI, 0.09-0.81; P=0.02) and 
experiencing renal disease recurrence persisted (HR, 18.48; 95% CI, 4.96-68.89; 
P<0.001) (Table 4).
Table 4 | Outcome of the multivariate analysis regarding graft loss
Multivariate model
Parameter P-value HR (95% CI)
Male gender recipient 0.02 0.27 (0.09-0.81)
Living donor 0.08 0.26 (0.06-1.18)
Renal disease recurrence <0.001 18.48 (4.96-68.89)
Acute rejection episode 0.25 1.94 (0.62-6.03)
Abbreviations: HR, hazard ratio; 95% CI, 95% confi dence interval.




We investigated the outcome of renal transplantation within the first five years of 
transplantation in a Dutch cohort of 113 AAGN patients transplanted between 1984 
and 2011. In this cohort, the 1-year and 5-year graft survival rates were 94.5% and 
82.8%, respectively, which is similar to graft survival rates reported by registry data 
of the general transplantation population in Europe and North America.22-24 Compared 
to the Dutch general renal transplantation population transplanted in the period 1984-
2011, the graft survival in our AAV cohort seemed to be better: 1-year graft survival 
94.5% vs. 86.0%, 5-year graft survival 82.8% vs. 70.0% (Dutch Transplantation 
Foundation (NTS) database; registers all transplantations in the Netherlands, 
accessed 12-06-2015). This discrepancy is most likely due to the larger proportion 
of transplantations in the earlier years in the general population compared to our 
cohort. In addition, compared to the European and North American registry data, 
transplantations from an earlier period have been included in the Dutch registry data. 
The risk of experiencing a first disease relapse or renal disease recurrence within 
5 years of transplantation was 3.3% and 2.8% per patient year, respectively. The 
principal finding in this cohort was that renal disease recurrence was an important 
cause of graft loss within the first 5 years of transplantation.
Our graft survival rates are similar to those reported in previous studies on AAGN, 
although some studies reported a slightly better 1- or 5-year graft survival rate.7-9,13 Most 
of these studies included transplantations performed in a later time period compared 
to our study; from the late 90’s on. In our cohort the era in which the transplantation 
was performed had no significant effect on graft survival. These slight differences 
can also be a consequence of the relative small cohorts in the different studies. The 
largest cohort with 919 recipients transplanted between 1997-2007 showed similar 
graft survival rates as our study.11 There were no noteworthy differences in treatment 
protocols between the studies that could explain the differences.
Our relapse and recurrence rates are slightly higher compared to those reported in 
other studies. Most studies on the outcome of renal transplantation in AAV described 
rates of 1.0-2.0% per patient year.6-9 Three studies reported higher rates of 7.6%, 6.0% 
and 10.0% per patient year.25-27 Several of these studies described patients with renal 
disease recurrence with consequent graft loss, sometimes in >50% of the patients with 
recurrence.7, 9-11, 13 Our study is the first study which specifically assesses the impact 
of renal disease recurrence on graft survival, showing that renal disease recurrence is 
associated with subsequent graft loss.
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The patients who lost their graft after renal disease recurrence were not treated more 
or less aggressively than the patients who did not lose their graft. In view of recent 
evidence from the RAVE trial (NCT00104299) showing that rituximab treatment has 
an advantage over cyclophosphamide treatment in case of relapse with severe disease 
manifestations,28, 29 we suggest that also in the transplantation setting there may be a 
benefi t of treating recurrent disease with rituximab. In fact, two patients in our cohort 
who were treated with rituximab for a renal disease recurrence did not lose their graft. 
Another study also described remission induction with rituximab in patients with renal 
disease recurrence in the graft.30 However, we were unable to compare the rituximab-
treated patients with standard cyclophosphamide-treated patients due to the small 
patient numbers. Our results show that the recurrence of AAGN is an important cause 
of graft loss, and therefore, continuously monitoring these transplanted patients for 
relapse is highly important.
Currently no distinction is made in the clinical setting based on the clinical defi ned 
diseases or ANCA-specifi ty. They are treated the same way and have the same 
procedure regarding renal transplantation in AAGN. Our study showed that there is 
no difference in graft loss, renal disease recurrence or disease relapse when comparing 
disease subtypes or ANCA-specifi city. This is also described in other studies on renal 
transplantation in AAGN.7, 9, 13 Further studies are needed to determine whether 
distinction in ANCA specifi city or disease subtype is needed for optimal clinical 
management.
Our study and other studies revealed that patients can relapse without a positive ANCA 
titer before the relapse. This fi nding is consistent with other renal transplantation 
studies.26, 31-34 A meta-analysis found that a rise in—or persistence of—ANCA has 
modest predictive value for future disease relapse in AAV patients without ESRF.35 
Therefore, it may be concluded that the isolated use of serial ANCA measurements is 
not reliable for management decision-making in transplanted AAGN patients.
This is the first study that formally reviewed the complete renal transplant 
histopathology and classifi ed renal disease recurrence in the graft according to 
the histopathological classifi cation of AAGN. With regards to the histopathological 
presentation of the renal disease recurrence in the grafts, we found that the disease 
can recur as a different class in the graft and that histopathological class can change 
over time in the renal graft after disease recurrence. These fi ndings, although based on 
small numbers (S Table 1 and S Table 4 in the supplementary material), may suggest 
that the histopathological classes represent different phases of the disease. This is 
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in line with recent evidence from a study by Hruskova et al. describing a class change 
over native renal biopsies in 86% of the patients in protocolized repeat biopsies after 
one year.36
In the last 30 years, important developments were made in the field of post-
transplantation immunosuppressive therapy. In 1983, cyclosporine was introduced 
after the ‘azathioprine era’. This resulted in improved graft survival rates.37 After 
increased use of cyclosporine over time, in 1992 new trends developed including 
waning of cyclosporine and the rise of induction therapy. The use of induction therapy 
gradually increased resulting in 59% of all recipients receiving induction therapy in 
2001. During this period, corticosteroid therapy was an important component of 
maintenance therapy. The waning of cyclosporine was accompanied with a rise of 
tacrolimus use. In 1992, azathioprine was predominantly used as antimetabolite, 
but by 2001 most centers used MMF. In 1996, rapamycine was introduced as an 
alternative to spare other immunosuppressive drugs, in particular the nephrotoxic 
CNI. These developments resulted in the currently most used regimen of induction 
therapy followed by a triple therapy consisting of prednisolone, MMF and tacrolimus.38 
This probably has decreased the relapse rates of AAV after renal transplantation when 
comparing the different studies over time, but none of them could demonstrate this, 
probably due to a lack of power.6-9, 25-27
AAV is diagnosed on the clinical manifestation compatible with AAV and substantiated 
by a positive ANCA serology and/or histology. In the 90s, solid phase assays (ELISAs) 
for PR3-ANCA and MPO-ANCA detection were developed and standardized.39 In 
addition, a disease specific activity index was introduced, which was revised two 
times since then; Birmingham Vasculitis Activity Score.40-42 The gold standard for 
establishing AAGN is a renal biopsy. These diagnostic tools are also used in the setting 
of transplantation for detecting disease relapse. When detecting disease relapse in 
general the patient receives induction therapy based on a cyclophosphamide regimen 
as is the case with newly diagnosed AAV. As discussed above, rituximab is now also 
more frequently used in case of renal disease recurrence after transplantation.
The retrospective design is a limitation of our study. Although complete data were 
available for most patients, some cases had missing data or material was not available. 
This made it impossible to determine the duration of remission prior to transplantation 
in relation to post-transplant outcome. Moreover, numbers were too low to detect 
an impact of maintenance immunosuppression or therapy of recurrent disease on 
graft loss. Nevertheless, given our data we do not expect that a specific regimen was 
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associated with a negative outcome, as the majority of patients who experienced 
disease relapse, renal disease recurrence and/or graft loss received conventional 
therapy.
We conclude that in a substantial proportion (36%) of AAGN patients with disease 
recurrence in the renal graft, the recurrence led to graft loss within fi ve years of 
transplantation. In a multivariate analysis, renal disease recurrence was independently 
associated with subsequent graft loss. So, although the risk of renal disease recurrence 
is rather low, once a recurrence of the disease occurs in the graft, the risk of graft loss is 
considerable. This study confi rms that renal transplantation is a viable treatment option 
for AAGN patients with ESRF, but it also serves as a warning that clinicians must remain 
cognizant of the risk of graft loss when the disease has recurred in the renal graft.
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SUPPLEMENTARY MATERIAL
The Dutch transplantation in vasculitis (DUTRAVAS) study: outcome of renal 
transplantation in ANCA-associated glomerulonephritis
S Table 1 | Overview of the patients with follow-up biopsies of their biopsy-confi rmed renal 
disease recurrence
Patienta Class recurrence 
- fi rst biopsyb
Class recurrence - 
follow-up biopsy 1b
Class recurrence - 
follow-up biopsy 2b
Second renal disease 
recurrence ≤5 years of Tx
Graft loss ≤5 
years of Txc
1 Focal (0.3) Focal (0.6) Focal (1.1) No Yes
2 Mixed (15.8) Crescentic (17.1) - No Yes
7 Focal (27.2) Mixed (32.8) - Yes No
8 Focal (8.1) Focal (10.0) - Yes No
aThe patient numbers correspond with Table 2.
bClass (months after transplantation).
cGraft loss within fi ve years of transplantation due to disease relapse with renal graft involvement 
(renal disease recurrence).
Abbreviations: Tx, transplantation.
S Table 2 | Outcomes of the univariate analyses regarding graft loss  
Parameter
Graft loss
P-value HR (95% CI)
Gender recipienta 0.03 0.33 (0.12-0.88)
Age at transplantation (years) 0.36 0.99 (0.96-1.02)
Diagnosisb 0.20 1.92 (0.72-5.17)
PR3-ANCAc 0.60 0.75 (0.25-2.24)
MPO-ANCAc 0.81 1.14 (0.40-3.29)
Time between diagnosis and transplantation (months) 0.85 1.00 (0.99-1.01)
Time on dialysis (months) 0.27 1.01 (0.99-1.04)
Donor typed 0.04 0.22 (0.05-0.95)
ANCA status at transplantatione 0.31 0.49 (0.12-1.96)
Renal disease recurrencef <0.001 12.43 (3.61-42.89)
Acute rejection episodeg 0.04 3.18 (1.08-9.36)
aRef: female.




fRef: patients experiencing no renal disease recurrence (time-dependent covariate).
gRef: patients experiencing no acute rejection episode (time-dependent covariate).
Abbreviations: HR, hazard ratio; 95% CI, 95% confi dence interval; PR3, proteinase 3; ANCA, anti-
neutrophil cytoplasmic antibody; MPO, myeloperoxidase.
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S Table 3 | Outcomes of the univariate analyses regarding renal disease recurrence and disease 
relapse
Parameter
Renal disease recurrence Disease relapse
P-value HR (95% CI) P-value HR (95% CI)
Gender recipienta 0.42 1.89 (0.41-8.74) 0.59 1.43 (0.39-5.19)
Age at transplantation (years) 0.64 0.99 (0.95-1.03) 0.27 0.98 (0.95-1.01)
Diagnosisb 0.52 1.50 (0.44-5.12) 0.81 1.15 (0.36-3.74)
PR3-ANCAc 0.64 1.35 (0.39-4.67) 0.43 1.62 (0.49-5.31)
MPO-ANCAc 0.81 0.86 (0.25-2.97) 0.58 0.72 (0.22-2.36)
Time between diagnosis and 
transplantation (months)
0.64 1.00 (0.99-1.02) 0.74 1.00 (0.99-1.02)
Time on dialysis (months) 0.20 1.02 (0.99-1.05) 0.10 1.02 (1.00-1.05)
Donor typed 0.78 0.84 (0.25-2.88) 0.51 0.67 (0.21-2.18)
ANCA status at transplantatione 0.27 2.54 (0.49-13.12) 0.47 1.69 (0.40-7.08)
aRef: female.




Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; PR3, proteinase 3; ANCA, anti-
neutrophil cytoplasmic antibody; MPO, myeloperoxidase.
S Table 4 | Overview of the patients with a native renal biopsy and a biopsy-confirmed renal 
disease recurrence after transplantation
Patienta
Class diagnostic native 
biopsy
Class follow-up native 
biopsy, if available
Class renal disease 
recurrenceb
1 Focal Mixed Focal (10.4)
2 Crescentic - Mixed (45.9)
3 Mixed* - Mixed (59.2)
4 Sclerotic - Mixed (142.4)
aPatient 1, 2 and 3 correspond with patient 6, 3 and 9, respectively, in Table 2.
bClass (months after transplantation). 
*One week after cyclophosphamide treatment was started.
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Consider antineutrophil cytoplasmic antibody (ANCA) associated vasculitis when 
inflammatory disease cannot be ascribed to any other disease and inflammation 
progresses despite antibiotics.
Avoid diagnostic delay to prevent end organ damage, particularly renal disease.
Test for ANCA in patients with chronic destructive upper airway disease, 
pulmonary nodules, renal and pulmonary inflammatory disease, rapidly progressive 
glomerulonephritis, skin vasculitis with systemic illness, mononeuritis multiplex, 
subglottic stenosis of the trachea, and retro-orbital mass.
Patients should be managed by a specialist in vasculitides.
Remission is usually induced with high dose glucocorticoids and cyclophosphamide 
and followed by remission maintenance treatment.
Adverse responses to treatment are common, as are relapses, so long term follow-up 
is needed.
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Diagnosis and management of ANCA-associated vasculitis
Vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA) are 
systemic autoimmune diseases of unknown cause that affect small to medium sized 
blood vessels. They include granulomatosis with polyangiitis (formerly Wegener’s 
granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with 
polyangiitis (formerly Churg-Strauss syndrome). This review mainly focuses on 
granulomatosis with polyangiitis and microscopic polyangiitis. Although they are 
relatively rare, they must be diagnosed and treated early because untreated disease 
may rapidly develop into multiple organ failure and death. With modern treatment, 
these diseases are no longer fatal but chronic. Early diagnosis and treatment may 
prevent progression to end organ damage and lengthen healthier life. A recent large 
survey of patients with ANCA associated vasculitis found a lag of three to 12 months 
between disease onset and diagnosis, suggesting that diagnostic delay is a problem.1 
We review the diagnosis and management of ANCA associated vasculitides for the 
generalist reader, drawing on the fi ndings of observational studies, randomised 
controlled trials, and meta-analyses.
SOURCES AND SELECTION CRITERIA
We searched PubMed (original search performed in August 2011, updated in 
December 2011) for relevant articles on epidemiology, diagnosis, and management 
of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Where possible, 
we sought data from prospective randomised clinical trials and meta-analyses. We also 
screened personal archives for relevant papers and consulted experts in otolaryngology 
(NR), nephrology (DJ), and rheumatology (RL). All relevant keyword variations were 
used. All searches contained the keywords “ANCA” or “vasculitis”, or both. We limited 
results to articles written in English.
WHO GETS IT?
The overall annual incidence of ANCA associated vasculitis in Europe and Northern 
America is approximately 20 per million (with point prevalence of 130/million for 
granulomatosis with polyangiitis and 47.9/million for microscopic polyangiitis in the 
United Kingdom in 2008).2,3 Disease onset usually occurs at 65-74 years, although 
it can occur at any age.3 Prevalence is generally higher in men, but women more 
often develop disease at a younger age.1 The overall prevalence of ANCA associated 
vasculitis is highest in Caucasians.1,4 The incidence of granulomatosis with polyangiitis 
is higher in northern Europe, whereas that of microscopic polyangiitis is higher in 
southern Europe and Japan.2,5
A. Goceroglu - Binnenwerk.indd   134 22-6-2020   13:02:02
134
Chapter 6
HOW DO PATIENTS PRESENT?
Patients typically present with prodromal “flu-like” symptoms of several weeks’ or 
months’ duration,6,7 such as fever, polymyalgia, polyarthralgia, headache, malaise, 
anorexia, and unintended weight loss. These non-specific symptoms overlap with 
symptoms of non-vasculitic processes such as post-viral syndrome, infections, or 
malignancy. Consider vasculitis as a differential diagnosis in patients with general 
symptoms and signs of inflammatory disease. Some patients may initially present with 
focal vasculitic disease such as rash, cutaneous vasculitis, bloody-purulent rhinitis, 
scleritis, or arthritis. In such patients, careful examination of other organ systems may 
show other disease manifestations.
Figure 1 shows the many ways in which vasculitis can manifest. Patients may 
report different symptoms over time. Symptoms of the different ANCA associated 
vasculitides overlap, but some symptoms are more common in certain diseases. For 
example, ear, nose, and throat problems—such as hearing loss, otalgia, (bloody nasal) 
rhinorrhoea, otorrhoea, sinusitis, nasal crusting, and recurrent otitis media—occur 
in about 90% of patients with granulomatosis with polyangiitis and in 35% of those 
with microscopic polyangiitis.6,7 Large observational studies have shown that the 
airways and lung parenchyma are commonly affected, as are the kidneys, although 
this may not be apparent until renal failure occurs.6,8,9 Urinalysis may therefore identify 
renal involvement early on in the disease. About 50% of patients have cutaneous 
manifestations of disease such as urticarial rash or tender skin nodules. The eyes 
and nervous system are also commonly affected.6,8,9 A careful physical examination is 
needed to determine the full extent of disease.
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Figure 1 | Clinical manifestations of antineutrophil cytoplasmic antibody associated vasculitis.
Alveolar haemorrhage is an important cause of mortality. Renal involvement manifests with 
early detectable haematuria, red cell and other casts, and proteinuria. It is an important cause 
of morbidity and mortality. The most common skin lesion is leucocytoclastic angiitis, which 
mostly causes purpura on the lower extremities, sometimes accompanied by focal necrosis and 
ulcerations. Skin lesions can appear on parts of the body not shown here. Eye disease presents as 
a painful or painless red eye. Mononeuritis multiplex is seen in 20% of patients. 
*These lesions can be seen on chest radiography and computed tomography.
HOW CAN IT BE DIAGNOSED?
Investigations that can be undertaken in primary care
Blood tests requested in primary care may show leucocytosis, thrombocytosis, 
raised erythrocyte sedimentation rate and C reactive protein values, normochromic-
normocytic anaemia, and a raised serum creatinine.6 Patients with symptoms and signs 
of vasculitis and abnormalities on these blood tests require urinalysis, including urinary 
sedimentation, to look for haematuria and proteinuria. An increased serum creatinine 
indicates that renal damage has already occurred. Chest radiography in patients with 
pulmonary symptoms such as dyspnoea, cough, or haemoptysis may show infi ltrates, 
nodules, or cavitations in the lung parenchyma.
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An ANCA assay can be requested in primary care. The test is indicated in a patient with 
unexplained illness that has lasted more than a few weeks (box 1) and is associated 
with a raised erythrocyte sedimentation rate or C reactive protein, particularly if more 
than one organ system is affected. Four large international randomised controlled 
trials found that the test is positive in 90-95% of patients with active generalised 
granulomatosis with polyangiitis or microscopic polyangiitis before treatment.10-13 Two 
types of assay are generally used: indirect immunofluorescence (IIF) and the enzyme 
linked immunosorbent assay (ELISA). Table 1 outlines the properties of these tests. 
An international multicentre observational study found that IIF is more sensitive but 
that ELISA is more specific.14 The current international standard approach is to use 
IIF as a screening test and ELISA to confirm positive results.15 ANCA assays should be 
performed only in experienced laboratories. Testing is not standardised, so sensitivity 
and specificity vary between laboratories and reference values are unavailable. 
Although the ANCA test is positive in most patients with untreated disease, a negative 
result does not exclude the diagnosis of ANCA associated vasculitis because 5-10% of 
patients do not develop ANCA. Neither does a negative ANCA test exclude the presence 
of other non-ANCA associated small and medium vessel vasculitic syndromes. Such 
patients may require more systematic investigation to ascertain the extent of their 
disease. Although the ANCA test is widely used as a routine screening tool for vasculitis 
in secondary care, it provides poor sensitivity and specificity in this setting.16,17 When 
there is a clearer indication and likelihood of vasculitis the yield from testing is higher. 
If there is a high index of suspicion on the basis of clinical findings but the ANCA test 
is negative, an ANCA assay can be repeated a few weeks after the original test, but if 
patients have disease manifestations in multiple sites immediate referral is indicated.
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Table 1 | Properties of ANCA tests and their clinical importance
PR3-ANCA MPO-ANCA
Test methods Finely granular staining of the 
cytoplasm (c-ANCA) is seen on IIF; PR3 
is the antigen in direct, capture, anchor, 
and luminex ELISAs
Perinuclear staining of the neutrophils 
(p-ANCA) is seen on IIF; MPO is used as 




Almost all patients in northern Europe 
with untreated acute granulomatosis 
with polyangiitis will be positive
Most patients in northern Europe with 
untreated acute microscopic polyangiitis 
and some with granulomatosis with 
polyangiitis will be positive
Relation to 
disease activity
Immunomodulatory treatment reduces 
positivity for PR3-ANCA, but positivity 
increases when treatment is tapered 
off; reappearance of PR3-ANCA in non-
treated patients may refl ect disease 
activity
Immunomodulatory treatment also reduces 
positivity for MPO-ANCA and it increases 
when treatment is tapered off, but 
fl uctuations often occur that are not related 
to disease activity
ANCA=antineutrophil cytoplasmic autoantibodies; ELISA=enzyme linked immunosorbent assay; 
IIF=indirect immunofl uorescence; MPO=myeloperoxidase; PR3=proteinase 3.
Refer any patient with a positive ANCA test result to a specialist in vasculitis, usually a 
rheumatologist or a nephrologist, or possibly a chest physician or ear, nose, and throat 
surgeon, depending on clinical presentation (box 2). Referral to specialists without 
experience with vasculitis may delay diagnosis. Many conditions can be associated 
Box 1 | Targeted testing for antineutrophil cytoplasmic antibodies
Test when patients have one or more of the following sets of symptoms:
·General: Persistent fl u-like condition with headache, myalgias, arthralgias, and weight 
loss
·Ear, nose, and throat: Hearing loss that slowly develops over days to weeks without a 
preceding cold, but with “chronic fl u”; slowly developing nasal stenosis with midfacial 
pain and increasing bloody purulent secretion with crust formation that does not 
respond to antibiotics (granulomatosis with polyangiitis)
·Eyes: Unexplained conjunctivitis combined with general symptoms, uveitis, unilateral 
proptosis, and paresis of the ocular motor nerves (granulomatosis with polyangiitis)
·Lungs: Slowly developing cough and shortness of breath possibly with bloody-purulent 
sputum, bilateral infi ltrates on radiography that do not respond to antibiotics, non-tu-
berculous cavitating lesions (granulomatosis with polyangiitis), alveolar haemorrhage 
(microscopic polyangiitis)
·Skin: Bursts of small cutaneous vasculitis elements, pyoderma gangraenosum, and 
oedema
·Kidneys: Haematuria, proteinuria, hypertension, decreasing renal function (granuloma-
tosis with polyangiitis and microscopic polyangiitis)
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with a positive ANCA test result, including infl ammatory bowel disease, chronic 
infections (such as tuberculosis), and autoimmune conditions such as systemic lupus 
erythematosus and rheumatoid arthritis, and ANCA can be induced by several drugs. 
This highlights the need for judicious testing. The clinical setting in which the test is 
performed is crucial for interpreting the results. We recommend ANCA testing routinely 
in the following circumstances: acute or chronic destructive upper airway disease; 
evidence of renal infl ammatory disease as indicated by an active urine sediment or 
laboratory parameters indicative of rapidly progressive glomerulonephritis; evidence 
of pulmonary infl ammatory disease as indicated by a variety of clinical symptoms 
or radiographic abnormalities; skin vasculitis associated with systemic illness; and 
mononeuritis multiplex. ANCA testing is also indicated in subglottic stenosis of the 
trachea manifesting as slowly progressive dyspnoea and retro-orbital mass manifesting 
as protrusion of the eye bulb and diplopia, although these conditions may be diffi cult 
to recognise without specialist tests.
Investigations performed in specialist care
Computed tomography scanning will provide additional information on the location 
and nature of lesions identifi ed on chest radiography. A diagnosis of ANCA associated 
vasculitis is confi rmed by specifi c abnormalities found on tissue biopsies obtained 
from sites of active disease, such as vasculitis, giant cells, “geographical necrosis,” and 
granulomas. In granulomatosis with polyangiitis, biopsies from the respiratory tract—
mainly nose and sinuses—often do not show more than one of the histopathological 
Box 2 | Specialist otolaryngological management of patients with 
granulomatosis with polyangiitis
These patients most often have problems in the nose and sinuses. Initially midfacial 
pain, nasal stenosis, bloody-purulent rhinorrhoea, crust formations that may grow 
into large “casts” of the entire nasal cavities, and hearing loss are important problems, 
but these symptoms often disappear on treatment. However, sometimes symptoms 
do not resolve or slowly reappear as treatment is tapered. Most patients with nasal 
symptoms have a chronic nasal infection with S aureus. Daily nasal lavage with saline is 
helpful but not curative. Long term antibiotics can be effective, but the infection often 
reappears when they are tapered. As chronic infection may be diffi cult to differentiate 
from smouldering disease, patients may need to be seen by ear, nose, and throat 
surgeons with experience in vasculitis.
Some patients eventually develop destructive midface lesions, such as the saddle nose 
deformity, and in these cases plastic surgery can be performed when the disease is 
inactive and patients are on low dose immunomodulatory treatment.
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hallmarks.18 In such cases, the doctor has to treat the patient on the basis of typical 
clinical fi ndings or a positive ANCA test (or both). Multiple biopsies from active 
lesions, if possible taken from different organs at different times, increase the 
chance of establishing a histological diagnosis. When the kidneys are affected, renal 
biopsies have a higher diagnostic yield, generally showing variable amounts of focal 
necrotising glomerulonephritis. In international randomised unblinded controlled trials 
that investigated more than 95 renal biopsies, a histopathological diagnosis of ANCA 
associated glomerulonephritis could be established in 80-98% of biopsies.11,13,19
HOW CAN A SPECIALIST IN VASCULITIS BE FOUND?
Not all hospitals will have an expert on vasculitis, but many regional centres have 
local or national experts or groups of experts. It is not always easy to contact such 
experts; local patient organisations, under the umbrella of Vasculitis UK or the Vaculitis 
Foundation are a useful resource because they have regular contact with regional 
experts in their area. In the UK, experts are often linked to societies or organisations 
because they run educational or research meetings and are usually engaged in active 
research programmes. International organisations such as the Vasculitis Foundation in 
the United States and the European Vasculitis Society (EUVAS) can help with inquiries 
to locate an expert.
WHAT IS THE NATURAL COURSE OF DISEASE IF LEFT 
UNTREATED?
A key natural history study of 56 patients in 1958 found that average patient survival 
was about fi ve months; 82% of patients did not survive the fi rst year after diagnosis 
and more than 90% of patients died within two years. The main cause of death was 
“uraemia” as a result of rapidly progressive renal failure, and the second most common 
cause was respiratory failure.20
HOW IS ANCA ASSOCIATED VASCULITIS CURRENTLY 
TREATED?
Standard treatment consists of inducing remission with high dose glucocorticoids and 
high dose oral or intravenous pulse cyclophosphamide for three to six months, and 
maintaining remission with azathioprine or methotrexate while glucocorticoids are 
slowly reduced and withdrawn.21
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Trials with intravenous pulse cyclophosphamide as induction therapy have used a 
minimum six month course. Courses of intravenous pulse cyclophosphamide of less 
than six months may still be appropriate when rapid disease control is obtained.
Treatment requires specialist supervision; it aims to control disease activity to prevent 
further damage to organs and to prevent the recurrence of vasculitis. Managing 
treatment toxicity is an important part of patient care, and the general practitioner 
may be confronted with this problem (box 3).
According to a large randomised unblinded trial, 75% of patients treated with daily 
oral cyclophosphamide and prednisolone achieve remission by three months. By that 
time, prednisolone is usually reduced to 10-15 mg/day,12 and cyclophosphamide is 
withdrawn because of the risk of cumulative toxicity and replaced with an alternative 
immunosuppressant. Patients who do not respond initially to treatment continue with 
induction treatment for longer and may be considered for second line treatment.22
The optimum duration of maintenance treatment is not known and practice differs 
widely between centres. Alternative maintenance immunosuppressive agents, such 
as mycophenolate mofetil, might be indicated in individual patients.
Although methotrexate has been used as induction therapy in place of the potentially 
more toxic cyclophosphamide for limited or non-severe disease, an unblinded 
randomised controlled trial of 100 patients found that it was associated with higher 
relapse rates, so its use remains controversial.10
In the longer term, regular visits to the specialist are needed (every three months 
at least) to check on disease activity and treatment side effects, and to manage the 
consequences of irreversible tissue damage, such as renal failure.
6
A. Goceroglu - Binnenwerk.indd   141 22-6-2020   13:02:03
141
Diagnosis and management of ANCA-associated vasculitis
With modern treatment ANCA associated vasculitis has changed from being an 
imminently life-threatening condition to a chronic condition prone to relapse 
throughout life. A large observational study of 107 patients found that about 50% of 
treated patients experience one or more relapses by fi ve years.23
Long term follow-up studies have clearly shown that reducing exposure to 
cyclophosphamide is associated with a higher risk of late relapse, so a balance is 
needed between reduced exposure to cyclophosphamide and the increased risk of 
relapse.24
Box 3 | Side effects of commonly used immunosuppressive agents
Cyclophosphamide*: Leucopenia or neutropenia, infections (usually respiratory 
and urinary tract), infertility, cancer (especially bladder cancer and leukaemia), 
haemorrhagic cystitis, alopecia, and amenorrhea.
Glucocorticoids: Osteoporosis, candida infection (oral and vaginal), other 
infections, weight gain, hyperglycaemia or diabetes, hypertension, Cushingoid 
appearance, skin atrophy, and cataract.
Azathioprine: Nausea, leucopenia or neutropenia, infection, hypersensitivity, 
cancer, alopecia, cholestasis, and thrombocytopenia.
Methotrexate: Nausea, oral ulcers, liver dysfunction, infection, hypertension, 
leucopenia.
Mycophenolate mofetil: Infection, leucopenia, gastrointestinal tract manifestations, 
anaemia, thrombocytopenia.
Rituximab: Infections (encephalitis is particularly dangerous), cancer, anaemia, 
neutropenia, thrombocytopenia, hypogammaglobulinaemia.
*Cyclophosphamide can be given in two ways: daily oral cyclophosphamide 
and pulse cyclophosphamide. In the CYCLOPS trial the group that received 
pulse cyclophosphamide had signifi cantly less leucopenia than the daily oral 
group. During pulse administration, the patient can be given prehydration and 
2-mercaptoethanesulfonate sodium to protect the bladder against the toxicity of 
cyclophosphamide.11
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Prospectively collected data from 524 patients showed that important risks of 
treatment with cyclophosphamide include infection, infertility, and incident cancer.25 
Long term treatment with corticosteroids also has many side effects. These adverse 
effects drive the search for more efficacious and safer treatment modalities.
NEWER THERAPEUTIC AGENTS UNDER STUDY
Two recent prospective randomised controlled trials found that the B cell depleting 
agent rituximab effectively induced remission in patients with ANCA associated 
vasculitis, and that its safety profile was comparable with that of standard 
treatment.26,27 Further investigation of the efficacy and safety of rituximab is needed, 
although it was recently approved by the Food and Drug Administration in the US for 
use in combination with glucocorticoids to treat patients with granulomatosis with 
polyangiitis and microscopic polyangiitis.
Plasma exchange has been investigated as an adjunct to standard treatment for 
patients with severe renal disease. In 2007, a large international randomised 
controlled trial of 137 patients favoured plasma exchange over methylprednisolone 
as adjunctive treatment with regard to recovery of renal function,13 but a recent meta-
analysis concluded that more data are needed to establish the long term benefit of 
this treatment.28
Plasma exchange is generally safe. A large study of 7538 exchanges in 887 patients 
showed side effects and technical incidents in 16.8% of all exchanges. This included 
a transfusion reaction in 6.9%, insufficient flow rate in 5%, hypotension in 2.9%, 
electrocardiographic alterations in 1.8%, hypocalcaemia in 1.4%, collapse in 0.9%, and 
pulmonary distress in 0.5%. Plasma exchange was discontinued in only 4% of cases.29
6
A. Goceroglu - Binnenwerk.indd   143 22-6-2020   13:02:03
143
Diagnosis and management of ANCA-associated vasculitis
WHAT IS THE LONG TERM OUTLOOK FOR PATIENTS WITH 
ANCA ASSOCIATED VASCULITIS?
With modern treatment the disease has changed from being universally fatal to being 
a chronic relapsing and remitting disease. Several organs are often affected; renal 
involvement is common, and glomerulonephritis results in end stage renal failure and 
a need for renal replacement in 20-40% of patients according to observational studies 
(within a median follow-up of 3.1 to ≥5 years).30-33
The risk of death for patients treated with current treatments is still 2.6 times higher 
than that of age matched background controls.34 The increased risk of death is greatest 
in the fi rst year after diagnosis, when infections and active vasculitis account for most 
early deaths. Older patients with severe renal impairment have a particularly high risk 
of dying in the fi rst few months after presentation; this refl ects the severity of their 
disease as well as their increased susceptibility to the toxicity of current treatments.34 
Mortality in patients who survive the fi rst year after diagnosis is still 1.3 times higher 
than that of age matched population controls. Death after the fi rst year is mainly caused 
by infections, cardiovascular disease, and cancer.34
Patients are at lifelong increased risk of infections and often need treatment with 
antibiotics. In a population based case-control study, many patients reported fatigue, 
which affected employment and overall quality of life, as a major problem.35 The 
socioeconomic impact of the disease, however, has proved diffi cult to assess.36
WHAT SHOULD GENERALISTS BE AWARE OF WITH REGARD 
TO TREATMENT?
Patients may turn to their general practitioner for support and information. The fi rst 
few weeks of treatment can be diffi cult because patients usually still have symptoms 
associated with vasculitis. Frequent hospital visits and blood tests are needed to 
monitor disease activity and response to treatment.
Before each treatment with high dose cyclophosphamide, platelet and white cell 
counts, particularly the neutrophil count, must be above the lower limit of normal and 
liver function must be stable. Creatinine concentrations are needed to make dose 
adjustments. For daily oral cyclophosphamide, azathioprine, or mycophenolate mofetil, 
and for weekly methotrexate, routine monitoring of blood counts, liver function, and 
renal function are important to avoid drug toxicity. It is usually more convenient for 
patients to attend the primary care practice for these routine blood tests, but this 
requires good communication between primary care and secondary care. Guidelines 
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on how treatment should be changed in response to unexpected results should be 
agreed on before treatment.
Patients are susceptible to infections particularly during induction treatment (most 
usually respiratory or urinary tract infections), and early intervention with antibiotics 
is necessary for confirmed infections. In case of pulse cyclophosphamide, which is 
routinely followed by antiemetics and oral antifungal treatment, the most vulnerable 
time for patients is seven to 10 days after each pulse. The drug suppresses the bone 
marrow, causing neutropenia and increased risk of infection. Patients are advised 
not to visit or be visited by anyone with an upper or lower respiratory tract infection 
during this time. Patients on pulse cyclophosphamide may become profoundly tired 
in the two to three days after administration but will gradually improve. However, be 
aware of potential drug interactions. For example, patients with granulomatosis with 
polyangiitis may be treated with high doses of methotrexate and could develop severe 
neutropenia if treated for a urinary tract infection with standard dose co-trimoxazole; 
prophylactic use of low dose co-trimoxazole (960 mg three times a week) is therefore 
suggested as standard concomitant treatment with methotrexate.
Remember to consider consequences of damage caused by the disease, such as 
chronic kidney disease, and the effects of treatment, such as osteoporosis and 
impaired glycaemic control caused by chronic exposure to glucocorticoids. Patients are 
also at increased risk of cancer and premature and accelerated atherosclerosis, which 
predisposes them to early cardiovascular disease, including strokes.37-41 It is important 
to control and treat all well known cardiovascular risk factors. Three observational 
studies found an increased incidence of venous thromboembolic events, which did not 
seem to be attributable to classic prothrombic risk factors.42-44 Proton pomp inhibitors 
are prescribed to prevent mucosal damage of the stomach as a result of high doses of 
glucocorticoids. Patients taking immunosuppressive drugs usually require prophylaxis 
with co-trimoxazole because of an increased risk of acquiring Pneumocystis jiroveci 
pneumonia (box 4).
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Because relapse can occur after many years in remission, patients often remain on 
indefi nite follow-up. Disease fl ares are common and patients must be encouraged 
to seek urgent medical attention if they experience a fl are—that is, recurrence, 
deterioration, or new onset of symptoms and signs attributable to active vasculitis 
(box 5). If patients have a fl are or experience serious complications of treatment they 
may require hospital admission. If early symptoms are missed or ignored, a serious 
episode of vasculitis with renal or respiratory failure may ensue. Patients are usually 
educated to look out for early symptoms of relapse so that this kind of avoidable 
disaster can be prevented.
Box 4 | Important points for generalists
Regularly follow up the patient and be aware of some specifi c problems and prophylactic 
strategies*
Specifi c problems and prophylactic strategies
· Osteoporosis: Use of bisphosphonates
· Cardiovascular disease: Use of statins and smoking cessation
· Hyperglycaemia or diabetes: Regular glycaemic control
· Hypertension: Regular blood pressure control
· Gastric mucosal damage: Use of a proton pump inhibitor
· Oral ulcers: Use of folic acid or folinic acid
· Pneumocystis jiroveci pneumonia: Prophylactic co-trimoxazole
· Fatigue: Informal support or formal counselling
*The specialist will supervise this, but generalists need to be aware. If one of these 
problems occurs, the patient must be seen immediately by the doctor in charge at the 
vasculitis clinic. Rapid referral to specialist care is also needed if patients become ill 
with no obvious cause, especially if they report unusual symptoms.




Although the precise causes are unknown, ANCA associated vasculitis probably results 
from an interplay between genetic and environmental factors. Several associations 
have been made with genes that encode proteins involved in immunity, which are 
also often associated with other autoimmune diseases.48 However, family members 
or twins of patients with granulomatosis with polyangiitis are rarely reported to have 
disease manifestations, which goes against a strong genetic predisposition.1 A recent 
study using Swedish nationwide registers did show some increased familial occurrence 
of granulomatosis with polyangiitis, which might denote genetic susceptibility to the 
disease, but exposure to similar environmental factors might also induce familial 
clustering.49 
Box 5 | Characteristics of a fl are
Flare: Recurrence, deterioration, or new onset of symptoms and signs attributable to 
active vasculitis.
Major fl are: Recurrence, deterioration, or new onset of at least one item on the 
Birmingham vasculitis activity score (see supplementary material),45-47 indicating a 
threat to vital organ function as a result of active vasculitis. Examples include:
o 30% increase of creatinine or 25% decrease of glomerular fi ltration rate within 
 three months
o Evidence of severe pulmonary haemorrhage or granulomata
o Threatened vision (including orbital granuloma and retinal vasculitis)
o Sensorineural deafness
o New multifocal neurological lesions or mononeuritis multiplex
o Gastrointestinal haemorrhage or perforation
Minor fl are: Recurrence, deterioration, or new onset of at least three other items on the 
Birmingham vasculitis activity score related to non-vital organs attributable to active 
vasculitis. Examples include:




o Myalgia, arthralgia, arthritis
o (Epi)scleritis
o Pulmonary symptoms not characteristic of a major relapse
6
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Among the environmental factors that have been implicated are occupational exposure 
to silica (such as farming, construction work), antithyroid and antihypertensive 
drugs (propylthiouracil and hydralazine), and several microbial agents, particularly 
Staphylococcus aureus.50 Chronic nasal carriage of this agent has been associated with 
a higher incidence of relapse in granulomatosis with polyangiitis,51 and a multicentre 
randomised double blind controlled trial showed that prophylactic treatment with co-
trimoxazole reduces the incidence of relapses in granulomatosis with polyangiitis.52
All these factors may play a role in the development of ANCA, which are generally 
considered a pathogenic factor. The most direct clinical evidence for their pathogenicity 
is the development of pulmonary renal syndrome in a neonate shortly after being born 
to a mother with myeloperoxidase (MPO)-ANCA positive microscopic polyangiitis, 
probably because of transplacental transmission of maternal MPO-ANCA.53,54 No 
other such cases have been reported, however, and a full term healthy normal child 
was recently born to a mother with microscopic polyangiitis, despite transplacental 
transfer of MPO-ANCA.55 The development of a mouse model in which injection of 
MPO-ANCA induced glomerulonephritis and vasculitis similar to that seen in human 
disease provides strong in vivo evidence for the pathogenicity of these antibodies.56 
However, to date, an equally good model has not been developed for proteinase 3 
(PR3)-ANCA.
A key role for neutrophils in the acute injury to the blood vessel wall is fi rmly established 
in ANCA associated vasculitis. Priming of circulating neutrophils by cytokines, possibly 
during infection, is thought to underlie local accumulation of neutrophils in the disease. 
Neutrophil priming causes PR3 and MPO to be expressed on the neutrophil cell 
membrane, where it becomes accessible to ANCA. Neutrophils activated by ANCA 
degranulate, produce reactive oxygen species, and release proteolytic enzymes that 
damage blood vessel walls.57,58 Apart from ANCA and neutrophils, abnormalities in 
cellular immunity are probably important,59 and in recent years an important role 
for the alternative pathway of complement has also been proposed. Because human 
ANCA associated glomerulonephritis is pauci-immune, with virtually no deposition 
of complement in the renal tissue, it had been assumed that complement played no 
role in this disease. However, recent studies support a role for the alternative pathway 
of complement in experimental models and in human pauci-immune MPO-ANCA 
associated vasculitis.60,61
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Questions for future research
What is the optimum duration of maintenance treatment? This question may be 
answered by the fi ndings of the REMAIN trial (AVERT project BIOMED-2: BMH-CT93-
1078, trial registration number REMAIN 08.022006; www.vasculitis.org) conducted by 
EUVAS, which is investigating benefi ts of prolonged maintenance treatment.
With increasing insights into the pathogenesis of the disease and the detection of new 
biomarkers, might new targeted treatments replace existing standard treatments?
How might we develop patient tailored treatments for patients on the basis of clinical 
signs and symptoms in combination with genetic information? CCX168, an antagonist 
of complement factor C5a, is currently a candidate for clinical development.
What are the benefi ts of plasma exchange? A EUVAS/Vasculitis Clinical Research 
Consortium (VCRC) trial (PEXIVAS), which is designed to confi rm and further explore 
the benefi t of adjuvant plasma exchange, is currently under way.
A question that is important to patients is “How can fatigue associated with vasculitis 
and its treatment be managed?”
What causes the development of antineutrophil cytoplasmic antibodies (ANCA) and 
how do we prevent ANCA-associated vasculitis? 
More basic research studies are needed to answer these questions.
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A patient’s perspective
Nine years ago I visited my general practitioner with pain in my right knee. He tested 
twice for rheumatoid arthritis but the results were negative. I was then referred to 
the rheumatologist at the university clinic. A few months later most of my joints were 
affected and it seemed that I would be condemned to a wheelchair. The rheumatologist 
diagnosed rheumatoid arthritis and treated me accordingly. One month later my 
condition had worsened—I was vomiting two or three times a day, my eyes were reddish, 
and I had nasal crusting. My rheumatologist had seen a patient with these symptoms 
once before and she tested me for various factors including antineutrophil cytoplasmic 
antibody. The next day I was seen by her and a nephrologist. The new diagnosis was 
Wegener’s granulomatosis. This news was a blessing in disguise. I would probably 
walk again, but I had lost 50% of my renal function. My treatment consisted of heavy 
immunosuppression including corticosteroids. Over the nine years that followed I had 
two cataract operations, a prosthetic knee implant, many erythropoietin injections, and 
a kidney transplant (a gift from my wife); I also experienced Guillain-Barré syndrome, 
cerebral haemorrhage, and constant bronchitis. Now I am fi ne. At the age of 69, I now 
have enough energy to enjoy life.
Henk van Wilpe, Utrecht
Additional educational resources
Resources for clinicians
Europe European Vaculitis Society (www.vasculitis.org/) and US Vasculitis Clinical 
Research Consortium (http://rarediseasesnetwork.epi.usf.edu/vcrc/)—Research 
collaboratives that focus on vasculitis.
Johns Hopkins Vasculitis Center (www.hopkinsvasculitis.org/)—Provides detailed 
information on vasculitis.
Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The 
American College of Rheumatology 1990 criteria for the classifi cation of vasculitis. 
Summary. Arthritis Rheum 1990;33:1135-6 
Resources for patients
Vasculitis Foundation (www.vasculitisfoundation.org)—US website providing 
relevant information for doctors and patients.
Vasculitis Foundation Canada (www.vasculitis.ca)—Canadian website providing 
information and support for patients.
The Dutch Vaculitis Patient Foundation (www.vasculitis.nl)—Dutch website 
providing useful information for medical professionals and patients.
Vasculitis UK (www.vasculitis-uk.org.uk/news.html)—Provides information on vasculitis 
and on local support groups.
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Birmingham Vasculitis Activity Score (version 3)
Patient ID:  Date of birth:   Total score:
Assessor:  Date of assessment:
Tick an item only if attributable to active 
vasculitis. If there are no abnormalities in a 
section, please tick ‘None’ for that organ-system.
If all abnormalities are due to persistent disease 
(active vasculitis which is not new/worse in the prior 
4 weeks), tick the PERSISTENT box at the bottom 
right corner







1. General ○ 6. Cardiovascular ○
Myalgia ○ Loss of pulses ○
Arthralgia / arthritis ○ Valvular heart disease ○
Fever ≥38° C ○ Pericarditis ○
Weight loss ≥2 kg ○ ◊ Ischaemic cardiac pain ○
2. Cutaneous ○ ◊ Cardiomyopathy ○
Infarct ○ ◊ Congestive cardiac failure ○
Purpura ○ 7. Abdominal ○
Ulcer ○ Peritonitis ○
◊ Gangrene ○ Bloody diarrhoea ○
Other skin vasculitis ○ ◊ Ischaemic abdominal pain ○
3. Mucous membranes / eyes ○ 8. Renal ○
Mouth ulcers ○ Hypertension ○
Genital ulcers ○ Proteinuria >1+ ○
Adnexal inflammation ○ ◊Haematuria ≥10 RBCs/hpf ○
Significant proptosis ○ Creatinine 125-249µ/L(1.41-2.82mg/dl)* ○
Scleritis / Episcleritis ○ Creatinine 250-499 µ/L(2.83-5.64mg/dl)* ○





◊Rise in serum creatinine >30% or fall in 
creatinine clearance >25%
○
Uveitis ○ *Can only be scored on the first assessment
◊Retinal changes (vasculitis / 








4. ENT ○ Organic confusion ○
Bloody nasal discharge / crusts / ulcers 
/ granulomata




Paranasal sinus involvement ○ ◊Spinal cord lesion ○
Subglottic stenosis ○ ◊Cranial nerve palsy ○
Conductive hearing loss ○ Sensory peripheral neuropathy ○
◊Sensorineural hearing loss ○ ◊Mononeuritis multiplex ○
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5. Chest ○
Wheeze ○ 10. Other                                                        ○
Nodules or cavities ○ a. ○
Pleural effusion / pleurisy ○ b. ○
Infi ltrate ○ c. ○
Endobronchial involvement ○ d. ○






(Tick here if all the abnormalities are due to 
persistent disease)

◊ Major items highlighted
References: 45-47
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There were some recent changes in the daily practice of antineutrophil 
cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) patients. Indirect 
immunofluorescence (IIF) for the detection of ANCA is not standardly used anymore. 
Recent study showed a large variability between different IIF methods and a high 
diagnostic performance of proteinase (PR3)-ANCA and myeloperoxidase (MPO)-
ANCA by Enzyme-Linked Immuno Sorbent Assay (ELISA). Therefore, the use of both 
IIF and ELISA testing of each sample is not necessary for maximal diagnostic accuracy.1 
Currently a biopsy is still the golden standard for obtaining a diagnosis. In case a biopsy 
is not possible or should be delayed, a presumptive diagnosis of AAV can be made 
in case there is a high probability of AAV based on the clinical presentation, ANCA 
positivity with ELISA and a low suspicion for another disease. With a presumptive 
diagnosis, initial therapy can be started, although a biopsy should be obtained as soon 
as possible to confirm the diagnosis.
The approach for initial therapy is based on the severity of the disease and the organs 
involved. In case of non-organ-threatening and non-life-threatening disease, i.e. in the 
absence of active glomerulonephritis, pulmonary hemorrhage etc., a regimen with 
glucocorticoids and methotrexate can be given. Rituximab or cyclophosphamide can 
be chosen instead of methotrexate. In case of organ-threatening or life-threatening 
disease glucocorticoids in combination with cyclophosphamide or rituximab can be 
started. In case of rapidly deteriorating kidney function, severe kidney dysfunction, 
pulmonary hemorrhage or severe respiratory impairment, adjunctive plasma exchange 
therapy is advised. Depending on local protocol, prophylaxis against opportunistic 
infections during induction therapy is given, i.e. trimethoprim-sulfamethoxazole.2 For 
maintenance therapy glucocorticoids in combination with azathioprine or methotrexate 
are mostly used, although rituximab is also being investigated as maintenance therapy 
in the MAINRITSAN trial3 and the RITAZAREM trial (RITAZAREM, ClinicalTrials.gov 
Identifier: NCT01697267). The MAINRITSAN trial showed that at 28 months more 
patients had remained in remission with rituximab compared to azathioprine. There was 
no difference in severe adverse events.3 The optimal duration for maintenance therapy 
was investigated in the REMAIN trial. This study showed that 48 months of maintenance 
therapy (azathioprine and prednisolone) had less relapses and an improved renal 
survival at 48 months compared to 24 months maintenance therapy. There was no 
difference in the incidence or severity of adverse events or patient survival between 
both groups.4 There is still controversy about the duration of glucocorticoids use.
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ANTI-PLASMINOGEN AUTOANTIBODIES
It is a big challenge in AAV to detect the presence of anti-plasminogen autoantibodies 
(α-PLG). We developed an optimized ELISA for the detection of α-PLG, focusing on 
its usefulness in studies on AAV. We tested different assay set-ups. Purifi ed lysine-
plasminogen (lys-PLG) showed better differentiation between positive samples and 
negative samples compared to glutamic acid-plasminogen (glu-PLG). Therefore, 
lys-PLG was used as coating antigen. With the optimized α-PLG ELISA we found the 
presence of α-PLG in 14.3% of MPO-ANCA patients, whereas all our PR3-ANCA 
patients tested negative in our newly developed assay.
The available studies on α-PLG show a discrepancy in the presence of these 
autoantibodies in patients with AAV. We mainly detected α-PLG in MPO-ANCA 
patients, while others detected these antibodies mainly in PR3-ANCA patients or in 
both patient groups. These discrepancies could be due to differences in the assays 
used in the studies.5-7 Examples of differences are different concentrations of coating 
antigen, different conjugates, different samples (sera vs. purifi ed immunoglobulin G), 
and different defi nitions of positivity. We have combined important technical fi ndings 
and methods from the previous studies which have led to the optimized α-PLG assay 
presented in chapter 2 of this thesis.
There are two main conformations of PLG, namely glu-PLG and lys-PLG, with glu-
PLG being the native form. Lys-PLG is formed after cleavage of a peptide consisting 
of 77 amino acids at the N-terminal of glu-PLG and is an intermediate step towards 
the formation of active plasmin.8 Both conformations differ in physical and functional 
properties.9-11 Lys-PLG is more effi ciently activated by PLG activators than glu-PLG.12-14 
The different studies on α-PLG published so far did not defi ne which subtype of PLG 
was used for coating. For the assay developed by us, we used lys-PLG as coating, 
because it was better at differentiating between positive and negative control samples 
in our study.
The epitope(s) recognized by α-PLG in AAV are not yet fully defi ned. Different 
autoantibodies against different (conformational) epitopes of PLG may exist and this 
could (partly) explain the described discrepancies. Originally, α-PLG were described 
in view of anti-complementary PR3 antibodies which were suggested to develop 
within an idiotypic/anti-idiotypic antibody response.5,15 Dual reactivity to PLG and 
complementary PR3 (cPR3) was described in PR3-ANCA patients.5 This scenario 
assumed a combined presence of α-PLG with only PR3-ANCA and not MPO-ANCA. 
The cPR3 sequence has similarities with genetic sequences of microbial and fungal 
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organisms that code for peptides large enough to be antigenic.15 If exogenous antigens 
like peptides of micro-organisms cause the development of autoantibodies against 
PLG, distinct geographic areas with different micro-organisms could influence the 
development of these autoantibodies. On the other hand, our study together with those 
of Berden et al. and Hao et al. reported the presence of α-PLG in MPO-ANCA patients 
in the absence of PR3-ANCA.6,7 This makes the hypothesis regarding cPR3 and α-PLG 
less likely. In addition, some studies describe α-PLG which did not react to denatured 
PLG, plasmin or thrombin, while other studies showed cross-reactivity of antibodies 
between PLG, plasmin and prothrombin.5,6,16-18 More knowledge about pathogenic 
epitopes is needed for further optimization of the α-PLG assay and to detect relevant 
autoantibodies in patients. In the meantime, our currently proposed α-PLG assay can 
be used for research purposes and further optimization.
The presence of α-PLG is associated with the presence of more active renal lesions in 
the biopsy, i.e. fibrinoid necrosis and cellular crescents, and worse renal function at 1 
year follow-up.6 The idea is that fibrinoid necrosis is a product of a flaw in the vascular 
repair system that fails to remove the fibrin clot caused by the vascular injury.19-23 
This flaw is caused by the inhibition of PLG due to α-PLG. In addition, the leaked fibrin 
seems to stimulate extracapillary proliferation.24-26 This shows that the presence of 
these antibodies has an influence on the severity of renal involvement. Therefore, 
detecting these patients early with a validated α-PLG assay will help improve clinical 
management of these patients with an improved renal outcome.
PREDICTION OF RENAL RELAPSE
One of the main questions in daily practice when confronted with patients with AAV is 
how to recognize those who are at risk for disease relapse and whether relapses can 
be prevented. Identifying patients at high risk of renal relapse may aid in optimizing 
clinical management. Our study on risk factors for renal disease relapse showed that 
the histopathological class of ANCA-associated glomerulonephritis (AAGN) and the 
absence/presence of interstitial inflammatory infiltrates in the renal biopsy at diagnosis 
are risk factors for renal relapse. More specifically, sclerotic class is associated with a 
higher rate of renal relapse during long-term follow-up and the absence of interstitial 
inflammatory infiltrates is associated with the risk of renal relapse.
Previous European Vasculitis Society (EUVAS) studies focused on predictive clinical 
and serological parameters for relapse in general. Predictive parameters described 
in the literature are the presence of PR3-ANCA, lower serum creatinine levels at 
presentation, lung or cardiovascular involvement, and diagnosis of GPA.27-37 Our 
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fi nding that the absence of interstitial infi ltrates in renal biopsies predicts renal disease 
relapse is in line with better renal function increasing the risk for a relapse in general, 
because absence of interstitial infi ltrates also correlates with better renal function at 
the time of biopsy.38,39 Interestingly, in a cohort of 535 patients, no clinical parameter at 
baseline was associated with developing renal relapse.40 Our study showed histological 
parameters at baseline that are risk factors for developing renal relapse. A clinical 
manifestation that is described to be predictive of renal relapse is persistent hematuria 
during follow-up.41 Experiencing a renal disease relapse has a negative infl uence on 
renal outcome and is associated with end-stage renal failure (ESRF).40,42 Therefore, 
clinicians should realize that renal disease relapses must be identifi ed and treated 
as such.
In the sclerotic class most glomeruli are non-functioning with a decreased 
compensatory ability of the kidneys. Therefore, renal relapse may become more readily 
apparent and the functioning glomeruli may become more vulnerable to a second hit, 
i.e. a relapse. In the focal, crescentic and mixed class, minor relapses may remain 
subclinical. Patients with interstitial infi ltrates (acute disease activity), have a more 
aggressive clinical disease presentation, making it easier to diagnose the disease 
early. Treatment will be started earlier and can therefore decrease the risk for renal 
disease relapse. Therefore, clinicians must keep in mind that those patients with a 
presumably benign clinical course at onset in particular might be prone to developing 
a renal disease relapse.
We hypothesize that patients may have smoldering disease in the kidney in which renal 
relapses may go by unnoticed in case of focal, crescentic and mixed class AAGN. This 
phenomenon has been described in systemic lupus erythematosus patients after renal 
transplantation, where subclinical class I, II or III recurrences in the kidney have been 
encountered unexpectedly in protocol biopsies of 22 patients from a total cohort of 
41 patients.43 Smoldering progression of disease may be devastating to the graft.43,44 
Smoldering disease in general and specifi cally in the upper and lower airways in AAV 
has been described.45-47 In addition, autopsy studies in patients with AAV/GPA showed 
that persistent airway infl ammation is more common than has been appreciated 
clinically.48 In our study cohort several patients achieved remission, did not experience 
a renal disease relapse, but still developed ESRF after achieving remission. In these 
patients ESRF could be the result of smoldering disease with subclinical renal relapses.
It is also possible that the histopathological classes represent distinct autoimmune 
syndromes, rather than representing phases according to which the disease progresses. 
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In our cohort the ANCA-specificity was associated with the histopathologic class. PR3-
ANCA was associated with focal class biopsies and MPO-ANCA was associated with 
sclerotic class. A recent genome-wide association study and meta-analysis in AAV 
showed that the pathogenesis of AAV has a genetic component. The differences found 
between GPA and microscopic polyangiitis (MPA) regarding genetic associations were 
driven by ANCA-specificity and not by clinically defined syndromes. So, PR3–AAV and 
MPO-AAV seem to have distinct genetic backgrounds and this supports the concept 
that PR3-AAV and MPO-AAV might be two distinct autoimmune syndromes.49,50
HISTOPATHOLOGICAL CLASSIFICATION OF ANCA-
ASSOCIATED GLOMERULONEPHRITIS
Several studies described an association between renal histological parameters and 
renal outcome, for example percentage of normal glomeruli, crescentic glomeruli 
and sclerotic glomeruli.38,39,51,52 This led to the introduction of a histopathological 
classification of AAGN in 2010.53 This classification classifies each diagnostic renal 
biopsy into one of four classes; focal, crescentic, sclerotic and mixed class, based 
on the predominant glomerular phenotype. The first validation of this classification 
system in 100 patients showed an association with ESRD and renal function at 1- and 
5-year follow-up.53 Several subsequent validation studies confirmed this association 
regarding focal and sclerotic class, but had contradictory results regarding crescentic 
and mixed class.54 Our worldwide validation study also confirmed a favorable outcome 
in the focal class and a poor outcome in the sclerotic class. Regarding crescentic and 
mixed class, there was no difference between renal outcome. This is in contrast to the 
findings of the original study, but is in line with results from 2 recent meta-analyses.54,55
The overall histopathological classification showed to be associated with renal 
function, even after correcting for other baseline parameters, and the development 
of ESRD during follow-up. However, the crescentic and mixed class were indiscriminate 
regarding renal function and developing ESRD. There are different possible 
explanations for these conflicting results regarding crescentic and mixed class. First, 
there could be differences between the patient populations studied. GPA, MPA and 
ANCA-specificity are differently distributed around the globe.56,57 Our validation study 
showed that the histopathological class and diagnosis are associated with each other, 
and both variables are associated with renal outcome. Together, differences in patient 
population could partly be an explanation for the conflicting results. Unfortunately, 
our cohort was not large enough to analyze this hypothesis. Second, treatment 
regimens could be different between the patients in the different validation studies. 
Third, the interobserver agreement between nephropathologists was moderate in 
7
A. Goceroglu - Binnenwerk.indd   163 22-6-2020   13:02:05
163
Summary and general discussion
our validation study. It is hard to translate this fi nding to the clinical practice in a 
one-on-one fashion, because of the differences in experience, but scoring the same 
diagnostic biopsy differently can cause the observed differences between the studies. 
Fourth, the current classifi cation only incorporates normal, crescentic and sclerotic 
glomeruli. Adding other histological parameters could possibly refi ne the classifi cation 
system. Fibrous crescents are not yet incorporated, although they showed to have 
some predictive value for long-term renal outcome.39,58 In addition, tubulointerstitial 
parameters are not considered in the current histopathologic classifi cation of AAGN, 
while histological studies showed that tubulointerstitial parameters have an association 
with renal outcome, even when used in addition to the histopathologic classifi cation 
of AAGN.38,39,58-67 Our study on renal relapse (chapter 3) and our validation study 
(chapter 4) confi rmed this association.68 Including tubulointerstitial parameters in the 
classifi cation system might lead to refi nements for the prognostication of patients at 
time of diagnosis.
The histopathological classifi cation of AAGN is a valuable tool in the management 
of patients with AAV, but in the near future, adjustments are needed to improve its 
prognostic value, especially for the crescentic and mixed class. We are not considering 
to lump the crescentic and mixed class, in particular because other studies showed 
that cellular crescents are an important factor for predicting potential reversibility of 
renal impairment during follow-up.38,39,53 Adding tubulointerstitial parameters could 
lead to refi nements for the prognostication of patients at time of diagnosis, although 
the poor to moderate interobserver agreement regarding tubulointerstitial variables 
must also be considered. Currently, we are performing a study to evaluate a more 
detailed scoring system for both glomerular and interstitial variables. Results from 
that study will determine how to adjust the histopathological classifi cation for AAGN 
for more sophisticated prognostic value.
RENAL TRANSPLANTATION
Approximately 20-40% of patients with AAGN progress, with or without clinically 
evident renal disease relapse, to ESRF.27,47,69,70 One of the therapeutic options for 
these patients is a renal transplantation. The Dutch cohort described in this thesis of 
113 AAGN patients transplanted between 1984 and 2011 showed one year and fi ve 
year graft survival rates of 94.5% and 82.8%, respectively. This is similar to previous 
studies on AAGN and to the general transplantation population in Europe and North 
America.71-80 The risk of experiencing a fi rst disease relapse or renal disease recurrence 
within fi ve years of transplantation was 3.3% and 2.8% per patient year, respectively. 
This is slightly higher compared to other studies, which described rates of 1.0-2.0% 
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per patient year.72,73,75,79,81 Renal disease recurrence was an important cause of graft 
loss within the first five years after transplantation. Renal transplantation is a viable 
treatment option for patients with ESRF due to AAGN with rather low renal disease 
recurrence rates, but once renal disease recurrence has occurred the risk for graft 
loss is considerable.
The DUTRAVAS study showed that disease recurrence in the renal graft can occur at 
any time after transplantation. The first disease recurrence in the renal graft occurred 
nine days after transplantation. This patient was transplanted with ongoing disease 
activity, which explains the early recurrence. One patient even had a disease recurrence 
in the renal graft after 142 months. Early (even within days after transplantation, 
although transplanted during disease remission) and late recurrences of AAGN in the 
graft have also been described by others.82-85 This supports that disease recurrence 
in the renal graft can occur at any time after transplantation. In case of deterioration 
of renal function, proteinuria and hematuria, even several years after transplantation, 
disease recurrence in the renal graft should be considered. Continuous and careful 
monitoring of these patients is important.
An important clinical question with no current formal consensus is time to renal 
transplantation after reaching clinical remission. A questionnaire sent out by Little 
et al. to transplant units in different countries revealed that 100% of the transplant 
physicians consulted (n=32) claim that a patient should be in remission at the moment 
of transplantation.75 One patient in our cohort was transplanted with ongoing disease 
activity, had a renal disease recurrence and consequent graft loss within a month. An 
association between renal transplantation <12 months after reaching clinical remission 
and mortality was reported.75 No association was found between the duration of 
remission before transplantation and disease relapse when taking three months of 
remission as a cut-off point.72 However, current practice seems to be delaying the 
transplantation until the disease is in remission.73,75,86,87
Another important question regarding renal transplantation in AAV is whether a patient 
with a positive ANCA-test can be transplanted. There is still controversy whether a 
patient must be ANCA negative at the moment of transplantation.75 Evidence is 
accumulating that patients with a positive ANCA can be transplanted.69,72,73,86-92 A paper 
in 2013 pooled different studies and described an association between ANCA positivity 
at transplantation and relapse rate, although they mention very scarce information 
about how they pooled and analyzed these data.84 The DUTRAVAS study shows that 
ANCA status at transplantation is not associated with renal disease recurrence and 
7
A. Goceroglu - Binnenwerk.indd   165 22-6-2020   13:02:05
165
Summary and general discussion
graft survival. The number of patients in the cohort was too small to discuss PR3-ANCA 
and MPO-ANCA separately. Therefore, it seems that ANCA positivity at transplantation 
is not predictive for disease relapse and/or graft loss, which suggests that a patient 
with a positive ANCA can be transplanted safely. More research on this aspect is 
needed.
In the DUTRAVAS-study, 36% (4/11) of the patients with disease recurrence in the 
renal graft lost their graft due to the recurrence within fi ve years after transplantation. 
Renal disease recurrence in the graft was an important cause of graft loss in this 
study; four of the 16 graft losses. Graft loss due to AAV recurrence in the graft has 
also been described in other studies; range 18-60%.75,85,87,89,91 Briganti et al. described 
a cohort of 1505 patients with biopsy-proven glomerulonephritis due to various 
causes transplanted between 1988 and 1997 in which at one, fi ve and 10 years after 
transplantation, recurrent glomerulonephritis was the third most common cause of 
graft loss. Acute rejection, chronic rejection and death with a functioning graft were 
more common. In the subgroup analysis, the same order of causes of graft loss was 
found at 10 years for the pauci-immune crescentic glomerulonephritis patients.93 
Concluding, renal disease recurrence is an important cause of graft loss and the risk 
for graft loss due to disease recurrence is something clinicians must be aware of.
FUTURE ISSUES
Although a substantial amount of research has been performed and much insight in 
AAV has been gained, there are still many questions for future research.
One of the clinical challenges in the care of AAV is to predict which patients will have a 
(renal) relapse of the disease. As literature and our study showed, clinical parameters 
and histologic lesions in the renal biopsy (glomerular and interstitial) might be of value 
for this. Future research should focus on specifying these predictors and investigating 
whether the current histopathological classifi cation of AAGN needs adaptations. 
These clinical and histological parameters can help the clinician in determining the 
right therapy.
The use of ANCA titer to predict the course of disease, i.e. disease relapse, and 
measure current disease activity is controversial. A biomarker which can help the 
clinician regarding disease course would be very helpful for the clinical management. 
Therefore, the search for a biomarker should continue. α-PLG, as described in this 
thesis, has the potential to become such a biomarker to some extent. Other potential 
biomarkers described in the literature that need further research are B-cells, cytokines, 
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complement, inflammatory mediators (CXCL13, MMP-3, TIMP-1),94 hLAMP-2 and 
urinary biomarkers (MCP1, CD 164, CD 25).95
One of the main questions regarding renal transplantation in AAV is how long a patient 
should be in remission before being transplanted. Currently there is only weak evidence 
that we should wait for at least one year.75 The ideal way to answer this question would 
be an international randomized clinical trial (RCT) of countries with the same organ 
donor system in which patients are transplanted after different remission times.
There has to be a balance between the risk for adverse events due to the therapy 
and the chance for disease relapse. The last one still being a big challenge to prevent 
and treat in AAV. The risk for disease relapse has not changed much for the last 
few decades.41 Currently, rituximab with longterm maintenance therapy seems the 
best option to treat disease relapse, although more research is needed in this field 
with a RCT specifically focusing on patients with a severe disease relapse. It is also 
investigated how to taper corticosteroid therapy.
An interesting therapeutic target is the complement system. A randomized trial showed 
that C5a receptor inhibition with avacopan was an effective treatment in replacing 
high-dose glucocorticoids in treating AAV patients with newly diagnosed or relapsing 
disease.96
Based on the different genetic background of PR3-ANCA and MPO-ANCA, it remains 
the question whether these two are different disease modalities and whether they 
should be treated differently. Until now PR3-ANCA and MPO-ANCA have been treated 
the same way. These insights will provide us the opportunity to provide better patient-
tailored therapy.
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Vasculitis is een verzamelnaam van verschillende ziekten gekenmerkt door ontsteking 
van bloedvaten. Aankelijk van de soort vasculitis kunnen dit grote en/of kleine 
bloedvaten zijn. Vasculitis betekent vertaald ontsteking (‘=itis’) van bloedvaten. Dit 
proefschrift gaat over één specifiek soort vasculitis, namelijk ANCA-geassocieerde 
vasculitis (AAV). Bij deze ziekte zijn vooral de kleine bloedvaten betrokken.
ANCA staat voor Anti-Neutrofiel Cytoplasmatische Autoantilichamen en de 
aanwezigheid hiervan in het bloed is een kenmerk van AAV. ANCA’s zijn afweerstoffen 
die zich richten tegen twee eiwitten: proteïnase 3 (PR3) en myeloperoxidase (MPO). 
Beide eiwitten bevinden zich in bepaalde soorten witte bloedcellen: neutrofielen en 
monocyten.
AAV kan verder onderverdeeld worden in drie subtypen:
· Granulomatosis met polyangiitis (GPA, voorheen bekend als de ziekte van 
 Wegener)
· Microscopische polyangiitis (MPA)
· Eosinofiele granulomatosis met polyangiitis (EGPA, voorheen bekend als de 
 ziekte van Churg-Strauss)
Dit proefschrift gaat over de eerste twee subtypen, namelijk GPA en MPA.
AAV is een zeldzame ziekte. De ziekte wordt in de Westerse wereld per jaar bij ongeveer 
twintig op de één miljoen mensen gediagnosticeerd. AAV komt het meest voor bij 
mensen tussen de 65 en 74 jaar en wordt vaker bij mannen gezien. Hoe vaak de 
aandoening precies voorkomt verschilt per land en per ras.
Patiënten met deze ziekte presenteren zich in het begin met griepachtige verschijnselen 
zoals koorts, hoofdpijn, spierpijn, gewrichtspijn en verminderde eetlust. Deze ‘vage’ 
klachten kunnen weken tot maanden aanhouden en komen ook bij veel andere ziekten 
voor. Hierdoor is het voor een arts in het begin heel moeilijk om de ziekte te herkennen. 
Meestal duurt het tussen de drie en twaalf maanden voordat de ziekte herkend 
wordt. Vaak wordt een patiënt door meerdere artsen gezien voordat de diagnose 
wordt gesteld. Naarmate de ziekte vordert, begint de ziekte zich steeds duidelijker 
te uiten. AAV kan in één orgaan beginnen en gedurende het beloop kunnen meer 
organen betrokken raken. Aankelijk van de betrokken organen, worden de klachten 
steeds specifieker. De meest betrokken organen zijn: keel, neus, oren, nieren, longen, 
huid, ogen en het zenuwstelsel. De diagnose wordt uiteindelijk gesteld op basis van 
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de klachten, bloedonderzoek en weefselonderzoek. In dit proefschrift richten wij ons 
vooral op nierbetrokkenheid.
Zonder behandeling overlijdt 82% van de patiënten binnen één jaar en 90% binnen 
twee jaar. De meest voorkomende doodsoorzaken zijn nier- en/of longfalen ten gevolge 
van de ziekte. Dankzij de huidige behandeling met medicijnen is het een chronische 
ziekte geworden die zich kenmerkt door perioden van rust en opvlammingen van de 
ziekte. Medicijnen richten zich vooral op het onderdrukken van het afweersysteem of 
‘immuunsysteem’. De behandeling is langdurig: het is bekend dat te kort behandelen 
een groter risico op opvlammingen geeft. Een van de grote uitdagingen van AAV is dat 
ondanks een goede behandeling, de ziekte toch kan opvlammen: ongeveer de helft van 
de patiënten heeft binnen vijf jaar een of meer opvlammingen doorgemaakt.
DE PATIËNT
Onderzoek laat zien dat artsen anders naar de ziekte en de impact daarvan kijken dan 
patiënten. Om deze reden krijgt het perspectief van de patiënt steeds meer aandacht in 
het onderzoek dat verricht wordt naar AAV. Meerdere studies laten zien dat patiënten 
met AAV een verslechtering van hun kwaliteit van leven ervaren. Dit wordt vooral 
bepaald door de fysieke belasting van de ziekte. Patiënten geven aan het meeste last 
te hebben van klachten als moeheid, verlies van energie en pijn aan gewrichten.
HET ZIEKTEPROCES
Het is onbekend hoe de ziekte precies ontstaat. Waarschijnlijk spelen de eerder 
genoemde witte bloedcellen -neutrofi elen en monocyten- een belangrijke rol. Deze 
witte bloedcellen bevatten de eiwitten PR3 en MPO. Bij AAV worden deze eiwitten 
door afweerstoffen – de ANCA’s – herkend. ANCA’s worden geproduceerd door een 
ander type witte bloedcel: de B-cellen. Op het moment waarop ANCA’s zich binden 
aan PR3 of MPO ontstaat er een reactie welke leidt tot ontsteking van bloedvaten. Dit 
is een zichzelf versterkend proces waardoor de ontstekingen van de bloedvaten in het 
lichaam steeds heviger worden. Om deze reden is het belangrijk dat de behandeling 
tijdig wordt gestart.
AFWEERSTOFFEN
ANCA’s gericht tegen PR3 en MPO zijn de belangrijkste afweerstoffen bij de ziekte AAV. 
De aanwezigheid van ANCA’s in het bloed kan gebruikt worden voor het diagnosticeren 
van de ziekte.
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Hoewel de aanwezigheid van ANCA’s in het bloed een belangrijk kenmerk is van 
AAV, laten studies tegenstrijdige resultaten zien als het gaat om de relatie tussen 
de hoeveelheid ANCA’s in het bloed en de activiteit van de ziekte. Een patiënt kan 
bijvoorbeeld inactieve ziekte hebben en toch aantoonbaar ANCA’s in het bloed. Aan 
de andere kant zijn er wel aanwijzingen dat bij patiënten met nierbetrokkenheid een 
stijging van het aantal ANCA’s in het bloed kan duiden op toename van ziekteactiviteit. 
Verder kan het zijn dat een stijging bij de ene patiënt meer voorspellende waarde heeft 
voor een opvlamming dan bij de andere patiënt. In ieder geval is het bepalen van de 
ANCA-waarde in het bloed alleen onvoldoende om behandelkeuzes te maken.
Naast ANCA’s zijn nog andere afweerstoffen beschreven bij patiënten met AAV 
welke mogelijk een bijdragende rol spelen. Voorbeelden zijn afweerstoffen tegen 
plasminogeen en human lysosomal-associated membrane protein-2 (hLAMP-2). Beide 
afweerstoffen zijn gericht tegen eiwitten die zich van nature in het menselijk lichaam 
bevinden. In dit proefschrift wordt in hoofdstuk 2 een onderzoek beschreven waarin 
we kijken naar het bepalen van afweerstoffen tegen plasminogeen in het bloed van 
patiënten. Plasminogeen is een eiwit dat een rol speelt bij het stollen van bloed.
Samengevat wordt in hoofdstuk 2 een geoptimaliseerde methode gepresenteerd om de 
aanwezigheid van afweerstoffen tegen plasminogeen in het bloed van AAV-patiënten 
te onderzoeken. We hebben verschillende methodes uit eerdere studies onderzocht en 
samengevoegd. Met onze verbeterde methode zagen we in 14.3% van de patiënten met 
ANCA’s tegen MPO ook afweerstoffen tegen plasminogeen. Deze anti-plasminogeen 
afweerstoffen zagen we in geen van de patiënten met ANCA’s tegen PR3. Deze uitkomst 
verschilt met de eerdere studies. Een mogelijke verklaring is dat onze methode verschilt 
van de eerder gebruikte methoden. Een andere mogelijke verklaring voor het verschil 
in aantonen of ‘detectie’ van afweerstoffen is dat er wellicht verschillende soorten 
afweerstoffen tegen plasminogeen bestaan, welke tegen een ander stukje van het 
plasminogeen reageren. Dit moet verder onderzocht worden, omdat het hebben van 
deze afweerstoffen tegen plasminogeen mogelijk relevant kan zijn voor de patiënt. Een 
eerdere studie toonde aan dat de aanwezigheid van afweerstoffen tegen plasminogeen 
bij patiënten gepaard ging met meer schade in het nierbiopt en een slechtere uitkomst 
van de nierfunctie na één jaar.
DE DIAGNOSE
Voor de diagnose AAV wordt gekeken naar de combinatie van klachten en aanwezigheid 
van ANCA’s in het bloed. Daarbij moet uitgesloten zijn dat een andere ziekte de 
verklaring is voor de klachten. Uiteindelijk moet de diagnose (het liefst) met een 
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biopt (stukje weefsel voor microscopisch onderzoek) bevestigd worden. Een biopt 
is de gouden standaard voor het diagnosticeren van nierbetrokkenheid bij AAV. 
Verschillende studies hebben laten zien dat de afwijkingen die in het biopt van de nier 
worden gezien voorspellend kunnen zijn voor het beloop of ‘de prognose’ van de nier. 
In hoofdstuk 3 wordt een studie beschreven waarin voor het eerst wordt gekeken naar 
het voorspellen van terugkeer van de ziekte in de nier middels de afwijkingen in het 
nierbiopt. Het is belangrijk opvlammingen van de ziekte in de nieren te voorkomen of 
snel te herkennen, aangezien ze negatief van invloed zijn op de nierfunctie en de kans 
op nierfalen vergroten.
Gebaseerd op een aantal van deze afwijkingen in de nier is er in 2010 een 
classifi catiesysteem geïntroduceerd welke nierbiopten afgenomen op het moment van 
diagnose indeelt in één van de vier groepen: de ‘focal’, ‘crescentic’, ‘mixed’ en ‘sclerotic’ 
groep (fi guur 1). De ‘focal’ groep bevat nierbiopten die weinig afwijkingen laten zien; 
de ‘crescentic’ groep bevat nierbiopten waarin actieve ontstekingen worden gezien; 
de ‘sclerotic’ groep bevat voornamelijk verlittekening en de ‘mixed’ groep laat een 
mengbeeld zien van de andere drie groepen. Meerdere studies lieten een relatie zien 
tussen de groep waarin het biopt was ingedeeld en de nierfunctie na één en vijf jaar. 
Omdat de gevonden relatie in de verschillende studies niet helemaal eenduidig was, 
hebben we een groot internationaal onderzoek gedaan naar de voorspellende waarde 
van de classifi catie. De resultaten uit dit onderzoek staan in hoofdstuk 4 beschreven.
Figuur 1 | Classifi catie die nierbiopten afgenomen op het moment van de diagnose AAV indeelt in één 
van de vier groepen a ankelijk van de afwijkingen die in het biopt worden gezien. 
AAV= ANCA-geassocieerde vasculitis. Gebruikt uit Berden et al. (J Am Soc Nephrol 2010;21:1628-
1636) met toestemming.
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In hoofdstuk 4 wordt bevestigd dat de ‘focale’ groep de beste en de ‘sclerotic’ groep 
de slechtste uitkomst hebben als het gaat om de nier. Tussen de ‘crescentic’ en 
‘mixed’ groep vonden we geen verschil. Dit is verschillend van de studie waarin de 
classificatie voor het eerst is gepresenteerd, maar komt overeen met latere studies die 
door andere onderzoeksgroepen zijn verricht. Er is een aantal mogelijke verklaringen 
voor de verschillen tussen deze studies. Zo kunnen de onderzochte populaties van 
elkaar verschillen. Hierbij kan het ook zijn dat de verschillende populaties op een 
verschillende manier zijn behandeld. Daarnaast wordt in dit hoofdstuk aangetoond 
dat verschillende pathologen net op een andere manier naar hetzelfde nierbiopt kijken; 
dit kan ook deels de verschillen tussen de studies verklaren.
Verder is het zo dat het classificatiesysteem niet alle afwijkingen meeneemt die men in 
een nierbiopt bij AAV kan zien. Het is mogelijk dat het toevoegen van andere afwijkingen 
(bijvoorbeeld ontstekingen aan nierbuisjes of de hoeveelheid ontstekingscellen in het 
nierweefsel) de classificatie verfijnt. Echter moet wel rekening gehouden worden 
met het feit dat toevoegen van extra onderdelen de classificatie complexer maakt, 
waarbij de kans op verschillen tussen de beoordeling van nierbiopten door pathologen 
toeneemt. Momenteel wordt onderzocht of en hoe de classificatie verfijnd kan worden.
DE BEHANDELING
Als iemand zich presenteert met actieve ziekte en de diagnose AAV wordt gesteld, 
dan moet er gestart worden met de behandeling. Om de ziekte te onderdrukken 
start men met prednison met cyclofosfamide of rituximab (inductietherapie). Als 
de ziekte onderdrukt is, wat meestal na 3 tot 6 maanden het geval is, begint men 
een behandeling om de ziekte onderdrukt te houden (onderhoudstherapie). De 
cyclofosfamide wordt dan gewisseld naar azathioprine, methotrexaat of rituximab. 
Indien rituximab wordt gegeven als inductietherapie, kan deze gecontinueerd 
worden als onderhoudstherapie. Tijdens de onderhoudstherapie wordt de prednison 
afgebouwd. De onderhoudstherapie kan langdurig worden gegeven, echter is nog niet 
bekend hoe lang dit precies moet zijn; dit wordt nog onderzocht. Wel weten we al 
dat één jaar onderhoudstherapie te kort is en dat bijvoorbeeld 18-24 maanden beter 
is. Op de inductie- en onderhoudstherapie zijn kleine variaties mogelijk, aankelijk 
van de eigenschappen van de patiënt en manifestaties van de ziekte (bijv. soort 
klachten en betrokken organen). Zo kan bijvoorbeeld bij mildere ziekte methotrexaat 
of mycofenolaat mofetil als inductietherapie gegeven worden. Bij levensbedreigende 
situaties kan de behandeling uitgebreid worden met prednison via het infuus of kan het 
bloed schoongemaakt worden met een machine (dit heet ‘plasmaferese’ en is een vorm 
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van dialyse). Echter is er recent een grote studie gepubliceerd, welke geen toegevoegde 
waarde laat zien van plasmaferese; dit in tegenstelling tot een eerdere grote studie.
Een grote uitdaging van de behandeling is het evenwicht tussen hoe lang 
doorbehandeld moet worden met een bepaald medicijn en de kans op bijwerkingen van 
het medicijn. Een belangrijk voorbeeld van bijwerkingen is de hogere kans op infecties 
of verschillende vormen van kanker (vooral huidkanker) bij het langdurig gebruik van 
cyclofosfamide. De kans op infecties wordt nog eens vergroot door het simultaan 
gebruiken van prednison. Het liefst wil de arts zo lang mogelijk doorbehandelen om 
de ziekte te onderdrukken, echter betekent een langere behandeling meer kans op 
bijwerkingen. Dit is een delicaat evenwicht waar veel onderzoek naar gedaan wordt. 
Het huidig advies is om in ieder geval twee jaar te behandelen.
Een andere grote uitdaging bij AAV is de kans op een nieuwe opvlamming van de 
ziekte, ondanks dat de patiënt medicijnen krijgt. Het liefst wil de arts de patiënten 
met een grotere kans op een opvlamming van de ziekte herkennen op het moment 
van de diagnose. Zo kunnen deze patiënten intensiever worden behandeld. Studies 
zijn nodig om deze ‘voorspellers’ te ontdekken. In hoofdstuk 3 van dit proefschrift 
wordt gekeken naar risicofactoren en voorspellers van een opvlamming van de ziekte 
in de nier, ondanks adequate behandeling. Op het moment lijkt rituximab de beste 
behandeling te zijn bij een opvlamming van de ziekte.
DE NIEREN EN NIERTRANSPLANTATIE
In 80-90% van de patiënten met AAV raken de nieren tijdens de ziekte betrokken. Van 
deze groep verliest uiteindelijk 20-40% hun nierfunctie ten gevolge van de ziekte. Deze 
patiënten komen dan in aanmerking voor een niertransplantatie, waarbij ze een nier 
ontvangen van een donor. Na vijf jaar functioneert nog circa 70% van de donornieren. 
De kans op terugkeer van de ziekte in de donornier is 1-2% per jaar. Deze getallen 
komen uit verschillende kleine studies. In hoofdstuk 5 van dit proefschrift wordt 
middels een grote landelijke studie gekeken naar de uitkomst van niertransplantaties bij 
patiënten met AAV. Hierbij hebben we specifi ek gekeken naar de invloed van terugkeer 
van de ziekte in de donornier en het risico op het verliezen van de donornier hierdoor.
Samengevat laat onze studie zien dat de vij aars overleving van de donornieren 
82.8% is. Dit is gelijk aan de overleving van donornieren bij andere ziektes. De kans 
op terugkeer van de ziekte in de donornier is 2.8% per jaar. We zagen dat terugkeer 
van de ziekte in de donornier een belangrijke oorzaak was van het verliezen van die 
nier: in 36% van alle gevallen waarbij AAV is terug gekeerd in de donornier, zijn de 
A. Goceroglu - Binnenwerk.indd   182 22-6-2020   13:02:06
182
Chapter 8
donornieren verloren gegaan ten gevolge van de terugkeer van de ziekte. De terugkeer 
van de ziekte in de donornier kan op elk moment na de niertransplantatie gebeuren; 
van dagen tot jaren na de niertransplantatie. Om de kans op terugkeer zo klein mogelijk 
te houden, wordt bij voorkeur een niertransplantatie uitgevoerd op het moment dat 
de ziekte inactief is. Het lijkt erop dat patiënten met inactieve ziekte en enkel een 
positieve ANCA in het bloed wel een niertransplantatie kunnen ondergaan zonder 
verhoogd risico op verlies van de donornier. Hoe lang de ziekte rustig moet zijn moet 
nog verder onderzocht worden. Een niertransplantatie is dus een goede behandeling 
bij AAV patiënten met nierfalen, maar op het moment dat de ziekte in de donornier 
terugkeert, moet de arts zich bewust zijn van een verhoogd risico op verlies van de 
donornier.
VRAGEN VOOR DE TOEKOMST
Er zijn nog genoeg uitdagingen in AAV waarnaar verder onderzoek gedaan moet 
worden.
Zo willen we meer inzicht krijgen in welke patiënten wel of geen opvlammingen van 
de ziekte krijgen, ondanks behandeling. Er zijn in verschillende studies factoren 
beschreven die de kans op een opvlamming van de ziekte vergroten, zoals bijvoorbeeld 
de aanwezigheid van PR3-ANCA en long- en/of cardiovasculaire betrokkenheid. 
Onderzoek is nodig om dit soort factoren verder te specificeren. Hierbij moet ook 
gekeken worden naar afwijkingen in het nierbiopt die voorspellend kunnen zijn. Zo 
kan de arts in de toekomst patiënten met een grotere kans op een opvlamming eerder 
herkennen en intensiever behandelen.
Het gebruik van de ANCA-concentratie in het bloed om daarmee de huidige situatie 
van ziekte te meten of om een opvlamming te voorspellen blijft een punt van discussie. 
Het is goed mogelijk dat patiënten met AAV andere stoffen of ‘biomarkers’ in het bloed 
hebben, die beter samenhangen met ziekteactiviteit. Biomarkers kunnen de arts helpen 
bij besluitvorming over de behandeling. Er zijn een aantal potentiële biomarkers 
beschreven, waaronder ook anti-plasminogeen afweerstoffen.
Het is nog niet goed uitgezocht hoe lang een AAV-patiënt inactieve ziekte moet hebben 
voordat een niertransplantatie uitgevoerd kan worden met zo min mogelijk risico’s erna. 
Er is - weliswaar zwak- bewijs dat één jaar inactieve ziekte mogelijk een goede termijn 
is voorafgaand aan een niertransplantatie. Op dit punt is verder onderzoek nodig.
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Het blijft een uitdaging om een goede balans te vinden tussen behandelen met 
medicijnen om een opvlamming te voorkomen en de kans op bijwerkingen. De 
afgelopen decennia is het risico voor een opvlamming niet sterk veranderd. Er moet 
meer onderzoek komen naar nieuwe medicijnen die de ziekte goed behandelen en 
de kans op een opvlamming verkleinen. Een potentieel middel hiervoor is avacopan, 
een recent ontwikkeld medicijn dat ingrijpt op een specifi ek proces binnen ons 
afweersysteem. Momenteel is de beste behandeling voor een opvlamming van de 
ziekte rituximab met hierna langdurige onderhoudstherapie.
Momenteel wordt ook veel onderzoek gedaan naar genetica en AAV. Eerdere studies 
lieten zien dat er een genetische variatie is tussen patiënten met ANCA’s tegen PR3 en 
patiënten met ANCA’s tegen MPO. Dit wekt de vraag op of we hier te maken hebben met 
twee verschillende ziektes die verschillend behandeld moeten worden. Tot nu toe zijn 
PR3-AAV en MPO-AAV altijd op dezelfde manier behandeld. Dit soort inzichten in de 
verschillen tussen PR3-AAV en MPO-AAV geven ons de kans om betere behandelingen 
meer gericht op de individuele patiënt te ontwikkelen en te geven.
A
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